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Abstract 
 
In the course of this work we tried to design and create new ligands acting on 
the different dopamine receptors but with novel affinity and selectivity profiles 
so that we could come up with new medical agents characterized by higher 
curing potential towards different CNS disorders and lower side effects 
relative to the currently available medications. 
In the first part, some thieno and benzothieno azecine derivatives have been 
synthesized and biologically screened towards the 5 receptor subtypes of 
dopamine. Among these derivatives, compound 3 has shown to be the first 
reported azecine to show a unique selectivity profile towards D2 and D5 
receptor subtypes with the same order of magnitude (Ki D2: 1.5 nM; D5: 1.9 
nM). 
In a second part, some arylmethylphenylpiperazine derivatives have been 
synthesized to serve as D4 acting ligands and had their Ki values towards the 
5 dopamine receptor subtypes determined. Among this set of compounds, 
compounds 32a and 36a have shown superior affinity to D4 receptors with Ki 
values of 0.7 and 0.03 nM respectively. Docking experiments to D4 homology 
model have revealed a first to report arene cation interaction in which the 
unique D4 residue Argenine 186 is involved in. 
In the last part of this work, some arylamidoalkylphenylpiperazine derivatives 
were synthesized and tested against the different dopamine receptors for the 
sake of getting new probes with modulated selectivity towards D3 and D4 
receptors rather than D2 subtypes. Among this series, compound 44a has 
shown to be 200 times more selective to D4 rather than D2 subtypes and 
compound 45a was about 900 times more selective to D4 rather than D2 and 
100 times more selective to D3 rather than D2 receptor subtypes.   
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1. Introduction 
 
1.1 Biosynthesis and metabolic fates of 
dopamine 
 
Dopamine is a neurotransmitter that belongs to the family of catecholamines 
and can be released from its neurons either in the central or the peripheral 
compartments (1). The biosynthesis of Dopamine starts by the action of 
tyrosine hydroxylase, also known as tyrosine-3-monoxygenase, on L-tyrosine 
to yield L- dihydroxyphenyl alanine that is commonly known as L-DOPA which 
is further subjected to decarboxylation process mediated by aromatic L-amino 
acid decarboxylase enzyme that is always referred to as dopa decarboxylase 
to yield dopamine. After biosynthesis, dopamine is stored inside special 
vesicles in the neurons which are then released into synapse following 
stimulation through presynaptic action potential (2, 3). 
Among the most important biochemical fates of dopamine is its conversion 
into norepinephrine and epinephrine by the action of dopamine-ȕ-hydroxylase 
and phenylethanolamine-N-methyl transferase enzymes successively (4). 
As for the degradation of dopamine, it occurs via the reuptake mechanism 
either through specific Dopamine transporter known as DAT-1 or through the 
Norepinephrine transporter NET in the areas where there are very few 
amounts of dopamine transporter proteins such as prefrontal cortex. After the 
reuptake, comes the enzymatic degradation of dopamine that is mediated 
either by monoamine oxidase with its both subtypes MAO-A and MAO-B or 
catechol-O-methyl transferase (COMT) enzymes, Figure 1. 
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Figure 1: Biosynthesis and metabolism of dopamine  
The action of MAO enzyme involves oxidative deamination of dopamine to 
produce 3,4-dihydroxyphenyl acetic acid, while the COMT enzyme converts 
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dopamine to 3-methoxy tyramine. Both metabolites are considered inactive 
when compared to dopamine (5, 6). 
1.2 Central functions of dopamine 
 
Central dopaminergic neurons originate mainly at four areas in the brain, 
namely substantia nigra, pars compacta, ventral tegmental area, and 
hypothalamus. From these areas, axons extend to many other areas in the 
brain through four major pathways which are Mesocortical pathway, 
Mesolimbic pathway, Nigrostriatal pathway, and tuberoinfundibular pathway, 
Figure 2 (7).   
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Major dopaminergic pathways in the brain (7) 
Among these pathways, the Nigrostriatal and Mesolimbic ones have attracted 
a plenty of interest due to their assured involvement in lots of pathological 
conditions related to disturbed Dopamine neurotransmission, where the 
former is responsible for controlling the motor functions while the latter is 
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involved in cognition and emotionality. Degeneration of dopaminergic neurons 
in the nigrostriatal area is the main cause of developing Parkinson’s Disease 
(PA) with its associated symptoms of tremors and rigidity, meanwhile the over 
activity of Dopamine neurotransmission in the mesolimbic pathway is the 
major responsible for delusions and hallucinations that are the utmost 
noticeable signs of Schizophrenia (8, 9).  
1.2.1 Control of locomotion and motor functions 
Dopamine is considered to be a key regulator for the motor functions in CNS, 
where it has a stimulatory effect on locomotion via activating D2 receptors and 
lately it was shown that stimulating D1 and D5 receptors may also show 
synergetic action regarding controlling the motor functions. Accordingly, 
Dopamine plays an essential role in the pathogenesis of many motor 
disorders such as PD, Restless leg syndrome, Tourette’s syndrome, and 
Huntington’s disease (8, 10- 12).   
1.2.2 Control of cognition  
As many neurocognitive functions as memory, attention, and problem solving 
are under the control of Dopamine, where in the frontal lobes, it controls the 
flow of the information from other areas of the brain. A Low Dopamine level in 
the prefrontal cortex is the major contributor to Attention Deficit Hyperactivity 
Disorder (ADHD) (13). 
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1.2.3 Prolactin regulation 
 
Dopamine also plays an important role in adjusting the levels of prolactin 
hormone where it is considered to serve as Prolactin Inhibiting Hormone (PIH) 
or Prolactostatin as it inhibits the secretion of prolactin from the anterior 
pituitary gland (14).  
1.2.4 Dopamine and reward system 
 
Dopamine is known to be involved in the brain reward’s system as it is 
released upon rewarding experiences such as sex, food, some drugs such as 
cocaine, amphetamines, and nicotine that increase the level of Dopamine in 
brain through blocking its reuptake. Dopamine is then ensuring the feelings of 
enjoyment and reinforcement to motivate the person to perform certain tasks 
and activities. Animal studies have been conducted and confirmed the role of 
Dopamine in motivation, desire and pleasure, where in one of these 
experiments, rats depleted from Dopamine have shown no longer initiation to 
eat on their own will.  
This crucial role of Dopamine has put great value for some dopaminergic 
receptors agonists and antagonists in the scope of treating cocaine addiction. 
Several studies have proved the role of D2, D3, and D5 receptors in this 
regards as it was found that the signaling mechanisms of D2 and D3 
particularly play an integral function in the transduction of cocaine’s 
discriminative stimulus effects. On the other hand D5 receptors were proved 
to mediate the increase of NMDAR in the ventral tegmental area (VTA), an 
action by which cocaine promotes synaptic plasticity of VTA neurons and thus 
leads to development of addictive behaviors at the end (15). 
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It is worth to mention that both D2 agonist PNU-95666 and D3 agonist 
PD128907 were able to reproduce and prime cocaine’s effects, while both D2 
antagonist L-741626 and D3 antagonist PG01037 were managed to attenuate 
the effects of cocaine (16).   
       
 
 
PNU-95666                         PD128907                                 L-741626           
 
 
 
 
 
                             PG01037 
 
 
1.2.5 Pain processing 
 
Dopamine has also proved to play a role in pain processing in CNS, where its 
decreased level in brain was shown to be associated with painful symptoms 
that accompany PD frequently. It was also shown that disturbed Dopamine 
neurotransmission is observed in some painful clinical conditions such as 
burning mouth syndrome and restless leg syndrome. It has been reported that 
the analgesic effect of Dopamine is mediated most properly through D1 and 
D2 receptors in CNS (17). 
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1.2.6 Stimulation of Chemoreceptor Trigger Zone 
 
Dopamine as well as other neurotransmitters such as histamine and serotonin 
is able to stimulate a certain area in the brain medulla known as 
chemoreceptor trigger zone (CTZ), an area of the brain located outside the 
blood brain barrier and communicates with the vomiting center. Stimulation of 
this area leads mainly to initiation of nausea and vomiting. As many drugs and 
bacterial toxins as opiates, cardiac glycosides, chemotherapeutics, and 
staphylococcal enterotoxin are able to stimulate CTZ and initiate emesis, an 
action that can be offset by the use of Dopamine and/or Serotonin antagonists 
such as Sulpiride and ondansetron respectively (18).   
 
 
 
                Sulpiride                                                           Ondansetron 
 
1.3 Peripheral functions of dopamine 
 
The most common peripheral actions of Dopamine are mainly observed on 
cardiovascular system, kidney, and immune system. Low doses of Dopamine 
have been proved to be able to dilate renal blood vessels increasing the renal 
blood flow and hence increase the overall renal perfusion resulting in about 
five units increase in the urine output, thus Dopamine is said to be of a 
diuretic effect. 
Intermediate doses of Dopamine is shown to activate ȕ1 receptors in the heart 
leading to positive inotropic and chronotropic effects, meanwhile large doses 
of Dopamine exert a vasopressor action on the blood vessels through 
OCH3
H2NO2S N
H
N
CH2CH3O
N
O
CH3
N N
H3C
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stimulation of α1 receptors leading to increasing peripheral resistance and 
blood pressure (19). 
Regarding the immuno-regulatory function of Dopamine, it has been shown 
that some dopaminergic receptors subtypes are expressed on B-cells and 
natural killers, moderately expressed on neutrophils and esinophils, while with 
low degree of expression on T-cells and monocytes. Moreover, Dopamine 
was demonstrated to be synthesized and released from the immune cells 
themselves. 
It was shown that Dopamine activates resting T-cells and in a reverse action 
inhibits them when they are activated. It is worth to mention that disorders 
associated with disturbed levels of Dopamine are accompanied with altered 
immune functions (20). 
1.4 Dopaminergic receptors  
 
Dopamine mediates its different pharmacological actions via stimulating five 
different but closely related receptor subtypes that are classified under two 
families, the D1-like family which includes D1 and D5 subtypes and the D2-
like family that includes D2, D3, and D4. This classification is mainly based on 
the biochemical way by which Dopamine is able to modulate Adenylyl Cyclase 
(AC) activity, and accordingly the cAMP production. All of these dopaminergic 
receptors belong to the super family of G-protein Coupled Receptors 
(GPCRs) (21). 
GPCRs are considered to be a super family of transmembrane receptors that 
are encoded by about 791 genes. They sense its ligands outside the cell and 
then activate signal transduction pathways inside, so that cellular responses 
are ultimately observed. The stimulatory ligands that bind to GPCRs vary in 
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size from small molecules to peptides to large proteins and in nature from light 
sensitive compounds to hormones to neurotransmitters. These receptors are 
involved in many diseases and considered to be the target of for 
approximately 30% of the newly developed drug candidates (22, 23). 
1.4.1 Molecular structure of dopaminergic receptors  
 
Like other GPCRs, dopaminergic receptors are considered to be integral 
membrane proteins that possess seven transmembrane helices. The 
extracellular loops of the receptors contain two highly conserved cysteine 
residues that contrive to afford disulphide bonds to stabilize the structure of 
the receptor (24). 
Deeper view to the structure of GPCRs to which belong the dopaminergic 
receptors, show that the receptor structure is characterized by the presence of 
an extracellular N-terminal, followed by seven transmembrane α-helices that 
are denoted as 7-TM α-helices (TM-1 to TM-7). The seven transmembrane 
helices are connected together by three intracellular loops and 3 extracellular 
loops denoted as IL-1 to IL-3 and EL-1 to EL-3 respectively, and finally comes 
the intracellular C-terminal, Figure 3 (7). 
These receptors arrange themselves into a tertiary structure in which the 
seven transmembrane helices form a cavity within the plasma membrane that 
serves as the ligand binding domain.  This cavity is often covered by EL-2 that 
resembles the lid that covers the top of the ligand binding site (25, 26). 
It’s worth to mention that the sequence identity between the members of D1- 
like and D2-like families is only 44%, where D1-like family receptors have a 
shorter intracellular third loop than D2- like  family receptors. Also the C-
Introduction 
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terminal of D1- like family receptors is about seven times longer than that of 
the D2- like family receptors (24). 
  
 
 
 
 
 
 
 
 
Figure 3: Structural features of D1- like and D2- like receptors (7) 
Both D1 and D5 receptors share about 80% degree of homology in their 
primary sequence. D1 receptors contain 446 amino acids, while D5 have 477 
ones. The primary structure of the two subtypes is observed mainly in the 
third intracellular loop and in the external loop between the transmembrane 
domain TM-4 and TM-5 (27). 
As for the D2- like family, D2 and D3 share about 75% degree of homology, 
while D2 and D4 share only 53% homology degree. D2 receptor subtype is 
characterized by having two different variants. These variants have been 
termed D2S (D2- short) and D2L (D2- long). The D2L differs than the other 
isoform in regards of the presence of an additional 29 amino acids in the third 
intracellular loop (28).  
As for D4 receptor subtype, several polymorphic variants with a 48-base-pair 
repeat sequence in the third cytoplasmic loop were described. Some of these 
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polymorphic variants might have a slightly altered affinity for the antipsychotic 
clozapine; however no evidence has been reported that indicates an 
increased incidence of schizophrenia in the subjects with these variants (29). 
1.4.2 Mechanisms of dopaminergic receptors 
signaling 
 
As already mentioned, all dopaminergic receptors belong to the super family 
of GPCRs that mediates its action via the activation of heterotrimeric G-
proteins to induce intracellular signaling mechanisms. Moreover, there is a 
strong accumulating evidence suggests that these receptors do not signal 
exclusively through G-proteins but may also be involved in G-protein 
independent signaling cascades. In general, G-proteins consist of three 
associated protein subunits termed α, ȕ, and Ȗ and they are classified into 
four broad classes according to the nature of the α- subunit sequence. These 
four classes are Gαs, Gαi, Gαq, and Gα12. Before an agonist binds to its 
GPCR, α- subunit of the G-protein is bound to GDP and tightly associated 
with ȕȖ- complex to form the inactive trimeric protein complex. Upon agonist 
binding, a sequence of events results in GDP release and instead GTP binds 
to the α- subunit leading to its disconnection from the ȕȖ- complex. Both the α- 
subunit and the ȕȖ- complex can then transduce signals to activate some 
effector systems (30, 31).  
The D1- like family receptors (D1 and D5) are generally coupled to Gαs/olf that 
their stimulation leads to activation of AC that provokes the production of 
cAMP secondary messenger that in turn activates Protein Kinase A (PKA). On 
the contrary, activation of D2- like family (D2, D3, D4) that are coupled to Gαi/0 
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leads to negative regulation of the production of cAMP and accordingly a 
decrease in PKA activity (32, 33). 
1.4.2.1 D1- like receptors signaling 
 
As already mentioned before, D1 and D5 are coupled to Gαs/olf protein. Upon 
stimulation of these receptors, Gαs and presumably Gαolf bind primarily to C2 
cytosolic domain of AC, bringing the C1 and the C2 domains together in a 
way that enhances the catalytic activity of the enzyme which in turn leads to 
the conversion of ATP into cAMP that binds to the regulatory subunit of PKA 
leading to its activation (32, 34-36).  
Once activated, PKA phosphorylates a number of proteins involved in signal 
transduction and regulation of gene expression, Figure 4 (34). 
Activation of PKA  as a result of D1- like family receptors stimulation not only 
stimulates PKA catalyzed phosphorylation of numerous protein substrates but 
also prevents the phosphatase 1 (PP1) catalyzed dephosphorylation of these 
phosphoproteins through phosphorylating and hence activating Dopamine 
and Cyclic AMP- regulated Phosphoprotein (DARPP-32) (37, 38).   
       
 
 
 
 
 
 
 
Figure 4: D1- like receptors signaling pathways (34)  
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Among the substrates that are phosphorylated as a result of PKA activation in 
response to D1- like receptors stimulation are GABA receptors and the two 
subtypes of glutamate receptors namely AMPA and NMDA. Moreover, 
regulation of several ion channels including Na+, K+, and Ca2+ channels also 
occur by modulating the phosphorylation states of these ion channels (39).  
1.4.2.2 D2- like receptors signaling 
 
The signaling of the D2- like receptors family is mediated mainly through the 
activation of the heterotrimeric inhibitory G proteins Gαi/0 (40).  
Regarding the D2 receptor subtype, it seems likely that both receptor variants 
D2L and D2S are able to activate multiple Gαi/0 including Gαi2, Gαi3, Gα0 but 
the interactions with particular G proteins are restricted in a cell type 
dependent manner according to the availability of appropriate effectors and 
scaffolding proteins (41). 
As for the D4 receptor subtype, it is similar to D2, where it activates multiple G 
protein subtypes including Gαi2, Gαi3, and Gα0 (42).  
Several working groups have identified Gα0 to be activated by the D3 receptor 
and mediating D3 signaling (43). 
Contrary to D1- like family, stimulation of D2- like receptors leads to the 
inhibition of AC activity and thus decreases the phosphorylation of PKA 
substrate such as DARPP-32 for instance, Figure 5 (34). It is worth to mention 
that it was noted that D3 stimulation inhibits AC by a weaker degree than D2 
and D4 (44). 
Among the other signaling pathways modulated via the activation of D2- like 
receptors are phospholipases, Na+, K+, Ca2+ ion channels, as well as NMDA, 
AMPA, and GABA receptors (45).  
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Figure 5: D2- like receptors signaling pathways (34) 
 
1.4.3 Dopaminergic receptors expression and tissue 
distribution 
 
Dopamine receptors are characterized by having broad expression patterns 
both in central and peripheral compartments. 
In the brain, D1 receptors subtype are expressed at high level in the 
nigrostraiatal, mesolimbic, and mesocortical areas such as striatum , 
substantia nigra, amygdale, and the frontal cortex. D1- receptors also show 
low level of expression in some central areas like hippocampus, cerebellum, 
and hypothalamic areas. D5 receptors are with relatively lower expression 
levels but yet in multiple regions of the brain such as prefrontal coretex, 
substantia nigra, hypothalamus, and hippocampus. 
The highest level of D2 receptors are found in striatum, nucleus accumbens. 
They are also expressed at significant levels in substantia nigra, ventral 
tegmental area, hypothalamus, and hippocampus. 
The D3 receptors show more limited distribution pattern, where the highest 
level of expression was being observed in the limbic areas such as the 
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nucleus accumbens, the olfactory tubercle, and the islands of calleja. These 
receptors are of very low expression in the striatum, ventral tegmental area, 
and cortical areas. 
As for the D4 receptors, they have the lowest level of expression in the brain 
with confirmed expression in the frontal cortex, hippocampus, hypothalamus, 
and substantia nigra.  
Regarding the periphery, D1, D2, and D4 receptors have been detected in 
retina. All subtypes of Dopamine receptors have been detected also in kidney, 
adrenal glands, sympathetic ganglia, gastrointestinal tract, blood vessels, and 
the heart (25, 46, 47).  
1.5 Dopaminergic Ligands 
 
Dopaminergic receptors ligands are structurally diverse, however the majority 
shares some common structural features which are necessary for binding to 
the receptor. From a medicinal chemistry perspective, generally when the 
chemical properties of the agonist for a specific receptor system are 
compared with those of the corresponding antagonists, the agonists are 
relatively small molecules and hydrophilic in their chemical nature, while the 
antagonists are usually larger, more lipophillic, and lacking the essential 
pharmacophore elements for displaying agonistic properties (48). 
Except for D3 receptors, the binding pockets of dopaminergic receptors is still 
not completely identified, however all of them comprise an Asp residue at 
position 3.32 which affords ionic interaction with a protonated basic nitrogen 
of the ligand that is usually surrounded on either sides by two hydrophobic 
cavities (49, 50). 
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The majority of the agonists on these receptors share in their structures the 
common catechol ethylamine skeleton, while the antagonists always lack 
certain essential pharmacophore element such as the catechol group and the 
correct conformation and/or distance separating the basic nitrogen from the 
aromatic moiety. It is worth to mention that this rule is not always equivocal, 
where some dopamine agonists such as benzergoline derivatives lack the 
essential catechol group (50- 52).  
1.5.1 D1-like family receptors ligands 
 
This part will mainly focus on classes of dopamine receptors ligands bearing 
the previously mentioned structural features. 
1.5.1.1 Phenylbenzazepine derivatives 
 
This class represents one of the most important classes of D1 selective 
agonists and antagonists that have served a major role in the pharmacology 
of dopamine receptors. The prototype SCH23390 is the first discovered D1 
antagonist showing higher selectivity towards D1 rather than D2 receptor 
subtypes (53, 54). All the antagonists of this class bear a halogen substitution at 
position 7 whereas compounds having the catechol system are serving as 
potent agonists (SKF series) (55). Neumeyer et al introduced minor changes 
into the structures of SKF series by changing the substituent at the terminal 
nitrogen and C6 of the benzazepine moiety as well as the phenyl ring. Most of 
the resulted compounds have shown more or less high affinities to D1-like 
family receptor subtypes (56). 
Several structural modifications have also been carried out on the prototype 
D1 selective antagonist SCH23390. The phenyl ring was substituted with a 
benzofuran and dihydrobenzofuran moiety, resulting in highly selective D1-like 
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antagonists namely NNC112, NNC687, and NNC756. Further structural 
variations on SCH23390 included rigidifying the structure and reducing the 
flexibility of the phenyl ring leading to the development of a new series in 
which SCH39166 was the prototype (57). It showed nanomolarar affinities on 
D1-like receptors that is though weaker than SCH23390, but with higher 
selectivity over D2-like receptors (58, 59). Table 1 illustrates the binding affinity 
constants of some of the compounds belonging to these series (53- 59).  
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Compound Structure Ki (nM) 
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Table 1: Binding affinity constants (Ki) values for some Phenylbenzazepine derivatives 
(53- 59) 
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1.5.1.2 Tetrahydroisoquinoline derivatives 
 
Tetrahydroisoquinoline ring is one of the most frequently encountered 
components in the structure of a class of dopaminergic ligands that have 
made a breakthrough in the pharmacology of dopamine receptors. Numerous 
dopamine agents contain a tetrahydroisoquinoline ring either substituted with 
phenyl/benzyl group or incorporated in a tetracyclic skeleton with different 
annulation patterns. 
Apomorphine, Dihydrexidine, Dinapsoline, and their derivatives are 
considered the major representatives of this class (60, 61). 
R(-)-apomorphine, the well known agonist, is used in the treatment of 
Parkinson's disease and erectile dysfunction. It displays high affinities for all 
dopamine receptors and has a rather interesting binding profile, showing the 
highest affinity for D4 followed by D5 receptor, with markedly lower affinities 
for the D1 receptor (62). Numerous structural variations have been introduced 
into apomorphine structure for the sake of modulating its special selectivity 
and affinity profiles. Derivatives bearing only one hydroxyl substituent at 
position 11 were found to possess antagonistic rather than agonistic 
properties and this completely matched with the previously mentioned 
structural features necessary for the functional activity of dopaminergic 
ligands (63). The nature of N-alkyl substituent was shown to have also great 
effect on both the affinity and selectivity of these ligands, where N-propyl 
substituent was found to be more selective to D2 receptors. Moreover, while 
the (R) enantiomers generally showed greater affinities than their (S) congers, 
the latter have shown antagonistic activity rather than agonistic effects. For 
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instance, S(+)-apomorphine has been reported to possess dopaminergic 
antagonistic properties (64). 
Dihydrexidine is considered to be the first potent D1 full agonist, showing an 
intrinsic efficacy comparable to dopamine itself. Similar to appomorphine, 
dihydrexidine has a conformationally rigid structure. Compared to the 
previously mentioned dopamine ligands, N-methyl substitution of 
dihydrexidine resulted in the loss of D1 selectivity, while in the N-propyl 
derivative the affinity for D2 was higher than for D1. Dinapsoline is another 
conformationally rigid analogue which is similar to dihydrexidine showed 
potent D1 full agonistic properties (55, 60, 61). 
Table 2 sums up the binding affinity constants for some representatives of this 
class (60- 64).  
 
Compound Structure Ki(nM) 
D1 D2 
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Table 2: Binding affinity constants (Ki) values for some Tetrahydroisoquinoline 
derivatives (60- 64) 
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1.5.1.3 Indolobenzazecines and Dibenzazecines 
 
Indolo[3,2-f]benzazecines and dibenz[d,g]azecines present a structurally 
novel class of dopamine receptors antagonists with interesting 
pharmacological profiles. The scaffold of the prototype LE300 has been 
designed to incorporate the structures of both dopamine and serotonin in a 
relatively flexible backbone as the more rigid pentacyclic precursor of LE300 
was found to be inactive, indicating that a moderate amount of flexibility is 
crucial for the dopaminergic binding properties of this class of compounds (65), 
Figure 6. 
 
 
 
 
 
 
 
Figure 6: Design of LE300 based on serotonin and dopamine structures 
Various modifications have been introduced to the structure of LE300 for the 
sake of imaging a comprehensive SAR for this class of compounds. The 
results can be summed up as follows: 
Removal of the indole ring as well as substitution of the annulated benzene 
ring with a phenyl group has abolished the activity. 
Replacement of the indole ring with benzene and other aromatic systems 
keeps the activity. 
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Methyl substitution of the central alicyclic nitrogen atom was most favored; 
derivatives with longer alkyl groups or aralkyl ones have shown to be much 
less active. Methoxylation and/or hydroxylation of the indole ring increased 
the activity. Ring expansion to an 11-membered central ring showed different 
effects; members had their tryptamine structure maintained and the ring is 
elongated from the benzene side possessed similar activity to LE300. On the 
other hand, expanding the ring from the indole side has much decreased the 
activity while contraction of the central ring to a 9-membered one lead to 
almost complete loss of activity (65- 69). 
As for the dibenzazecine derivatives, LE410 is considered the prototype, on 
which numerous modifications have been made to establish the SAR for such 
a class. 3-Hydroxylated or methoxylated dibenzazecines mostly showed 
higher affinities. 2,3-dihydroylated or methoxylated derivatives were shown to 
be with much lower activities. The most active compound within this series 
was the 4-chloro-3-hydoroxydibenzazecine, which displayed very high affinity 
towards D1-like family. Like the indolobenzazecine, expansion of the central 
ring was more or less keeping the activity on the target receptor subtypes (69, 
70). 
Table 3 summaries the binding affinity constants for some members of this 
class (65- 70).   
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Compound Structure Ki(nM) 
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Table 3: Binding affinity constants (Ki) values for some Azecine derivatives (65- 70) 
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1.5.2 D2-like family receptors ligands 
 
Drugs known to activate or block D2-like receptor subtypes are widely used 
for treatment of several diseases. Majority of the agonists at these receptor 
subtypes for instance are used for treatment of Parkinson’s disease, Restless 
leg syndrome, other agonists can serve as antiemetic and prolactin inhibitors. 
Recent studies have also proved the ability of D2-like receptors agonists for 
counteracting male erectile dysfunction (71, 72). On the other hand D2-like 
receptors antagonists are commonly used for reducing symptoms of 
schizophrenia and counteracting anxiety. Drugs used for treating 
schizophrenia are classified into typical antipsychotics and atypical 
antipsychotics based on their receptor subtype selectivity profile and their 
dissociation rate off the receptor. Typical antipsychotics are known with either 
limited selectivity and /or slow dissociation rate. They are also characterized 
by having extrapyramidal adverse effects manifested as some acute dystonic 
reactions and movement disorders like akinesia, akathisia, dyskinesia, 
muscular spasms of the neck, and rigidity of tongue and jaws. On the 
contrary, atypical members show better selectivity towards D3, D4, and/or 5-
HT receptor subtypes and/ or rapid dissociation rate off D2 receptor subtype, 
and much lower extrapyramidal symptoms (73, 74).  
Starting with the agonists, lots of D2-like receptors agonists are widely used 
and already available in the market, Figure 7. 
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Figure 7: Some D2-like receptors agonists used in medicinal market 
Among these agonists come the tetrahydrobenzthiazole derivative 
Pramipexole, the tetrahydrothiazoloazepine derivative Talipexole, and the 
indole-2-one derivative Ropirinole that are mainly used for treating PD. Also 
the ergot alkaloids derivatives Bromocriptine and Pergolide are available for 
treating male and female sterility associated with hyperprolactinemia (71).  
Table 4 lists the binding affinity constants of the previously mentioned 
agonists towards the D2-like receptor subtypes (71, 75).  
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Table 4: Binding affinity constants (Ki) values for some D2-like receptors agonists (71, 75) 
Moving to the antagonists, Figure 8 illustrates variety of D2-like receptors 
antagonists available in the medicinal market for treating psychosis and 
anxiety. 
Drugs belonging to the structural class known as phenothiazines such as 
Chlorpromazine are considered the most classical (typical) antipsychotics that 
have been used widely for counteracting this disorder. Among the other 
classical antipsychotics come the classes of thioxanthenes such as 
Chlorprothixene, butyrophenones such as Haloperidole, and the diphenylbutyl 
piperidines such as Pimozide. Enlarging the middle ring of the phenothiazine 
and keeping appropriate electron cloud around this ring lead to the 
development of the non classical (atypical) antipsychotics characterized by 
their enhanced subtype selectivity to D3/D4 receptors and/or their high 
dissociation rate off D2 receptors subtype and most importantly minimal 
exrapyramidal symptoms. Major representatives of this family are Clozapine 
and Olanzapine (76).  
Drug Ki(nM) 
D2 D3 D4 
Pramipexole 6.9 0.9 15 
Talipexole 5.8 7 5.2 
Ropirinole 7.2 19 >1000 
Bromocriptine 10 87 370 
Pergolide 4 4 6.2 
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Figure 8: Some D2-like receptors antagonists used in medicinal market 
Other structural classes of D2-like antagonists include the Methoxybenzamide 
derivatives such as Sulpiride and Nafadotride, and the Benzisoxazole 
derivative Resperidone that has shown to have 5-HT2 antagonistic properties.  
 Table 5 lists the binding affinity constants of some of the previously 
mentioned antagonists towards the D2-like receptor subtypes (76).  
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Table 5: Binding affinity constants (Ki) values for some D2-like receptors antagonists 
(76) 
 
In addition to the drugs already available in the market, lots of ligands 
belonging to other structural classes are still under investigation. The following 
context will summarize the most important classes showing appreciable 
affinity to D2-like family receptor subtypes. 
1.5.2.1 4-Phenylpiperidine derivatives 
 
In the search for novel D2-like receptors ligands, Pettersson et al have 
introduced a series of 4-Phenylpiperidine/piperazine derivatives to serve as 
antagonists at the target receptors subtypes (77). 
The key to this approach was to maintain the chemical pharmacophore of the 
natural substrate, Dopamine, with performing some modifications in such a 
way that the hydrophilicity is retained or even higher to lead to compounds 
that antagonize dopamine, but unlike the lipophillic antagonists, lack the ability 
to stabilize the inactive state of D2 receptors, so that they could exert 
modulatory effects on dopamine transmission and possibly state dependent 
activity invivo. 
Drug Ki(nM) 
D2 D3 D4 
Chlorpromazine 5.4 5 15.9 
Chlorprothixene 3.3 ---- 0.64 
Pimozide 2.51 2.84 1.8 
Sulpiride 51 120 2100 
Nafadotride 3 0.31 ------ 
Risperidone 4.9 12.2 7.5 
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The first ligand introduced among this series was 3-(3-hydroxyphenyl)-N-n-
propylpiperidine, known as 3-PPP. This candidate has shown partial agonistic 
activity at the D2 receptor subtype and it was found that its phenolic hydroxyl 
function is essential for its activity as it affords hydrogen bonding interaction 
with the target protein. Replacing the 3-OH group of the 3-PPP with the 
electron withdrawing group, methylsulfonyl, lead to an analogue that showed 
a unique neurochemical effects, where it displayed an in vivo effects similar to 
classic D2 antagonists such as the increase in the synthesis and turnover of 
dopamine, but in sharp contrast to these classic antagonists, it could 
stimulate, suppress, or show no effect on the motor and behavioral symptoms 
depending on the prevailing dopaminergic tone. Moreover, this compound has 
also shown to stabilize high state of D2 (D2High) rather than the low state 
(D2Low). Therefore, the effects on the motor and behavioral symptoms have 
been regarded as state dependent and this analogue has been classified as 
dopaminergic stabilizer. These results have triggered the group to investigate 
the ability of various ligands bearing the main skeleton to inhibit D2 receptors 
at different dopamine concentrations (77). Table 6 shows the Ki Low/Ki High ratio 
of this series of compounds (77).  
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Compound Structure D2 Ki Low/Ki High 
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Table 6: Ki Low/Ki High ratio of some 4-Phenylpiperidine derivatives (77) 
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1.5.2.2 Aminotetralin derivatives 
 
A series of aminotetralin derivatives has been designed and synthesized by 
Cannon et al utilizing ligand based drug design approach based on dopamine. 
It was known from previous studies that dopamine can adopt both the alpha 
and beta conformations and SAR studies have shown that only the meta 
hydroxyl group of the catechol system is necessary for dopaminergic activity. 
The conformational regidification of the ethyl chain of dopamine and inserting 
N-alkyl substituents on the terminal nitrogen lead to generating this series of 
compounds, Figure 9 (78). 
     
 
 
 
 
 
 
 
 
 
 
Figure 9: Design of Aminotetralin derivatives (78) 
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Two alternatives of bridging the dopamine structure are possible resulting in 
the formation of the 5,6 and the 6,7 dihydroxy derivatives which represent the 
beta and alpha conformers of dopamine respectively. Interestingly, the 5,6-
dihydroxy derivatives bearing n-propyl side chains on the terminal nitrogen 
were found to be among the most potent derivatives. Among the 
monohydroxylated dipropylamino tetralins is the 7-hydroxy substituted 
derivative 7-OH-DPAT that was shown to display high selectivity towards D3 
receptors. On the other hand, the 5-OH-DPAT revealed higher potency with 
mixed D2/D3 affinity profile. In an attempt to improve the pharmacokinetics of 
DPAT derivatives, several bioisosteric replacements of the hydroxyphenyl 
structure with substituted and unsubstituted heterocycles have been 
investigated (78- 80). Table 7 illustrates the binding affinity constants of some 
candidates belonging to this series of compounds (78- 80). 
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Compound Structure Ki (nM) 
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Table 7: Binding affinity constants (Ki) values of some Aminotetralin derivatives (78- 80) 
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1.5.2.3 Phenylpiperazine derivatives 
 
Dopaminergic receptors ligands belonging to this structural class are 
considered among the most widely spread dopamine candidates. The general 
pharmacophore of this class includes an aryl or heteroaryl ring that is 
connected via a linker to a 4-aryl substituted piperazine unit (81), Figure 10. 
 
     
 
 
Figure 10: General Pharmacophore of Phenylpiperazines 
The structural class of phenylpiperazines is known to be a privileged structural 
moiety simulating the native biogenic amine, dopamine, where by the virtue of 
containing an aromatic ring system and basic nitrogen, the phenylpiperazine 
skeleton can be regarded as the primary recognition element targeting the 
neurotransmitter binding site on the target receptor (81).    
It is worth to mention that the nature of the aryl rings, the positioning of the 
substituentes on these rings, the nature, length, and the degree of rigidity of 
the linker are the major contributes to the subtype receptor selectivity and 
functional activity. Different natured aryl rings have been used to serve as the 
Ar1 part in this pharmacophore, among of which phenyl, benzothiophene, 
indole, azaindole, benzimidazole, and pyrazolopyridine systems were 
identified as excellent hits for maintaining selectivity towards D2-like family 
receptors (81-  85).  
For the linker part, as many suitable units as saturated or unsaturated 
aliphatic chains, cyclic and bicyclic carbon based systems have been used. It 
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was found that a short linker such as one methylene unit linking the primary 
recognition element results in D4 subtype receptor selectivity, while increasing 
the length to a one propyl unit, shifts selectivity to D2 receptors, however a 
further increase by using one butyl unit yields highly selective D3 ligands. 
Degree of unsaturation and rigidity of the linker units also play an important 
role in directing the subtype receptor selectivity. It was reported that D2 and 
D3 affinity is strongly reduced upon using propenyl and butenyl linker units 
respectively. Replacing the butyl chain with a cyclohexyl unit also resulted in 
reducing D3 binding affinity. However, inserting amide group into the linker 
units improved the binding affinity on the target receptor over the same 
analogues deprived of this functional group (81, 82, 86, 87). 
The second aromatic moeity that is attached to the piperazine ring is usually 
represented by a substituted phenyl ring. It was noticed that using 2-methoxy 
and 2,3-dichloro, and 2,3-dimethylphenyl piperazines resulted in greater D3 
subtype receptor selectivity over D2 and D4 (88- 90).  
Table 8 shows the binding affinity constants for some phenylpiperazine 
derivatives at D2-like family receptors (81- 90). 
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Compound Structure Ki (nM) 
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Table 8: Binding affinity constants (Ki) values of some Phenylpiperazine derivatives (81- 
90) 
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1.6 Binding pockets of some dopaminergic 
receptors 
 
With the implication of GPCRs – to which dopaminergic receptors belong – in 
many diseases, the need to solve the 3D structure of this class is crucial for 
enabling structural based drug design. This lack of GPCRs structures is due 
to the fact that these receptors are bound to the membrane making it difficult 
to express in sufficient quantities for crystallization. Moreover, the poor 
aqueous solubility of membrane proteins makes it difficult to obtain crystal 
structures of this type of receptors (51). 
Dopaminergic receptors are known to share structural homology with 
rhodopsin and ȕ-adrenergic receptors, on the basis of which comparative 
molecular modeling of the dopamine receptors and ligands docking have 
been investigated, where the emergence of the high resolution crystal 
structures of ȕ-adrenergic receptors has inspired many researchers to use 
them as a main template for dopaminergic receptors modeling (91, 92).  
The results revealed differences in the size and the shape of a common 
ligand binding site, where it was suggested that particular microdomains in 
transmembrane helix 2 (TM2), TM3, and TM7 might be relevant for ligand 
selectivity, while some other amino acids residues in TM3, TM5, and TM6 are 
necessary for interaction with ligands in all the receptor subtypes (51, 81, 93- 95). 
Starting with D2 and D4 receptor subtypes, Ortore et al, in agreement with 
data reported in literature, have proved similar binding fashion between 
dopamine and the receptor pocket in case of D2 and D4 subtypes, where the 
para-OH and meta-OH of dopamine have been found to be hydrogen bonded 
to Serine residues, Ser 5.43 and 5.46 in the TM5 of the target receptors. The 
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protonated nitrogen of dopamine afforded ionic interaction with Asp 3.32 and 
finally the aromatic moiety of dopamine afforded hydrophobic interaction with 
the amino acid residues constituting the TM6 in the binding pocket of D2 and 
D4 receptor subtypes. The major residues in this area are Trp 6.48, Phe 6.51, 
Phe 6.52, and His 6.55 that are conserved in both receptor subtypes. Other 
amino acid residues in TM7 were found to share to constitute the hydrophobic 
pocket of the binding site of the two target receptors. These amino acids 
include Thr 7.39, Trp 7.40, Tyr 7.43, and Ser 7.46 (96- 98), Figure 11 (96). 
Regarding the antagonist binding fashion, Kalani et al have suggested two 
binding modes between the antagonist and the D2 receptor subtype (51). The 
first binding mode is for clozapine like antagonists, where docking clozapine 
to the predicted 3D structure of D2 receptors in this work has shown that the 
ligand occupied the region of the agonist binding site between TM3, TM4, 
TM5, and TM6. Clozapine has shown to make salt bridge to Asp 114 (3.32), 
hydrogen bond to Ser 193 in TM5, and a mostly hydrophobic pocket shown in 
Figure 12 (51) formed by Val 87, Trp 90 (TM2), Phe 110, Leu 113, Val 115, Met 
117, and Cys 118 (TM3), Phe 164 (TM4), Phe 189, Val 190, Ser 194, Ser 197 
(TM5), Phe 382, Trp 386, Phe 389, and Phe 390 (TM6), and finally Thr 412, 
Trp 413, Tyr 416, Ser 419 in TM7 (51, 99, 100). 
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The second binding mode suggested by this group is for haloperidol like 
antagonists. Docking haloperidol to the predicted 3D structure of D2 receptors  
 
 
 
 
 
 
 
Figure 11: D2 and D4 binding complexes with dopamine (96) 
has shown that the ligand occupied the region between TM2, TM3, TM6, and 
TM7. Haloperidol afforded salt bridge to Asp 114 in TM3, hydrogen bond to 
Ser 197 in TM5, and a mostly hydrophobic pocket shown in Figure 12 (51) 
provided by Val 87, Val 91, Leu 94 (TM2), Phe 110, Leu 113, Val 115, Met 
117, and Cys 118 (TM3), Trp 160, Phe 164 (TM4), Phe 189, Val 190, Val 196 
(TM5), Trp 386, Phe 389, Phe 390, His 393 (TM6), and finally Ser 409, Thr 
412, Trp 413, Tyr 416, Val 417 in TM7 (51, 99, 100). 
 
 
 
 
 
 
 
 
Figure 12: Residues within 5.5 A0 of Clozapine (left) and Haloperidol (right) bound to 
human D2 receptor model (51) 
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As for the D4 antagonist FAUC 213, Lober et al have studied the binding 
fashion of this phenyl piperazine derivative to the D4 receptor binding cavity, 
Figure 13 (101). The protonated aliphatic amine of the ligand interacts with Asp 
3.32 in TM3. The chlorophenyl moiety is supposed to contribute to D4 affinity 
and selectivity by recognizing Phe 2.61 in TM2. Finally the azaindole ring of 
the ligands was bound to Ser 5.46 in TM5 via hydrogen bonding (101). 
 
 
 
 
 
 
 
Figure 13: Docking the D4 antagonist FAUC 213 to the binding cavity of human D4 
receptor model (101) 
 
In contrast to the binding mode of the agonist, the partial agonist and the 
antagonist have afforded weaker hydrogen bonding with Ser 5.46 due to 
higher distance between the ring Nitrogen atom and the OH of the serine 
residue. This distance can be controlled through varying the positioning of the 
substituent on the aromatic ring of the ligand (101).   
The main difference between D2 and D4 receptors as configured by previous 
studies seems to be due to the lipophillic region in the binding site which is 
situated in a different position in the two receptors. In D2 receptors it is due to 
Phe 3.28 and Tyr 7.35, while in D4 the lipophillic region is due to Phe 2.61. 
Therefore, the selectivity towards the D4 receptors with respect to the D2 one 
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could be due to the ability of a D4 selective ligand to interact with the region 
near Phe 2.61 of the lipophillic region of D4 receptor (96- 98). 
A further mutagenesis study done by Ehrlich et al has confirmed the role of 
the amino acids at positions 2.60, 2.61, 3.28, and 3.29 in providing key 
structural determinants for drug selectivity between D2 and D4 receptor 
subtypes (81). The amino acid residues that correspond to these positions are 
as follow: 
- At position 2.60, it is Tryptophan in D2 and Leucine in D4. 
- At position 2.61, it is Valine in D2 and Phenylalanine in D4. 
- At position 3.28, it is Phenylalanine in D2 and Leucine in D4. 
- At position 3.29, it is Valine in D2 and Methionine in D4. 
Figure 14 (96) illustrates the subset of residues involved in the ligand binding at 
D2 and D4 receptor subtypes. This study has proved also the importance of 
the histidine residue 6.55 as a key residue for the interaction with the primary 
recognition element of the ligand which was shown to be the phenyl 
piperazine unit of the used ligands in this study (81).   
As for D3 binding pocket, Chien et al have managed to crystallize the target 
receptor bound to the D2/D3 selective antagonist Eticlopride, Figure 15 (102). 
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Figure 14: Subset of residues involved in the ligand binding at D2 (a) and D4 (b) 
receptors (96) 
 
Eticlopride occupies the part of the binding pocket defined by side chains from 
helices II, III, V, VI, and VII. The tertiary amine in the ethyl-pyrrolidine ring of 
eticlopride is likely charged at physiological pH and forms a salt bridge to the 
carboxylate of Asp 3.32, which is highly conserved in all aminergic receptors.  
This salt bridge is structurally and pharmacologically critical for high-affinity 
ligand binding to the aminergic subfamily of GPCRs. Another key component 
of the eticlopride pharmacophore is a substituted aromatic ring connected to 
the pyrrolidine by an amide bond that fits tightly within a hydrophobic cavity  
 
 
 
 
 
 
 
Figure 15: A. Binding cavity of Eticlopride in D3 receptor, B. Interactions of Eticlopride 
with the amino acid residues in D3 binding cavity (102) 
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formed by Phe 6.51 and Phe 6.52 in helix VI, Val 5.39, Ser 5.42, and Ser 5.43 
in helix V, and Val 3.33 in helix III, as well as Ile 183 in EL2. Polar substituents 
such as OH, OCH3 in the phenyl ring form intramolecular hydrogen bonds 
with both the N and O of the amide, thereby maintaining the compound in an 
almost planar conformation (102, 103). 
Of the 18 eticlopride contact residues in the D3 receptor structure, 17 are 
identical in the D2 receptor (Val 6.56 is an isoleucine in D2 receptors). 
Qualitatively, this agrees with the finding that eticlopride, and some of its 
analogs, share similar affinities for the D2 and D3 receptors. The structural 
determinants of pharmacological specificity in the D2 and D3 receptors are 
more subtle considering that the residues lining the binding pocket are 
essentially identical. In accordance with high conservation of the eticlopride 
binding site between D3 and D2 receptors, the available structure-activity 
relationship data suggest that, to achieve targeted selectivity, the ligand must 
extend toward the extracellular opening of the binding pocket. The D3 
selective pharmacophore consists of an extended aryl amide connected to an 
amine-containing scaffold by a relatively flexible four-carbon linker (81-84, 86, 87, 
102, 104). 
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2. Research Objectives 
 
Dopaminergic system plays an important role in regulating neuronal motor 
control, cognition, emotion, and vascular function. Neuropsychiatric diseases 
such as schizophrenia, Parkinson’s disease, or addiction are strongly related 
to disturbed dopamine transmission in CNS, thus dopamine receptors are 
attractive therapeutic targets for ligands design and synthesis. This work aims 
at developing novel dopaminergic ligands showing better pharmacokinetics 
relative to the previously prepared ones and with modulated affinity and/or 
selectivity towards the five subtypes of these receptors, where single subtype 
selectivity or more favorable combinations of affinities to several subtypes of 
dopaminergic receptors may reduce the unfavorable side effects and/or 
potentiate the activity of the classic ligands. Further more the introduction of 
novel ligands for dopaminergic receptors is still needed to help in studying the 
molecular structure and/or crystallizing some of the members of this receptors 
family whose exact molecular structure is still not well figured out.    
(1) Modulating affinity and selectivity of LE300 and some of its 
analogues towards dopamine receptor subtypes by variation of the 
chemical structure 
 
Annelated azecines represent a new family of dopaminergic antagonists 
characterized by their high affinity more or less unselectively towards the D1- 
and the D5-receptor and by moderate to weak affinity towards the D2-like 
receptors(67- 69). Designing a highly selective ligand for either one of the two 
receptor subtypes of the D1-like family still stands as a challenge due to the 
fact that both receptor subtypes share high level of molecular structure 
identity within their transmembrane helices (27). Such D1/D5-subtype-selective 
ligands may not only serve as novel atypical antipsychotics but also would 
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contribute to investigate the functions of each receptor subtype separately. 
Moreover, D1/D5-selective ligands might be of further therapeutic interest 
after recent studies have shown evidence that these receptors elicit certain 
effects in different organs, among them the kidney (105). Furthermore, 
compounds equipotent at members of both the D1 and the D2 family seem to 
be favorable with respect to lower undesired side effects as demonstrated by 
olanzapine, asenapine, and clozapine, Figure 16. 
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Figure 16: Ki values* of olanzapine, asenapine, and clozapine towards some 
dopaminergic receptors 
*values taken from PDSP database; Source: human, cloned. 
In this work we tried to modulate the selectivity/affinity profiles of lead azecine 
derivatives, namely the indolobenzazecine derivative LE 300 and its dibenzo 
analogues, Figure 17, for the sake of learning more about SAR of azecine-
type dopaminergic ligands and getting derivatives with novel selectivity 
profiles. These lead compounds exhibit moderate affinity to D2-like receptor 
subtypes and higher to the D1-like members. Regarding subtype receptor 
selectivity, it is noticeable that symmetrical dibenzazecine LE 410 is slightly 
selective for D1, while further increasing the electron cloud on the aromatic 
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rings by hydroxylation reverses the selectivity pattern and shifts affinity it 
towards the D5 receptor subtype (67). 
In order to achieve a high electron density at one of the aromatic systems 
without substitution we designed and prepared two regioisomers carrying a 
thiophene in different orientations, namely the benzo[d]thieno[2,3-g]azecine 1, 
and the benzo[d]thieno[3,2-g]azecine 2 and furthermore the benzothiophene 
derivative 3. 
Furthermore, selection of sulfur containing arene systems was based on the 
observation that Olanzapine shows for D1, D2, and D5 a much higher affinity 
than Clozapine. 
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Figure 17: Novel target compounds 1, 2, 3 based on the lead compounds  
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(2) Synthesis of novel potent and selective D4 arylmethylphenyl- 
piperazine derivatives  
  
Among the D2-like family, D4 receptor subtypes have recently shown great 
interest as a result of its involvement in treatment regimes of variety of 
neuropsychiatric disorders (106). Beside counteracting Parkinson's disease, 
selective D4 agonists and partial agonists have proved to be of benefit in 
relieving Attention Deficit Hyperactivity Disorder, and other mood disturbances 
(107, 108). This is related to the contribution of this receptor subtype in some 
personality traits such as novelty seeking or impulsive, compulsive, and 
addictive behavior (109). Moreover, other D4 selective agonists have been 
reported to induce penile erection in rats when administered in vivo, an action 
that is inhibited by concurrent ingestion of selective D4 antagonist confirming 
the mechanistic pathway (72, 110). 
Antagonists with remarkable affinity to D4 receptors are considered among 
the powerful marketed antipsychotic drugs that show minimal Parkinson's like 
side effects that characterize the classical non selective members (76, 111). 
Unlike D3 receptor subtype, the exact molecular structure of the D4 binding 
pocket is still not characterized by X-ray crystallography leaving the field in a 
still need for selective chemical probes that might help in identifying the 
binding fashion to this valuable target protein. Ligands bearing the 
arylmethylphenylpiperazine scaffold are known with their remarked selectivity 
and affinity towards D4 receptor subtype (81, 85). 
As an example of these ligands, comes PD-168077 that was demonstrated to 
be unstable in acidic solution, precluding its chances for oral administration 
(112). L-745870 is another member that is induced for clinical trials but failed to 
Research Objectives 
 48
exert clinical efficacy (113). Structure of these compounds and another D4 
selective ligand, FAUC 113, are shown in Figure 18. 
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X= S, HC CH ,HC N X= S, HC CH ,NH  
Figure 18: Some D4 selective Phenylpiperazine derivatives and the new developed 
candidates  
 
In this work, we would start with synthesizing a series of 
thiophenylmethylphenylpiperazine derivatives (31a- j) bearing the thiophene 
as the heterocyclic arene moiety and different phenylpiperazine units to serve 
as the recognition element for the target D4 receptor. Thinking about centrally 
acting dopaminergic ligands, thiophene system would serve as an optimum 
aromatic heterocycle moiety as a start for this set of compounds for being 
more or less electronically similar to the catechole ring of the endogenous 
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Dopamine (molar refractivity of thiophene is 2.6 versus 3.0 for the catechol 
system, calculated with molar refractivity descriptor of  MOE (114), so that it 
would provide this area of the compound's scaffold with the optimum 
electrostatic potential required to ensure the affinity of the designed 
candidates to the target receptor (101). 
Concerning the factor of molar volume and its effect on CNS penetrability, 
thiophene bearing candidates would have a relative smaller molar volume 
when compared to those bearing other arenes and thus may show better 
ability to diffuse through the densely packed cells of brain and blood brain 
barrier. The molar volume of thiophene ring is shown to be 79.62 versus 
129.62 for benzothiophene, 127.50 for indole, 94.37 for benzene, and 86.87 
for pyridine, calculated using  the volume descriptor of MOE (114). 
Relative to other five member arenes such as pyrole (molar volume of 78.12 
and molar refractivity of 2.2) and furan (molar volume of 73.6 and molar 
refractivity of 2.0), thiophene system would stand as an optimum arene to 
start with.  
As for the phenylpiperazine part of the scaffold, we decided to use different 
substituents on the phenyl ring to investigate the electronic, steric, and 
polarity impact of this part of the compounds on the affinity and selectivity to 
D4 receptors. 
Based on affinity and selectivity data obtained after testing the synthesized 
candidates on the five dopaminergic receptor subtypes, some of the 
synthesized derivatives would have their thiophene ring replaced with other 
aryl and heteroaryl moieties to demonstrate the effect of this particular part of 
the structure on the affinity and selectivity towards the target protein, and to 
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configure out an interactive Structure Affinity Relationship study. In such way, 
two rounds of structural optimization could be adopted, where compounds 
bearing the phenylpiperazine units that showed best affinity would have their 
heteroarene moiety replaced with other ones for the sake of getting the 
optimum affinity. 
(3) Modulating the affinity and selectivity profiles of some previously 
marketed D2-like family antagonists via developing Thiophenylamido 
propyl/butylphenylpiperazines   
 
Among the well known D2-like family typical antagonists, comes the 
butyrophenone derivative Haloperidol as one of the most commonly marketed 
typical antipsychotic agents (76, 115). These typical medications are 
characterized by their ability to block the D2-like receptor subtypes 
unselectively and though being useful in curing the positive symptoms of 
psychosis, they possess marked Extra Pyramidal Parkinson's like adverse 
effects (116). This undesired propensity is thought to be a result of blocking D2 
receptor subtype that is mainly concentrated in striatal areas of the brain (117). 
On the contrary, atypical antipsychotic drugs relieve both positive and 
negative signs of the disease experiencing much lower incidence of the Extra 
Pyramidal symptoms (118). This special behavior of atypical antipsychotic 
drugs is believed to be as mentioned before either due to their ability to block 
D3/D4 receptor subtypes selectively over D2 ones, or due to their loose 
binding and their rapid dissociation off D2 receptor subtype, an action that 
allows normal dopamine transmission and thus this transient binding fashion 
would be the factor that obviates the Parkinson's like effects (74, 118). Recent 
studies have linked this special pharmacological behavior of atypical drugs to 
their cross interaction with 5-HT2A receptors (73).  
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From these atypical medications, the thienobenzodiazepine derivative 
Olanzapine and the benzamide derivative Sulpiride are commonly used. 
Ketanserine is another ligand characterized by its moderate interaction with 
D2 receptor subtype while exhibiting much higher binding affinity to D4 and 
5HT2A receptors. 
Unfortunately, the use of atypical antipsychotic medicines is still limited 
because of diverse of hazards including increased risk of brain stroke, 
cardiovascular diseases, metabolic and diabetic complications, weight gain, 
and impaired sexual function (119) leaving the field in a need of newer probes. 
Attempting to develop novel selective D3 and/or D4 ligands, we have 
designed our probes to serve as hybrids bearing combined structural features 
from both the typical and atypical lead compounds Haloperidole, Sulpiride, 
Olanzapiene, and Ketanserine, Figure 19. These designed probes are also 
bearing an optimum scaffold in which the aromatic ring appendage and the 
basic nitrogen of the phenylpiperazine separated with the amidoalkyl linker 
would keep the primary recognition elements that have been proved to be 
necessary for fitting into the binding pockets of the target dopaminergic 
receptors (81). 
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Figure 19: Design of hybrid dopaminergic probes based on marketed typical and 
atypical antipsychotic agents  
 
We would start with the first group of compounds (40a, 40b, 41a, 41b) having 
the phenylpiperazinylalkylisoindoledione skeleton in which the 
phenylpiperazin scaffold is substituted once with 2-OEt group and another  
with 2,3-Cl which have been shown by previous studies to be optimum for 
targeting dopaminergic receptors (81, 101). The spacer linking the aromatic 
appendage to the phenylpiperazine unit would be either a propyl or butyl 
chain. We would also replace the isoindoledione system with a benzamide 
one so we would synthesize the second group, compounds (42a, 42b, 43a, 
43b). Finally, we would go for a further structural modification utilizing a 
thienoamide appendage in place of the benzamide and accordingly the 
thienoamide bearing probes (44a, 44b, 45a, 45b) would be synthesized.   
The scaffold to show to have the best affinity towards the target receptors, 
would have further modifications at the phenylpiperazine unit through utilizing 
other different oxygenated and halogenated substituents on that part of the 
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scaffold in order to investigate the electronic, and steric impact of this part of 
the scaffold on the affinity and selectivity towards the target receptor subtypes 
and hence figuring out a comprehensive interactive SAR study. 
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3. Results and Discussion 
3.1 Chemistry 
3.1.1 Synthesis of Thieno and Benzothieno based 
azecine derivatives 
 
The general strategy adopted for the synthesis of the thieno and benzothieno 
the azecine derivatives was depending on the separate preparation of the 
respective ȕ-aryl ethyl amine and the 2-(2-bromoethyl) benzaldehyde which 
were then reacted together under Pictet-Spengler or modified Pictet-Spengler 
conditions mainly to afford the formation of the respective quinolizines that 
were then subjected to N-methylation followed by C-N hydrogenolysis to 
obtain the desired candidates. The structure elucidation of the synthesized 
target compounds have been confirmed through IR spectroscopy, GC/Mass 
spectroscopy, 1H-NMR, 13C-NMR, and elemental analysis.   
3.1.1.1 Synthesis of 6-Methyl-4,5,6,7,8,13-hexahydrobenzo[d] 
thieno [2,3-g] azecine (1) 
 
It was first necessary to prepare the corresponding thieno quinolizine namely, 
4,7,8,12b-Tetrahydro-5H-benzo[h]thieno[2,3-a]quinolizine 15, so that it would 
be followed with ring opening procedure to get the target azecine derivative.  
The synthesis of this quinolizine, as illustrated in scheme 1, started through 
reacting 2-thieophene carbonitrile and 2-phenylethylchloride in presence of 
stannous (IV) chloride to get the 3,4-dihydro-1-(2-thienyl)isoquinoline 4 that in 
turn reacted with 2-iodoethanol to get the quaternary N-hydroxyethyl 
isoquinolinium iodide salt 5 (120). 
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The quaternary salt was then subjected to a reduction procedure using 
sodium borohydride to get the corresponding 2-(2-hydroxyethyl)-1(2-thienyl)-
1,2,3,4-tetrahydroisoquinoline 6 that was in turn entered into a cyclization 
reaction with polyphosphoric acid to afford the desired quinolizine derivative. 
Unfortunately, the spectral analysis of the resulted compound showed that it 
was not bearing the structure of the desired quinolizine. The mass spectrum 
showed a molecular ion peak of 191 g/mol and the integration of the 1HNMR 
spectrum could elucidate the structure of 2,3,5,6-Tetrahydro-10bH-
thiazolo[2,3-a]isoquinoline 7. To confirm the structure of the resulted 
compound, we had to synthesize it adopting another route in which 2-(2-
bromoethyl) benzaldehyde was reacted with 2-aminoethane- thiol in presence 
of KOH using ethanol as a solvent. The 1HNMR spectra of the compound 
prepared from the two routes have been shown to be identical, Figure 20 (120).  
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Scheme 1: a: SnCl4    b: 2-Iodoethanol, acetone    C: NaBH4, MeOH     d: PPA, reflux    e: 
KOH, EtOH, RT  
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Figure 20: 1HNMR charts of compound 7 synthesized via two different routes 
In a trial to understand the mechanism of the formation of the thiazolo[2,3-
a]isoquinoline 7, we searched the organic literature for similar behavior. 
Interestingly it was reported that in rare cases, the thiophene sulfur atom 
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could be alkylated under acid catalysis followed by ring degradation (121, 122). 
Based on these findings we suggested a proposed mechanism that might 
explain this strange behavior, Figure 21.  
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Figure 21:  Proposed mechanism for the formation of the thiazolo[2,3-a]isoquinoline 
derivative 
 
In a second trial to synthesize the target azecine the regular Pictet-Spengler 
reaction procedure has been adopted.  
To prepare the 2-thiophene-3-yl-ethylamine 10, we started with the 
bromination of 3-methyl thiophene with NBS in presence of benzoyl peroxide 
so that the resulted 3-(2-bromomethyl) thiophene 8 is to be subjected to 
nucleophilic substitution reaction with KCN followed by reduction with LiAlH4 
to the respective 2-thiophene-3-yl-ethylamine. Actually the bromination step 
ended up in a mixture of the desired product and different poly and mono 
brominated analogues. The desired 3-(2-bromomethyl) thiophene 8 was 
separated by silica gel column chromatography using etheyl acetate: toluene 
1:1 but in an unsatisfactory yield (< 10%). Another route for the preparation of 
the desired amine was accomplished in which, the thiophene-3-
carboxaldhyde was subjected to aldol condensation reaction with 
nitromethane and ammonium acetate to obtain the 3-(2-nitrovinyl) thiophene 9 
that was treated with LiAlH4 in dry THF to get the target amine. 
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The respective thienoquinolizine derivative was then tried to be prepared 
using Pictet-Spengler reaction conditions where it has been refluxed with 2-(2-
bromoethyl) benzaldehyde 11 in presence of TFA and dry dioxane as a 
solvent. Unfortunately, the yield of the obtained product was lower than 
expected. To have our product in a higher yield, a modified Pictet-Spengler 
reaction was utilized, where the 2-thiophene-3-yl-ethylamine 10 was reacted 
with 2-(2-bromoethyl) benzaldehyde 11 in dry dioxane for 2-3 hours and the 
resulted imminum bromide salt was subjected to cyclization using 6M HCl and 
reflux for 8 hours. This resulted in the formation of the respective quinolizine 
in the form of its HCl salt, from which the free base was liberated using 33% 
NH3 solution with more satisfactory yield. 
The ring opening was done through reacting the respective thienoquinolizine 
with chloroethylformate in dry THF at -80 oc, using dry ice in methanol for 4 
hours followed by the addition of NaBH3CN to afford the ring opening and 
obtaining the corresponding carbamate derivative 16 that in turn was reduced 
with LiAlH4 in dry THF to get the desired benzo[d]thieno[2,3-g] azecine target 
candidate.  
Scheme 2 illustrates the adopted pathway for the synthesis of the target 
candidate (67- 69, 123, 124) 
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Scheme 2: a: NBS, benzoyl peroxide, benzene reflux   b: KCN, TEBA, H2O   c: LiAlH4, 
dry THF d: TFA, dry Dioxane   e: 33% NH3   f: NH4COOCH3, CH3NO2   g: LiAlH4, dry THF   
h: 2-(2-bromoethyl) benzaldehyde, dry Dioxane    i: 6M HCl   j: 33% NH3  k: 
ClCOOCH2CH3, dry THF   l: NaBH3CN, dry THF   m: LiAlH4, dry THF 
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3.1.1.2 Synthesis of 11-Methyl-4,9,10,11,12,13-
hexahydrobenzo [d] thieno[3,2-g] azecine (2) 
 
This started by Reacting 2-thiophene methanol and SOCl2 together resulting 
in the formation of 2-chloromethylthiophene 17 that was converted into the 
desired 2-thiophen-2-yl-ethylamine 19 adopting similar procedure as before. 
Reacting the previously synthesized 2-thiophen-2-yl-ethylamine with 2-(2-
bromoethyl) benzaldehyde and TFA in dry dioxane adopting Pictet-Spengler 
or modified Pictet-Spengler reaction to prepare the respective quinolizine, 
4,7,8,12b-Tetrahydro-5H-benzo[h]thieno[3,2-a]quinolizine 23 was 
unsuccessful trial. This is could be related to the low possibility of the thienyl 
C3 attack on the imminium quaternary nitrogen as the negative charge that 
affords this attack is predominantly localized on thienyl C2 so that the 
electrophillic substitution reaction could not have been happened. 
Alternatively, 3-Thiophenecarbonitril was reacted with 2-Phenylethylchloride in 
presence of stannous (IV) chloride to afford the formation of the oily 3,4-
dihydro-1-(3-thienyl)isoquinoline 20, that in turn reacted with 2-iodoethanol to 
give the corresponding N-hydroxyrthyl isoquinolinium iodide salt 21.   
The  resulted quaternary salt was then subjected to a reduction reaction using 
sodium borohydride to get the corresponding 2-(2-hydroxyethyl)-1-(3-thienyl)-
1,2,3,4-tetrahydroisoquinoline 22 that was in turn entered into a cyclization 
reaction with polyphosphoric acid to afford the desired quinolizine derivative 
as major product that was isolated from other minor side products via 
recrystallization from ethanol . 
In similar procedure as before, the obtained quinolizine derivative was 
subjected to ring opening procedure via its reaction with chloro ethylformate 
and NaBH3CN  to get the corresponding carbamate that was then reduced 
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with LiAlH4 in dry THF to have the desired benzo[d]thieno[3,2-g] azecine 
derivative (120). 
Scheme 3 illustrates the synthesis of the desired benzo[d]thieno[3,2-g] 
azecine. 
3.1.1.3 Synthesis of 8-Methyl-6,7,8,9,10,15-hexahydrobenzo 
[d][1] benzothieno [2,3-g]azecine (3)  
 
Scheme 4 illustrates the pathway utilized to synthesize the desired 
benzo[d][1] benzothieno[2,3-g] azecine derivative. 
First, the 2-benzo[b]thiophen-3-yl-ethylamine 27 was prepared starting from 
bezothiophene that was subjected to chloromethylation reaction using HCOH 
37% under continuous HCl gas passage to get the 3-choromethylbenzothio- 
phene 25, which in turn reacted with KCN and TEBA to afford the formation 
benzothiophene-3-yl-acetonitrile 26 that was converted to the desired amine 
under reduction conditions using LiAlH4 in dry THF.   
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Scheme 3: a: SOCl2   b: KCN, TEBA, H2O  c: LiAlH4, dry THF    d: 2-(2-bromoethyl) 
benzaldehyde, dry Dioxane, TFA    e: 33% NH3   f: SnCl4  g: 2-Iodoethanol, acetone h: 
NaBH4, MeOH  i: PPA  j: ClCOOCH2CH3, dry THF   k: NaBH3CN, dry THF   l: LiAlH4, dry 
THF 
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As for the preparation of the benzothienoquinolizine derivative 29, similar 
previously prepared analogues were obtained via reacting the respective ȕ-
aryl ethyl amine with isochromanone to afford the formation of the 
corresponding benzamide derivative which in turn was subjected to cyclization 
under Bieschler-Napieralski conditions to get the desired quinolizine. Here in, 
we adopted one step preparation for the desired quinolizine utilizing Pictet-
Spengler reaction conditions, where the previously prepared 2-
benzo[b]thiophen-3-yl-ethylamine 27 was refluxed with 2-(2-bromoethyl) 
benzaldehyde 11 in presence of TFA in dry dioxane to get the desired 
quinolizine in its triflouroacetate salt 28, from which the free base is liberated 
using 33% NH3 solution. The resulted quinolizine prepared using this method 
was formed with a satisfactory yield of 81%. 
Again, the ring opening was done through reacting the benzothieno 
quinolizine with chloroethylformate in dry THF at -80 oc, using dry ice in 
methanol for 4 hours to yield the very unstable carbamate chloride salt that 
was not isolated but to which directly added the milder reducing agent 
NaBH3CN to afford the ring opening and obtaining the corresponding 
carbamate derivative 30 that in turn was reduced with LiAlH4 in dry THF to get 
the desired benzo[d][1]benzothieno- [2,3-g] azecine target candidate in a 
good yield (125- 127).  
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Scheme 4: a: SOCl2, CH2Cl2   b: KCN, TEBA, H2O   c: LiAlH4, dry THF  d: TFA, dry 
Dioxane   e: 33% NH3   f:ClCOOCH2CH3, dry THF   g: NaBH3CN, dry THF   h: LiAlH4, dry 
THF. 
 
3.1.2 Synthesis of Phenylpiperazine derivatives 
 
Ligands bearing an aryl moiety separated with an alkyl spacer from a phenyl 
piperazine nucleus serve as good candidates for binding to the D2- receptors 
family. In this work, three sets of compounds bearing this skeleton have been 
synthesized with varying spacers between the aryl group and the phenyl 
piperazine moiety to manipulate selectivity towards the different subtypes of 
D2- receptors family. 
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3.1.2.1 Synthesis of Arylmethylphenylpiperazine derivatives 
The synthesis of the arylmethylphenylpiperazine derivatives as shown in 
scheme 5 depended on the reaction between the halomethylarene with the 
corresponding phenylpierazine derivative in TEA and acetonitrile under inert 
atmosphere (128). 
Except for the commercially available benzylbromide 39 all other 
halomethylarenes have been prepared by our group. The 1-
Chloromethylnaphthalene 38 and 3-Chloromethylbenzothiophene 25 were 
prepared utilizing chloromethylation reaction between the corresponding 
arene and HCHO 37% with continuous passage of HCl gas during the whole 
reaction time. The 2-Chloromethylthiophene 17 and the 3-
Chloromethylpyridine 37 building units have been prepared starting from the 
corresponding arenemethanol through reaction with SOCl2 in CH2Cl2. 
Similar reaction between Indole-3-methanol and SOCl2 did not afford the 
corresponding chloromethyl derivative. This may be related to the high 
reactivity of indole ring, where it could happen that the formed 3-
chloromethylindole product affords electrophillic substitution reaction at 
position 2 of another mole leading to polymerization. Inspired by Mannich 
synthesis of Gramine (129), the desired indolomethylphenylpiperazine 
derivatives were prepared as shown in scheme 6 in one step reaction 
between the indole, the corresponding phenylpiperazine free base, and 
HCOH 37% in acetic acid at 0oC for one hour. 
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Scheme 5: a: SOCl2, CH2Cl2 b: 37%HCHO, HCl gas, CH2Cl2 c: Corresponding 
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Scheme 6: Synthesis of 3-[4-Phenylpiperazin-1-ylmethyl]-1H-indole derivatives 
 
3.1.2.2 Synthesis of Phenylpiperazinylpropyl/butylisoindole-
1,3-dione and Arylpropyl/butylamidophenylpiperazine 
derivatives 
 
The synthesis of the phenylpiperazinylpropylisoindoledione derivatives as   
illustrated in scheme 7 has started from a fusion reaction between phethalic 
anhydride and 3-Chloropropylamine hydrochloride salt to afford the formation 
of 2-(3-Chloropropyl)-isoindole-1,3-dione 46 which in turn was subjected to a 
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nucleophilic substitution reaction with the corresponding phenylpiperazine to 
obtain the desired derivatives in a suitable yield (130, 131).  
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Scheme 7: Synthesis of Phenylpiperazinylpropylisoindole1,3dione derivatives 
 
Due to the non availability of the 4-Chlorobutylamine hydrochloride salt, the 
synthesis of the phenylpiperazinylbutylisoindoledione derivatives was done 
adopting Gabriel synthesis (132) in which the phethalimide potassium salt was 
N-alkylated with 1,4-dibromobutane to give 2-(4-Bromobutyl)isoindole-1,3-
dione 47 which was again subjected to a nucleophilic substitution reaction 
with the corresponding phenylpiperazine to yield the desired candidates, 
scheme 8. 
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Scheme 8: Synthesis of Phenylpiperazinylbutylisoindole1,3dione derivatives 
 
The synthesis of the benzamides and thienoamides as depicted in scheme 9 
was carried out starting from the corresponding previously synthesized 
phenylpiperazinylalkylisoindoledione derivatives, where they were subjected 
to Ing-Mansk reaction that involves refluxing with aqueous hydrazine in 95% 
ethanol to afford the corresponding primary amine which in turn was reacted 
with the corresponding acylchloride in presence of TEA to afford the formation 
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of the desired amide derivatives (133). Figure 22 illustrates the mechanisms of 
the Gabriel and Ing-Mansk reactions. 
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Scheme 9: Synthesis of benzamide and thienoamide derivatives 
 
 
N
O
O
.K+
R X
- KX
N
O
O
R
H2NNH2 NH
NH
O
O NH2
R
NH
NH
O
O
+ NH2R
 
Figure 22: Mechanism of Gabriel and Ing-Mansk reactions for the synthesis of primary 
amines 
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3.2 Pharmacology 
 
The target prepared compounds were screened for binding affinity towards 
human stably cloned dopamine receptor subtypes D1, D2, D3, D4, and D5 
utilizing radioligand binding studies according to our developed protocol (66). 
[3H]SCH23390 was used as radioligand for the D1-like family, and 
[3H]Spiperone for the D2-like family. Incubations at 27oC were terminated after 
90 minutes by rapid filtration with a Perkin-Elmer Mach III harvester. At least 
two independent experiments, each in triplicate, were carried out. 
3.2.1 Binding affinity data of Thieno and Benzothieno 
azecine derivatives 
 
The target azecines including their carbamate precursors were screened for 
binding affinity towards the 5 dopamine receptors subtypes. Ki values for our 
azecine derivatives 1, 2, 3 and their carbamate precursors are listed in table 9 
and compared with clozapine, olanzapine and asenapine. The respective Ki 
values are taken from the PDSP database and are also from human cloned 
receptors.  
The rational on which the thiophene scaffold was selected is based on the 
comparison of clozapine and its thiophene congener olanzapine, which has 
higher affinities for D1, D2 and D5 receptors than clozapine. For this couple 
not only the affinities are increased by the bioisosteric replacement of 
benzene to thiophene, but also the selectivity profile changed: Clozapine has 
a slightly higher affinity for D1 (266 nM) and D5 (255 nM) than for the D2 
receptor (343 nM), whereas olanzapine has a higher affinity for D2 (53 nM) 
than for D1 and D5 (70 and 82 nM). 
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11.3 
 
 
 
1.5 
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Olanzapine 
 
 
 
 
 
70 
 
 
 
 
53 
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Asenapine 
 
 
 
2.9 
 
 
 
1.4 
 
 
 
--- 
 
 
 
--- 
 
 
 
22.7 
 
Table 9: Binding affinity data of compounds 1, 2, 3, and their carbamate precursors to 
human cloned dopamine receptors subtypes compared to Clozapine, Olanzapine, and 
Asenapine 
At least two independent experiments were carried out in triplicate each. 
 
Selent et al. thoroughly analyzed the binding mechanisms of both compounds 
for 14 different homology models of GPCRs including various serotonin 
receptors, some dopamine receptors, but not the D1 and the D5 receptor (134). 
In their models, the binding cavity is lined by the following amino acids 
positions: 3.26, 3.28, 3.29, 3.32, 3.33, 3.36, 3.37, 3.40, 5.38, 5.39, 5.42, 5.43, 
5.46, 5.47, 6.44, 6.48, 6.51, 6.52, 6.55, 7.35, 7.39 and 7.43. We now 
extended their observation to the dopamine D1 family. The amino acids that 
surround the docked ligand in < 4.5 Å proximity are compared for the 
receptors that are the focus of our interest, Figure 23. 
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Figure 23: AlignMent of amino acid positions that are found in < 4.5 Å proximity to 
clozapine or olanzapine docked into 14 different GPCRs (134).Amino acids that are 
different in either receptor are highlighted in red and could be responsible for a certain 
selectivity profile 
 
This alignMent again shows the very high sequence identity between the D1 
and the D5 receptor. The only difference is position 3.26 with an asparagine 
at the D1 and an aspartate at the D5. Asparagine can act as an H-bond donor 
and acceptor whereas aspartate can only accept H bonds. 
There are 5 of 20 amino acids that make up a difference between the D1 
family and the D2 receptor and it was hypothesized that the SH/N motif (S 
5.43 and H or N at 6.55) forms additional polar interactions with the sulfur of 
the thiophene moiety, which in turn explains the higher affinity of olanzapine. 
Comparing our two thienoazecine regioisomers to olanzapine, in the case of 
compound 1, the sulfur is in a similar position. Surprisingly compound 2, in 
which the sulfur occupies a different position than in olanzapine, shows for the 
D1 distinctively higher affinities than the positional isomer where the 
thiophene has the same orientation like in olanzapine. This indicates a 
different binding mode. 
Regarding the molecular structures of the D1-like receptors, D1 and D5, 
neither homology models nor molecular docking in-silico data are so far 
available for the target proteins but Surgand et al have reported the most 
important amino acid residues involved in the binding pockets of the target 
receptors using alignMent studies relying on human beta-2 adrenergic 
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receptor as a template. According to this study, the most important amino acid 
residues thought to constitute the binding cavities of the respective receptors 
were residues 1.35, 1.39, 1.42, 2.58, 3.32, 4.56, 4.60, 5.38, 5.42, 5.43, 5.46, 
6.44, 6.48, 6.51, 6.52, 7.35, 7.39, 7.43, 7.45 (135).  For us to study the rare 
different amino acid residues in and near by the suggested binding sites of D1 
and D5, we aligned the reported D1 and D5 sequences according to 
Ballesteros and Weinreb numbering and via the aid of the sequence of the 
recently co-crystallized human D3 receptors we were able to define the 
beginning and the ending of D1 and D5 helices (134, 136).  
As expected, very few amino acids were found to be different between D1 and 
D5 in and surrounding the binding cavities, namely Phenylalanine 2.69 in D1 
faces Tyrosine in D5, Proline 4.39 in D1 faces Glutamine in D5, Lysine 5.67 in 
D1 faces Valine in D5, Aspartic 7.31 faces Serine in D5, and finally Aspergine 
7.33 faces Therionine in D5. In terms of the chemical nature of these different 
amino acids, it is noticeable that Tyrosine, Glutamine, Serine, and Therionine 
residues in D5 could serve as hydrogen bond acceptors from ligands owning 
electron donating moieties contrary to their counterparts in the D1 binding 
site. Also Valine residue 5.67 in D5 would afford better hydrophobic 
interaction with the binding ligand rather than its Lysine counterpart. Based on 
these finding we suggested that ligands bearing thiophene scaffold might 
serve as a D1 D5 distinguishing aid with enhanced preferentiality to D5 
subtype receptors, where the electron pair of the thiophene sulfur would role 
as the donor moiety. The use of the thiophene ring was also suggested in 
order to generally make the best use of the hydrophobic region of the studied 
binding pockets, where the large atomic polarizability of the sulfur atom and 
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the electron rich thiophene system would provide higher dispersion forces 
compared to benzene which may lead to better ╥ - ╥ stacking and/or van der 
waals interaction with the hydrophobic residues lining the hydrophobic pocket 
of the target receptors. 
Examining the binding affinity data of the test compounds versus the leads we 
observed that compound 1 showed to have the best selectivity towards the D5 
receptor subtype with D5/D1 selectivity index of 0.3 versus 2.5 for LE 410 and 
3.75 for LE 405 and D1/D5 of 3.1 versus 0.4 for LE 410 and 0.26 for LE 405. 
Shifting the position of the sulfur atom of the thiophene ring in the regioisomer 
2 has completely reversed the selectivity pattern, where it showed the best 
selectivity to D1 receptors subtype with D1/D5 selectivity index of 0.3 versus 
0.4 for LE 410 and 0.26 for LE 405 and D5/D1 selectivity index of 3.3 versus 
2.5 for LE 410 and 3.75 for LE 405 revealing the importance of the role and 
the position of the thiophene sulfur atom for binding D5 receptors subtype. 
It is also noticeable that generally, the developed compounds 1, and 2 
exhibited lower affinity to the target receptors pointing out the importance of 
the molar volume of the ring adjacent to the azecine scaffold, so we 
suggested that using other aromatic systems with similar electronic effect but 
larger molar volume would serve best in this case. Accordingly, we have 
synthesized the benzothienobenzoazecine derivative 3. 
Interestingly, examining the binding affinity data of the 
benzothienobenzoazecine derivative 3 versus compound 1 could show a 
comparable selectivity profile towards the D5 receptor subtype over D1 
receptors with D5/D1 Selectivity Index of 0.05 showing considerable higher 
selectivity towards D5 over D1 and confirming the importance of sulfur atom 
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position and the value of enlarging the size of the aromatic ring at this area of 
the compound scaffold.  
As for the affinity of the test compounds to the D2-like receptors, only 
compounds 1, 3 with the regular thiophene positioning were those that 
showed better affinity to D2 and D3 receptor subtypes when compared to the 
lead compounds LE 410 and LE 405. Compound 1 showed Ki values of 45.6 
and 24 nM for D2 and D3 respectively versus 60 nM on D1 receptor subtype. 
The most interesting compound 3, was found to be much more selective to D2 
and D3 receptors with Ki values of 1.5 and 18 nM respectively versus 40 nM 
on D1 receptor subtype showing to be the first azecine derivative with this 
reversed selectivity pattern and thus considered to be the first azecine 
derivative that is able to serve as prominent antipsychotic agent. Again this 
could be rationalized based on the molecular structure of the recently co-
crystallized human D3 receptors where it was approved that Serine residues, 
Ser 192, Ser 193, and Ser 196 serve as hydrogen bond acceptors in the D3 
binding pockets (102). Also the developed homology model by Kalani et al for 
the D2 receptors subtype with the antagonist clozapine showed that Serine 
residues, Ser 193 and Ser 197 contribute similarly to the interaction between 
ligand and the target protein suggesting a similar binding fashion of our thieno 
and benzothienobenzoazecine derivatives 1, 3 (51). Reversing the position of 
the sulfur atom in compound 2 again reversed the affinity profile on the D2-
like members with more or less similar binding affinity data to the lead 
compounds. 
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As for the carbamate precursors, all showed very poor affinity towards all 
receptor subtypes revealing the importance of specific steric and hydrophobic 
features at this part of the structure. 
3.2.2 Binding affinity data of Arylmethylphenyl- 
piperazine derivatives 
 
Examining the binding affinity data shown in table 10 the ten thienylmethyl 
phenylpiperazine ligands belonging to this series 31a- 31j showed high to 
moderate affinity towards D4 receptor subtype with Ki values ranging from 3.9 
to 214 nM and selectivity towards D4 subtypes over D2 and D3 with selectivity 
indices as high for certain candidate 31f as >1351 making it one of the most 
selective D4 ligands reported so far.  
Regarding the length of the spacer linking the arene moiety to the 
phenylpiperazine one, it was meant to be designed as methylene linker as 
ligands bearing such a feature are highly selective to D4 receptor subtypes 
over D2 and D3 ones due to the fact that these short ligands bearing only one 
carbon as a spacer between the aryl and the phenylpiperazine moieties can 
not stretch that far into the hydrophobic pocket at the transmembrane helix 2 
TM2/TM3 interface (81).  
Herein, the effects of two major factors on the affinity and selectivity towards 
D4 receptor subtypes can be possibly studied, namely the nature of the arene 
moiety in terms of size and electrostatic potential, the nature and the position 
of the substituent on the phenylpiperazine scaffold. 
Starting with the effect of the nature of the substituent of the phenylpiperazine 
scaffold on the affinity, it was found that ligands bearing ortho oxygenated 
substituents have shown better affinity towards D4 receptors rather than those 
Results and Discussion 
 77
bearing halogenated substituents at this area of the structure. Compound 31e 
having 2-OEt showed the best D4 binding affinity among this series followed 
by 5f (2-OH), 5d (2,3-Cl), 5c (2-Cl), 5b (2-F) with Ki values of 3.9, 7.4, 49.9, 
52, 57 nM respectively. This affinity pattern of the newly synthesized ligands 
may be rationalized in view of the results of recent mutagenesis studies that 
have confirmed that this part of the compound structure is supposed to 
interact with His 6.55 residue in the binding pocket of D4 receptors and 
accordingly the nature of the substituent at this area could affect such an 
interaction as shown by the binding data of our synthesized ligands, where 
the electron donating oxygenated substituent would ensure an electron rich 
aromatic system that is able to provide higher dispersion forces compared to 
that provided with a system bearing the electron withdrawing halogenated 
substituents thus leading to better Van der Waals interaction with the 
imidazole ring of His 6.55 (137, 138). 
Moreover, the substituent on the phenylpiperazine scaffold can influence the 
pKa of the basic piperazine nitrogen and hence affecting the key salt bridge 
interaction with Asp 3.32 residue, an interaction reported to be afforded by all 
aminergic GPCRs and their corresponding ligands (81, 94, 97, 102). Comparing the 
pKa values of the candidates bearing oxygenated phenylpiperazine scaffold 
versus those having the halogenated substituted scaffold would show that 
these pKa values followed the order 31f~31e>31b>31c>31d (7.74, 7.73, 7.47, 
7.24, and 7.13 respectively) explaining why compounds with ortho 
oxygenated substituents on the phenylpiperazine exhibited higher affinity to 
D4 receptors than those with halogenated phenylpiperazine scaffold. 
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N N X
R X
N
N
R
Formula 1 Formula 2
 
 
Compo 
und 
Structure Ki-values [nM] Average ± SEM 
 
Formula X R D1 D2 D3 D4 D5 
31a 1 S H >10000 >10000 1648 ± 126 65 ± 13 >10000 
31b 1 S 2-F >10000 >10000 1899± 97 57 ± 15 >10000 
31c 1 S 2-Cl >10000 2179 ± 569 
427 ± 
14 52 ± 13.5 >10000 
31d 1 S 2,3-Cl >10000 1545 ± 75 
44.5 ± 
0.5 49.9 ± 5.9 1743 
31e 1 S 2-OEt >10000 162 ± 42 112 ± 13 3.9± 0.3 >10000 
31f 1 S 2-OH >10000 >10000 >10000 7.4 ± 1.8 >10000 
31g 1 S 4-F >10000 >10000 >10000 105 ± 10 2059 ± 484 
31h 1 S 4-Cl >10000 >10000 >10000 214 ± 4.5 3523 
31i 1 S 3,4-Cl 2541 1593 ± 123 
62 ± 
4.1 78 ± 4.6 1534 
31j 1 S 4-OH >10000 2167 ± 58 
221± 
31 152 ± 12.2 >10000 
32a 1 HC=N 2-OEt >10000 255 ± 2 42 ± 1 0.7 ± 0.1 >10000 
32b 1 HC=N 2,3-Cl >10000 327± 6.5 41 ± 
2.5 
4.4 ± 0.8 >10000 
33a 2 HC=CH 2-OEt >10000 264 ± 6 59 ± 1 2 ± 0.7 >10000 
33b 2 HC=CH 2,3-Cl >10000 351 ± 4 92 ± 3 31 ± 5 >10000 
34a 2 S 2-OEt >10000 219 ± 6 45.1 ± 2 4.5 ± 0.2 
>10000 
34b 2 S 2,3-Cl >10000 383 ± 25 52.5 ± 5 22.5 ± 1 
>10000 
35a 1 HC=CH 2-OEt >10000 217 ± 5 42.7 ± 2 3 ± 1 
>10000 
35b 1 HC=CH 2,3-Cl >10000 242 ± 5.5 41± 0.5 11 ± 0.5 >10000 
36a 2 NH 2-OEt >10000 473 ± 18 103 ± 
12 
0.03 ± 0 >10000 
36b 2 NH 2,3-Cl >10000 502 ± 13 123 ± 7 6.2 ± 0.1 >10000 
 FAUC 113 -------- 3200 ± 
58 
5000 ± 
121 
3.1± 0.3 ------- 
 
Table 10: Binding affinity data of Arylmethylphenylpiperazine derivatives to cloned 
human dopamine receptor subtypes.  
At least two independent experiments were carried out in triplicate each. 
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Regarding the position of the substituent of the phenylpiperazine scaffold on 
the affinity, compounds bearing an ortho positioned substituent on the phenyl- 
piperazine scaffold have exhibited much better affinity to D4 than their para 
substituted congeners e.g. 31c versus 31h and 31f versus 31g. This ortho 
substituent would affect the degree of non co-planarity between the phenyl 
and the piperazine rings, a feature that seems crucial for the affinity aspects 
to the target receptor. This is obvious when comparing the dihedral angles of 
compounds 31c and 31f to their para substituted analogues 31h and 31j 
respectively; a dihedral angle of about 60o seems optimal for activity. This is 
confirmed by that the smaller in size fluorine atom in the ortho position of 
compound 31b did not greatly affect the dihedral angle and hence activity has 
not been reduced so much in its para analogue 31g, Figure 24. 
From receptor subtype selectivity perspective, compound 31f has shown to be 
highly selective towards D4 receptors over D2 with selectivity index D2/D4 of 
> 1351. Compounds 31a and 31b showed to be more than 100 folds more 
selective to D4 receptors over D2 with D2/D4 of 152 and 175 respectively, 
while other derivatives showed also appreciable selectivity with D2/D4 values 
ranging from 14 to 95.  
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Figure 24: Dihedral angles of compounds 31c (top left), 31h (top right), 31f (middle left), 
31j (middle right), 31b (bottom left), and 31g (bottom right)  
 
 
As for D4 over D3 selectivity, Compound 31f again showed to be >1351 folds 
more selective to D4 over D3. Compounds 31a, 31b, 31e, 31g, 31h also 
showed appreciable selectivity towards D4 with D3/D4 values ranging from 25 
to 95, while compounds 31c, 31j showed lower degree of selectivity to D4 
receptor subtype with D3/D4 values of 8 and 1.5 respectively. The most 
interesting compounds 31d and 31i bearing a dichlorinatedphenylpiperazine 
skeleton have shown to be with better affinity on D3 rather than D4 with Ki 
values of 44.5, 62.3 nM, respectively on D3 versus 49.9, and 78 nM 
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respectively on D4 receptors showing to be the first ligands of this class to 
violate the common selectivity pattern and pointing out that the nature of the 
substituents on the phenylpiperazine scaffold may control also ligand subtype 
selectivity. 
In an attempt to rationalize the selectivity pattern of the synthesized 
compounds among this series towards D4 receptor, we have docked all the 
synthesized compounds to the D4 homology model developed before (139) and 
also to the recently co-crystallized D3 receptor model with the antagonist 
eticlopride (PDB ID: 3PBL). The docking poses showed ionic salt bridge 
interaction with Asp 3.32 in D3 (Asp 110) and D4 (Asp 115), indicating the 
importance of the basicity of this piperazine nitrogen upon affinity to D4 
receptors. 
Figure 25 shows the docking poses of the highest affinitive D4 ligand from 
each series to the D4 receptor model. Figure 26 shows the 3D structures of 
the highest affinitive D4 ligands from each series relayed over each other 
while docked into the binding pocket of D4 receptor model. Figure 27 
illustrates the docking of compounds 31d and 31i that showed better D3 
affinity rather than D4 to D3 receptor model. 
Viewing the binding pockets of the D3 and D4 models could show that amino 
acid residues 2.61 and 3.28 are resembling Valine 86 and Phenylalanine 106 
in D3 while Phenylalanine 91 and Leucine 111 in D4 respectively and thus 
might manipulate the ligands’ selectivity towards either subtype and come in 
accordance with the results of the previous mutagenesis studies (81).  
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Figure 25: 2D interactions of the highest affinitive D4 compound from each series 
docked to human D4 model showing arene cation interaction between the ligands’ 
arene moiety and the unique D4 residue Arg 186. Tyr 192 is in contact to the 
phenylpiperazine unit of the ligands  
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Figure 26: 3D structures of the highest affinitive D4 compound from each series over 
relayed each other in the binding pocket of D4 receptor model  
                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: 2D interactions of compounds 5d (left) and 5i (right) docked to D3 binding 
pocket. Amino acid residue Val 86 is conserved in the binding pocket 
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Furthermore, we have observed that two other amino acid residues 
contributing to the binding pocket of the receptor subtypes were found to be 
different among them. The first one is the EL2 residue Arginine 186 in D4 that 
faces Serine 182 in D3 receptor subtypes. The second one is the residue 5.38 
that resembles Phenylalanine 188 in D3 subtype, while faces Tyrosine 192 in 
D4 receptors. Examining the docking poses of D4 receptor model, Figure 25 
could show that the unique D4 Tyrosine 192 is facing the phenylpiperazine 
unit of the docked ligands.  The chemical nature of this amino acid enables it 
to afford hydrogen bond interaction with the 2-OH group of compound 31f 
providing a possible explanation for its superior selectivity towards D4 
receptor subtypes. It is also important to note that this selectivity was 
dramatically reduced when shifting the hydroxyl function to the para position 
as in compound 31j. 
Comparing the selectivity data of compound 31f to that of 31b, 31c and 31e 
would reveal decrease in selectivity towards the D4 receptors over the other 
two subtypes. This might emphasis the contribution of the Tyrosine 192 
residue in controlling the subtype receptor selectivity of the synthesized 
candidates, where this specific residue faces Phenylalanine 188 in D3 and 
Phenylalanine 189 in D2 subtypes. These phenylalanine residues in D2 and 
D3 receptors would resemble a sort of incompatibility with the 2-OH group of 
compound 31f while afford better hydrophobic interaction with the more 
lipophillic 2-F, 2-Cl and the 2-OEt groups of compounds 31b, 31c, and 31e 
respectively explaining the better affinity of these compounds to the other two 
receptor subtypes relative to compound 31f itself. 
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Viewing the docking poses could also show that the Phenylalanine 91 residue 
is conserved in the binding pocket of D4 receptor and faces the also 
conserved and the less bulky Valine 86 in D3 binding pocket. This may 
provide a possible explanation why the relatively more bulky dihalogenated 
bearing compounds 31d and 31i have shown the best affinity towards D3 
(with a relative larger pocket than D4 subtypes) among the thienylmethyl- 
phenylpiperazine series. 
Moving to the effect of the heteroarene moiety on the binding affinity and 
selectivity to D4 receptors, we have replaced the thiophene ring of compound 
31e that showed the best affinity to the target protein among this series and 
compound 31d that showed better affinity to D3 rather than D4 receptor 
subtypes with benzene, benzothiophene, naphthalene, pyridine, and indole, 
so that factors like ring size and ring electron density could be tested and thus 
picturing the second round of our optimization plan. 
Relative to 31e, compounds 34a and 35a having benzothiophene and 
benzene had Ki values of 4.5 and 3 nM respectively that is almost similar to 
that of 31e (3.9 nM). Compound 33a with naphthalene ring showed little better 
affinity with Ki value of 2 nM. The binding affinity of compound 31e have been 
very much developed using pyridine ring in compound 32a that showed Ki 
value of 0.7 nM. Compound 36a having the indole ring as the heteroarene 
moiety was much more superior with Ki as low as 0.03 nM showing to be 
about 100 folds more affinitive to D4 than compounds 31e and the reference 
compound, FAUC 113. These findings could support the assumption that a 
specific negative electrostatic potential of the ring at this area of the 
compound structure does really matter rather than ring size, where the best 
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D4 affinity was obtained by the compounds bearing arenes with the highest 
negative electrostatic potential, namely compounds 32a and 36a having 
pyridine and indole arenes respectively.  
Interestingly all the docked compounds to D4 receptors model have afforded 
a first to report arene-cation interaction through their arene moiety with the 
unique Arginine 186 in EL2 of the binding pocket of the D4 receptors, Figure 
25. Such an interaction could be strengthen via increasing the negative 
electrostatic potential at this area of the compound skeleton explaining the 
high affinity and selectivity of compounds 32a and 36a towards D4 subtypes. 
Neither one of the 31d five analogues showed to bind preferentially to D3 over 
D4 like compound 31d itself; however they showed considerably good affinity 
to D3 with Ki values ranging from 41 to 123 nM. 
3.2.3 Binding affinity data of Phenylpiperazinylalkyl- 
isoindoledione and Arylmethylphenylpiperazine 
derivatives 
 
Viewing the Ki affinity binding data illustrated in table 11 could show that our 
designed probes lack the affinity towards D1-Like family receptor subtypes 
while exhibiting appreciable binding affinity towards D2-like family receptors 
showing a diverse of affinity and selectivity patterns. 
Starting with the isoindole-1,3-dione derivatives, the propyl derivatives 40a 
and 40b have shown lower affinity to the D2-like receptors and also fair 
selectivity to either D3 or D4 over D2 receptors  relative to their longer butyl 
analogues 41a and 41b.  
In the first round of optimizing affinity and selectivity of our probes, we 
decided to decrease the ring size and go for an open chain amide rather than 
the lactam system while keeping the linker as either propyl or butyl. 
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Accordingly, we have prepared the benzamide derivatives 42a, 42b, 43a, 
43b.  
Compounds 42a and 42b have shown increase in affinity to D2 and D4 
receptor subtypes, while a very slight improvement in affinity to D3 receptors 
when compared to compounds 40a and 40b. While the benzamidobutyl- 
phenylpiperazine counterparts, 43a and 43b, have shown grater improvement 
in affinity to all the D2-like members with preferentiality towards D3 and D4 
subtypes. 
In a second round of optimization we went for the thienoamide skeleton 
instead of the benzamide one, compounds 44a, 44b, 45a, 45b. As already 
mentioned before, theiophene has smaller molar volume than benzene (molar 
volume of thiophene is 79.6 versus 94.3 for benzene, calculated using MOE 
(114) volume descriptor) giving the candidates the privilege of better CNS 
penetrability through the densely packed cells of brain and blood brain barrier. 
 Relative to the benzamide derivatives 42a and 42b, the binding affinity data 
of the thienoamidopropylphenylpiperazine analogues 44a and 44b have 
shown slight improvement in affinity to all the D2-like receptor family 
members.  
The butyl linker bearing analogues 45a and 45b have also shown slight 
improvement in affinity to the target receptors and greater selectivity to D3 
and D4 over D2 receptor subtypes when compared to their benzamide 
counterparts 43a and 43b.  
We then decided to investigate the effect of changing the nature and the 
position of the substituent placed at the phenylpiperazine unit on the affinity 
and selectivity of the thienoamide derivatives, so we have synthesized 
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candidates 44c - 44j and 45c - 45j. The binding affinity data of these 
candidates is listed in table 11. 
From the obtained binding data we could discuss the effect of three major 
factors on the affinity and selectivity pattern of our synthesized probes.  
Starting with the length of the spacer separating between the aromatic 
appendage and the phenylpiperazine unit, it is obvious that compounds 
bearing the butyl linker among the whole series were having better binding 
data to the D2-like receptors than their propyl analogues. In terms of affinity, 
the length of the spacer could have a prominent effect on the pKa and hence 
the ionization of the basic nitrogen of the phenylpiperazine unit that is 
reported to be involved in a key salt bridge interaction with Asp 3.32 of the 
target receptors (81, 135, 102). From the calculated pKa values of this nitrogen 
atom in the synthesized ligands we could notice that this value ranges from 
6.8 to 7.8 in the compounds with the propyl linker while ranges from 7.3 to 8.3 
in their analogues with the butyl one. This could point out a better ionization 
and better ionic interaction with Asp 3.32 among the butyl derivatives and 
hence explain their better binding to the target receptors.  
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Cpd   
No. 
Structure Ki+ SEM [nM] 
 
Formula n X R D1 D2 D3 D4 D5 
40a I 1 - 2-OEt > 10000 1095± 28 810± 4 118± 1 > 10000 
40b I 1 - 2,3-Cl > 10000 1393± 40 806±12 124± 10 > 10000 
41a I 2 - 2-OEt > 10000 770± 4 39+ 0.5 10.7± 0.2 > 10000 
41b I 2 - 2,3-Cl > 10000 793± 2 40± 1.5 11± 2 > 10000 
42a II 1 HC=CH 2-OEt > 10000 185±9 797± 16 0.75± 0.02 > 10000 
42b II 1 HC=CH 2,3-Cl > 10000 273± 24 780± 20 7.3± 0.1 > 10000 
43a II 2 HC=CH 2-OEt > 10000 29.5± 0.7 0.93± 0.01 0.64± 0.02 > 10000 
43b II 2 HC=CH 2,3-Cl > 10000 34± 1 1.5+ 0.2 0.66± 0.1 > 10000 
44a II 1 S 2-OEt > 10000 138± 6 765± 13 0.62± 0.04 > 10000 
44b II 1 S 2,3-Cl > 10000 147± 4 754± 13 6.5± 0.3 > 10000 
44c II 1 S 2-F > 10000 253± 2 851± 8 14.7± 1.5 > 10000 
44d II 1 S 2-Cl > 10000 309± 27 805± 3 14.1± 0.3 > 10000 
44e II 1 S 2-OH > 10000 591± 26 1027± 9 13.8± 3.5 > 10000 
44f II 1 S 4-F > 10000 850± 45 1028± 10 63.2± 2.8 > 10000 
44g II 1 S 4-Cl > 10000 637± 3 872± 23 62.3± 0.7 > 10000 
44h II 1 S 3,4-Cl > 10000 290± 9 770± 14 60.1± 1.3 > 10000 
44i II 1 S 4-OH > 10000 618± 25 900± 12 60.9± 0.8 > 10000 
44j II 1 S H > 10000 253± 9 907± 4 15.1± 0.4 > 10000 
45a II 2 S 2-OEt > 10000 28.5± 0.4 0.26± 0.02 0.03± 0.01 > 10000 
45b II 2 S 2,3-Cl > 10000 27.2± 0.2 0.5± 0.01 0.54± 0.01 > 10000 
45c II 2 S 2-F > 10000 34± 0.2 1.04±  0.02 6.6± 1.2 > 10000 
45d II 2 S 2-Cl > 10000 29± 1 0.7± 0.01 5.9± 0.6 > 10000 
45e II 2 S 2-OH > 10000 54±1 0.53± 0.03 6± 0.1 > 10000 
45f II 2 S 4-F > 10000 53± 2 33± 3 31.6± 0.5 > 10000 
45g II 2 S 4-Cl > 10000 38± 0.4 20± 1 30.9± 0.1 > 10000 
45h II 2 S 3,4-Cl > 10000 40± 0.5 9.6± 0.4 29.3± 1.2 > 10000 
45i II 2 S 4-OH > 10000 65± 5 1.07± 0.03 30.4± 0.6 > 10000 
45j II 2 S H > 10000 33± 0.7 1± 0.01 6.8± 0.3 > 10000 
 Haloperidol 
 
3.93± 1.7 0.28± 0.2 0.18± 0.03 3.53± 0.9 4.17± 0.3 
Table 11: Binding affinity data of Phenylpiperazinylalkylisoindoledione and 
Arylamidoalkylphenylpiperazine derivatives to cloned human dopamine receptors      
At least two independent experiments were carried out in triplicate each. 
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In terms of selectivity, the length of the spacer might play a crucial rule in 
enabling the ligand’s aromatic appendage to afford the hydrophobic 
interaction with the corresponding amino acids that are reported to figure the 
D2/D3 subtype receptor selectivity in the EL2 of these receptors. Namely, 
these amino acids are Glu 181 and Ile 183 in D2 that are occupied with Val 
180 and Ser 182 in D3 (81).  
It is clear from the obtained data that the butyl linker bearing candidates 
among all series have shown to be 20 to 110 times more selective to D3 over 
D2 receptor subtypes. In accordance with the previously published 
mutagenesis and docking results (81), this selectivity may be explained by the 
idea that the longer butyl linker bearing ligands have been able to stretch 
farther toward the extracellular side EL2 of the binding pocket of the target 
receptors to afford hydrophobic interaction between the aromatic appendage 
and Val 180 residue in D3 that faces the more polar Glu 181 residue in D2.  
On the other hand the propyl linker bearing ligands in the benzamide and the 
thienoamide series have shown to have preferentiality towards D2 rather than 
D3 receptor subtypes. This again might be explained in view of the results of 
the recent modeling studies where this selectivity pattern could be contributed 
to the Ile 183 residue in D2 that affords much better hydrophobic interaction 
with the ligand's aromatic appendage than its Ser 182 counterpart in D3 
receptor subtype.  
As for the D4 selectivity over D2 receptor subtypes, both propyl and butyl 
linker bearing ligands among all series have shown to keep moderate to 
appreciable selectivity to D4 over D2 receptor subtypes. It was important to 
figure out the amino acids occupying the residues proved to manipulate the 
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D2/D3 selectivity at the D4 binding site. It was found that Ile 183 of D2 is 
occupied with Arg 186 in D4 and the Glu 181 in D2 is occupied with Val 184 in 
D4 receptor subtypes. Both Val and Arg residues are able to interact properly 
with the aromatic appendage of our probes and this might explain the 
noticeable preferentiality of both propyl and butyl linker bearing ligands 
towards D4 receptor subtypes rather than D2 ones.  
It is noteworthy to mention that the general enhanced binding affinity of all the 
butyl linker bearing candidates towards all the D2-like members emphasizes 
the role of the butyl spacer in enabling the compound to afford a specific 
folded conformation stabilized by an intramolecular hydrogen bond between 
the amide carbonyl and the protonated piperazine. This conformation is 
supposed to possess optimum distance between the pharmacophores leading 
to optimum binding affinity to the target receptor subtypes (140). 
Moving to the second factor affecting the affinity and selectivity of the 
synthesized ligands towards the target receptor, it is worth to consider the 
effect of changing the aromatic appendage responsible for attaining the 
required hydrophobic interaction with the target receptor. Among the whole 
series, the thienoamide system has shown the highest binding affinity at all 
the D2-Like receptor subtypes followed by the benzamide and finally came 
the largest in size isoindole-1,3-dione system with the least binding affinity 
data.  As already mentioned before, the superiority of the thiophene system 
relative to the benzene ones may be a function of better hydrophobic 
interaction at the binding pocket. This is mainly due to the fact that the 
thiophene system has higher electron rich properties as the lone pair of 
electrons in the P orbital of the sulfur atom contributes to the Huckel aromatic 
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sixtet and pushes high electron density toward the ring carbons that 
accordingly acquire partial negative charge. Thus, it was suggested that the 
large atomic polarizability of the sulfur atom and the electron rich thiophene 
system would provide higher dispersion forces compared to benzene which 
may lead to better ╥ - ╥ stacking and/or van der Waals interaction (141) with 
the hydrophobic residues lining the hydrophobic pocket of the target 
receptors.  
Pushed by the binding affinity pattern of the synthesized compounds, we were 
determined to carry out some in-silico experiments to configure the binding 
fashion of these compounds to the target receptor subtypes. The synthesized 
probes have been docked to the human D3 model (PDB ID: 3PBL), and the 
validated D2 and D4 homology models developed before (139).  
Compound 44a that showed the highest preferentiality to D2 over D3 among 
all derivatives bearing the propyl linker was docked to the D2 receptor 
homology model and showed the contact between the ligand’s arene and Ile 
183 residue. Docking the same compound to D3 receptor model have 
illustrated the contact between the ligand’s arene and the Ser 182 in the EL2 
of the binding site of the D3 receptors that is occupied with the more 
hydrophobic Ile 183 in the D2 receptor subtype confirming the rule of this 
amino acid in manipulating the ligands’ preferentiality towards D2/D3. The 
other propyl linker bearing compounds 42a, 42b, 44b have been also docked 
to D2 and D3 receptor models and showed to over relay compound 44a in the 
binding site of the target receptors, Figure 28. 
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A)                                                                             B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C)                                                                                D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: A) 2D interactions of compound 44a docked to human D2 model showing 
the key salt bridge interaction with Asp 3.32 (Asp 114) and the ligands’ aromatic 
appendage in contact to Ile 183 in EL2.  B) 2D interactions of compound 44a docked to 
human D3 model showing the key salt bridge interaction with Asp 3.32 (Asp 110) and 
the ligands’ aromatic appendage in contact to Ser 182 in EL2. C) Compounds 42a, 42b, 
44b over relayed compound 44a in the binding site of D2 receptor model. Hydrogen 
atoms of the ligands and the amino acid residues have been removed for clarity. D) 
Compounds 42a, 42b, 44b over relayed compound 9a in the binding site of D3 receptor 
model. Hydrogen atoms of the ligands and the amino acid residues have been removed 
for clarity 
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Compound 45a that showed the highest preferentiality to D3 over D2 among 
all the derivatives bearing the butyl linker has docked to both D2 and D3 
models. The docking revealed the rule of the butyl spacer to get the ligands’ 
arene in contact to the Glu 181 that is conserved in the binding site of the D2 
subtype and faces the more hydrophobic Val 180 in D3. Although Val 180 is 
conserved in the binding site of D3 receptor subtypes, our 2D interactions of 
compound 45a with D3 receptor model did not show this residue in the 
binding site. The other butyl linker bearing compounds 43a, 43b, 45b have 
been also docked to D2 and D3 models and showed to over relay compound 
45a in the binding site of the target receptors, Figure 29.     
As for D4 receptor subtypes, docking both compounds 44a and 45a that were 
among the probes with the highest D4 affinity through over the whole series 
have configured the rule of the unique D4 amino acid residue Arg 186 that 
turned out to be involved in affording hydrogen bond interaction with the 
carbonyl moiety of the synthesized ligands. The other propyl linker bearing 
compounds 42a, 42b, 44b and the butyl linker bearing compounds 43a, 43b, 
and 45b have been also docked to D4 model and showed to over relay 
compounds 44a and 45a respectively in the binding site of the target receptor, 
Figure 30. 
Finally comes the effect of the substituent on the phenylpiperazine scaffold 
upon the affinity to the target receptors, it is noticeable that the propyl linker 
bearing ligands, 44c- 44j, have shown appreciable affinity to D4 receptor 
subtypes. The best affinity was obtained by ligands bearing ortho oxygenated 
and di-halogenated derivatives followed by those having an ortho 
monohalogenated substituent. 
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A)                                                                                  B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C)                                                                                   D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: A) 2D interactions of compound 45a docked to human D2 model showing 
the key salt bridge interaction with Asp 3.32 (Asp 114) and the ligands’ aromatic 
appendage in contact to Glu 181 in EL2.  B) 2D interactions of compound 45a docked 
to human D3 model showing the key salt bridge interaction with Asp 3.32 (Asp 110). 
C) Compounds 43a, 43b, 45b over relayed compound 45a in the binding site of D2 
receptor model. Hydrogen atoms of the ligands and the amino acid residues have been 
removed for clarity. D) Compounds 43a, 43b, 45b over relayed compound 45a in the 
binding site of D3 receptor model. Hydrogen atoms of the ligands and the amino acid 
residues have been removed for clarity 
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A)                                                                                 B) 
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Figure 30: 2D interactions of compounds 44a (A) and 45a (B) docked into human D4 
model showing the key salt bridge interaction with Asp 3.32 (Asp 115) and hydrogen 
bond interaction between the ligand’s carbonyl and the unique D4 residue Arg 186. 
C) Compounds 42a, 42b, 44b over relayed compound 44a in the binding site of D4 
receptor model. Hydrogen atoms of the ligands and the amino acid residues have been 
removed for clarity. D) Compounds 43a, 43b, 45b over relayed compound 45a in the 
binding site of D4 receptor model. Hydrogen atoms of the ligands and the amino acid 
residues have been removed for clarity 
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The affinity of the synthesized ligands exhibited four to ten folds decrease 
when the substituent was shifted to the para position. This is clear when 
comparing the Ki value data of compounds 44b, 44c, 44d, and 44e to their 
para substituted analogues 44h, 44f, 44g, and 44i. This would point out the 
importance of having an ortho substituted phenylpiperazine unit with a specific 
electrostatic potential to manipulate affinity towards D4 receptor subtypes. 
Regarding the butyl linker bearing ligands, 45c- 45j, all of them have shown 
superior affinity to both D3 and D4 receptor subtypes relative to D2 ones. 
Again the nature and position of the substituent at the phenylpiperazine 
scaffold manipulated the affinity of these derivatives in a similar fashion 
exhibited by their propyl counterparts.  
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4. Experimental 
4.1 Chemistry 
4.1.1 General experimental details 
1. Melting points were measured in open capillary tubes using a 
Gallenkamp melting-point apparatus and were not corrected. 
2.  IR data were obtained from a Magna-IR FT-IR spectrometer, system 
550 by Nicolet (WI). KBr disc used for sample preparation. 
3.  1H-NMR and 13C-NMR spectra were obtained from Bruker Avance 250 
and Avance 400 spectrometers (250 MHz, 400 MHz, respectively) 
using CDCl3 or DMSO-d6 as a solvent; chemical shifts (δ) were 
reported in parts per million (ppm) downfield from TMS; multiplicities 
are abbreviated as: s: singlet; d: doublet; q: quartret; m: multiplet; dd: 
doublet of doublet; brs: broad singlet. 
4.  MS data were determined by GC/MS, using a Hewlett-Packard GCD-
Plus (G1800C) apparatus (HP-5MS column; J&W Scientific). For all 
compounds M+ was corresponding to the respective Mwt. of the 
compound. GC/MS was used to obtain MS data and so retention times 
are not given here.  
5.  Elemental analyses were performed by Institute of Organic Chemistry, 
Jena University, and were performed on a Hereaus Vario EL 
apparatus.   
6.  Column chromatography was performed using silica-gel 60 63-200µm.  
7.  Reaction progress was monitored by TLC using fluorescent precoated  
plates and detection of the components was made by short UV light.  
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8. All starting materials were obtained from Sigma –Aldrich or Alpha Acer 
and were used without further purification.  
4.1.2 Methods 
Procedure for the preparation of 3,4-dihydro-1(2-thienyl)isoquinoline (4) 
(120) 
 
2-Thiophene carbonitrile (11g, 100 mmol) was added gradually with stirring at 
room temperature to 21.6g (100 mmol) of stannous (IV) chloride. The 
temperature was raised gradually to 90oC, and 14g (100 mmol) of 2-Phenyl 
ethylchloride was added gradually to the reaction mixture. After 3 hours of 
reaction at a temperature of 100-120 oC, the mixture was allowed to cool and 
20% Sodium hydroxide solution was added gradually till brown oil is 
separated. The crude oily product is then left to dry under vacuum overnight. 
Yield and spectral data of the prepared intermediate matched data described 
in literature (120).  
N
S
 
Procedure for the preparation of 3,4-dihydro-1(3-thienyl)isoquinoline 
(20) (120) 
 
3-thiophene carbonitrile (11g, 100 mmol) was added gradually with stirring at 
room temperature to 40g (185 mmol) of stannous (IV) chloride. The 
temperature was raised gradually to 90oC, and 14g (100) mmol of 2-phenyl 
ethylchloride was added gradually to the reaction mixture. After 3 hours of 
reaction at a temperature of 100-120 oC, the mixture was allowed to cool and 
20% Sodium hydroxide solution was added gradually till brown oil is 
separated. The crude oily product is then left to dry under vacuum overnight. 
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Yield and spectral data of the prepared intermediate matched data described 
in literature (120). 
N
S  
Procedure for the preparation of 2-(2-hydroxyethyl)-3,4-dihydro-1(2-
thienyl) isoquinolinium iodide (5) (120) 
 
3,4-dihydro-1(2-thienyl)isoquinoline (1.5g, 7 mmol) was dissolved in 50 ml dry 
acetone and to the solution was gradually added 2.5g (14 mmol) of 2-
iodoethanol. The reaction mixture was stirred under nitrogen atmosphere at 
90 oC for 48 hours. The solvent was then evaporated under reduced pressure 
and the resulted compound was then washed with 50 ml acetone and dried 
under vacuum. Yield and spectral data of the prepared intermediate matched 
data described in literature (120). 
N
S
OH
.I-
 
 
Procedure for the preparation of 2-(2-hydroxyethyl)-3,4-dihydro-1(3-
thienyl) isoquinolinium iodide (21) (120) 
 
3,4-dihydro-1(3-thienyl)isoquinoline (10g, 47 mmol) was dissolved in 100 ml 
dry acetone and to the solution was gradually added 10g (58 mmol) of 2-
iodoethanol. The reaction mixture was stirred under nitrogen atmosphere at 
90 oC for 48 hours. The solvent was then evaporated under reduced pressure 
and the resulted compound was then washed with 50 ml acetone and dried 
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under vacuum. Yield and spectral data of the prepared intermediate matched 
data described in literature (120). 
N
S
OH
I-
 
Procedure for the preparation of 2-(2-hydroxyethyl)-1(2-thienyl)-1,2,3,4-
tetrahydroisoquinoline (6) (120) 
 
N-hydroxyethyl-3,4-dihydro-1(2-thienyl) isoquinolinium iodide (5g, 130 mmol) 
were  dissolved in methanol and to the solution was added gradually 8g (212 
mmol) of sodium borohydride over a period of 2 hours. The reaction mixture 
was allowed to reflux for further half an hour. After cooling, the solvent was 
removed under reduced pressure. The residue was then suspended in water 
and the mixture was extracted with ethyl acetate (2 X 100 ml). 
The collected organic layers were evaporated under vacuum to give a crude 
residue from which the target compound was recrystallized from ethanol. 
Yield and spectral data of the prepared intermediate matched data described 
in literature (120). 
N
S
OH
 
Procedure for the preparation of 2-(2-hydroxyethyl)-1(3-thienyl)-1,2,3,4-
tetrahydroisoquinoline (22) (120) 
 
N-hydroxyethyl-3,4-dihydro-1(3-thienyl) isoquinolinium iodide (5g, 130 mmol) 
were  dissolved in methanol and to the solution was added gradually 8g (212 
mmol) of sodium borohydride over a period of 2 hours. The reaction mixture 
was allowed to reflux for further half an hour. After cooling, the solvent was 
Experimental 
 102
removed under reduced pressure. The residue was then suspended in water 
and the mixture was extracted with ethyl acetate (2 X 100 ml). 
The collected organic layers were evaporated under vacuum to give a crude 
residue from which the target compound was recrystallized from ethanol. 
Yield and spectral data of the prepared intermediate matched data described 
in literature (120). 
N
S
OH
 
Procedure for the preparation of 2,3,5,6-tetrahydro-10bH-thiazolo[2,3-a] 
isoquinoline (7) (120) 
   
To a solution of 30 mg of potassium hydroxide in 50 ml ethanol, was added 1g 
(88 mmol) of 2-aminoethanthiol and 1.87g (88 mmol) of 2-(2-
bromoethyl)benzaldehyde. The reaction mixture was allowed to stir at room 
temperature for 24 hours. The precipitated compound was filtered and dried 
under vacuum.  
N
S  
Yield: 77%,  white crystals  
 
m.p.: 90- 91 oC 
1HNMR (CDCl3): 2.60- 2.95 (m, 3H, aliphatic), 3.01- 3.33 (m, 4H, 
aliphatic), 3.57- 3.60 (m, 1H, aliphatic) 5.79 (s, 1H, 
C10b),  7.00- 7.25 (m, 4H, aromatic) 
  
Elemental 
analysis: 
for C11H13NS: calcd. C 69.11, H 6.49, N 7.30 ; found C 
69.07; H 6.80; N 6.88 
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Procedure for the preparation of 2-Chloromethylthiophene (17) 
To a 100-ml round bottom flask in an ice bath containing 0.45g (4 mmol) of 
thiophene-2-methanol was added slowly and with continuous stirring  10g (85 
mmol) of thionyl chloride. After the complete addition, the ice bath was 
removed and the reaction mixture was allowed to reflux for 3 hours. The flask 
was then cooled to room temperature, the solution was neutralized with 
saturated solution of sodium bicarbonate, and the desired organic product 
was extracted with methylene chloride (2X50 ml). The organic layers were 
collected and dried over anhydrous sodium sulphate and evaporated under 
reduced pressure. The final product was retrieved in a form of brownish black 
oil and was used for the further reaction without extra purification. Yield and 
spectral data of the prepared intermediate matched data described in 
literature (126).     
 
 
Procedure for the preparation of 3-Chloromethyl benzo[b]thiophene (25) 
To benzo[b]thiophene (13.5g, 100 mmol) was added 15g (500 mmol) 37% 
HCHO solution and 15g (411 mmol) 36% HCl solution. To the mixture, HCl 
gas that is generated from the reaction between H2SO4 and NaCl in a 
separate connected flask was then passed to the reaction mixture that was 
stirred under the temperature of 60 oC for 6 hours. The reaction mixture was 
then allowed to cool to room temperature and then poured into 50 ml of water 
and extracted with diethyl ether (2X5O ml). The combined organic layers were 
then dried over anhydrous Na2SO4 and evaporated under reduced pressure to 
yield straw yellow oil that was directly used without further purification. Yield 
S Cl
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and spectral data of the prepared intermediate matched data described in 
literature (125). 
 
 
Procedure for the preparation of 3-Chloromethylpyridine (37) 
To an ice cooled solution of 5.5g (50 mmol) of pyridine-3-methanol in 40 ml 
methylene chloride was added in a dropwise manner a solution of 1g thionyl 
chloride in 10 ml methylene chloride. The reaction mixture was allowed to stir 
for 15 minutes in the ice path and then 20 minutes under reflux. The solution 
was then neutralized with saturated solution of sodium bicarbonate and 
extracted twice with 40 ml methylene chloride. The combined organic layers 
were then dried over anhydrous Na2SO4 and evaporated under reduced 
pressure to yield yellow oil that was directly used without further purification. 
Yield and spectral data of the prepared intermediate matched data described 
in literature (126). 
N
Cl  
Procedure for the preparation of 1-Chloromethylnaphthalene (38) 
To a solution of 13g (100 mmol) naphthalene in 60 ml methylene chloride was 
added while cooling in ice bath 15g (500 mmol) 37% HCHO solution and 15g 
(411 mmol) 36% HCl solution. To the mixture, HCl gas that is generated from 
the reaction between H2SO4 and NaCl in a separate connected flask was then 
passed to the reaction mixture that was stirred at room temperature for 6 
hours. The reaction mixture was then poured into 50 ml of water and 
extracted with diethyl ether (2X5O ml). The combined organic layers were 
S
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then dried over anhydrous Na2SO4 and evaporated under reduced pressure to 
yield yellow oil that was directly used without further purification. Yield and 
spectral data of the prepared intermediate matched data described in 
literature (125). 
Cl
 
General Procedure for the preparation of Thiophene-2-yl-acetonitrile and 
Benzo[b]thiophene-3-yl-acetonitrile  
 
To an ice-cooled solution of 6.5g (100 mmol) potassium cyanide and 22g (20 
mmol) triethylbenzylammonium chloride in water, was added 100 mmol of 
(17) or (25) respectively over a period of 5 minutes. The ice path was then 
replaced with water path that was heated to 90-95 oC. The reaction mixture 
was allowed to stir under this temperature for 2 hours and it was then allowed 
to cool to room temperature, diluted with 50 ml of water, and extracted with 
methylene chloride (4X30 ml).  The combined organic layers were then dried 
over Na2SO4 and evaporated under reduced pressure. The obtained black oil 
was then subjected to purification on silica gel column chromatography using 
a mixture of Hexane: Acetone 9:1 as an eluent. Yield and spectral data of the 
prepared intermediates matched data described in literature (126). 
Thiophene-2-yl-acetonitrile (18) 
 
 
Benzo[b]thiophene-3-yl-acetonitrile (26) 
 
 
S
CN
S
CN
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Procedure for the preparation of 3-(2-nitrovinyl) thiophene (9) 
To a solution of 1g (10 mmol) of thiophene-3-carboxaldhyde in 30 ml of 
nitromethane, was added 0.4g (5 mmol) of ammonium acetate. The mixture 
was heated to 110 oC in an open flask for 4 hours. The excess nitromethane 
was then evaporated under reduced pressure. The residue was then poured 
into crushed ice and the separated product was filtered off, washed with water 
(2X50 ml), and dried under vacuum.  
 
 
General procedure for the preparation of the β-aryl ethylamine (10, 19, 
27)  
 
To an ice-cooled suspension of LiAlH4 (2.3g, 60 mmol) in 250 ml dry THF, 
was added slowly and with stirring under inert atmosphere over a period of 15 
minute a solution of 20 mmol of the respective aryl acetonitrile precursor (2 or 
15) or the 3-(2-nitrovinyl) thiophene (9) in 20 ml dry THF. The ice bath was 
then removed and the reaction mixture was heated to reflux for 10 hours. It 
was then cooled to room temperature and the excess LiAlH4 was quenched 
by the careful addition of saturated Rochelle solution under inert atmosphere 
and with cooling in an ice bath till no H2 evolves. The reaction mixture was 
then filtered, washed with dry THF, and the filtrate was evaporated under 
reduced pressure to yield an oil of the respective ȕ-aryl ethylamine. The 
desired amine product was introduced to the following step without further 
purification.  Yield and spectral data of the prepared intermediates matched 
data described in literature (126). 
 
 
 
SO2N
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2-(thiophene-3-yl) ethylamine (10) 
 
 
 
 
2-(thiophene-2-yl) ethylamine (19) 
 
 
 
2-(benzo[b]thiophene-3-yl) ethylamine (27) 
 
 
 
 
Procedure for the preparation of 2-(2-bromoethyl) benzaldehyde (11) 
To an ice-cooled solution of isochroman (12.5g, 93 mmol) in methylene 
chloride (50 ml), was added bromine solution (5g, 31.2 mmol) slowly over a 
period of 5 minutes. The ice bath was removed and the reaction was refluxed 
until it becomes pale yellow (about 4 hours). The reaction was then allowed to 
reach room temperature and the solvent was removed under reduced 
pressure. To the obtained yellow oil, 48% HBr solution (30 ml) was added and 
the mixture was refluxed for additional 20 minutes. The mixture was then 
allowed to reach room temperature, extracted with tert. butyl methyl ether 
(2X30 ml). The organic layer was then washed with water (2X30 ml), dil. 
NaHCO3 (2X50 ml), and then dried over anhydrous Na2SO4. Evaporation of 
the organic solvent under reduced pressure produced an irritant, lacrimatory 
orange oil of the desired aldehyde in 82% yield which was used without 
further purification.  
S
NH2
S
NH2
S
NH2
Experimental 
 108
 
 
 
Procedure for the preparation of 4,5,7,8 tetrahydro-12bH-benzo[h] thieno 
[2,3-a]quinolizine (15) 
   
To a solution of 2.8g (13 mmol) of 2-(2-bromoethyl) benzaldehyde (11) in 40 
ml of dry dioxane, was added slowly a solution of 1.4g (11 mmol) of the 2-
(thiophene-3-yl) ethylamine (10) in 15 ml of dry dioxane under inert 
atmosphere. The reaction mixture was allowed to stir at room temperature till 
the separation of the corresponding imminium bromide salt in the form of thick 
oily syrup. After further 3 hours of stirring at the same conditions, the syrup 
was separated, and washed with dry dioxane (2X10 ml) and then with diethyl 
ether (2X15 ml). The obtained syrup was then immediately dissolved in 20 ml 
of 6M HCl and the reaction mixture was heated to reflux for 24 hours to afford 
the formation of the halo salt of the corresponding quinolizine. 
The excess HCl was then evaporated under reduced pressure and the 
residue obtained was suspended in 15 ml of water, treated with drops of 33% 
NH3 solution, and extracted with diethyl ether (2X15 ml). The organic solvent 
was evaporated under reduced pressure to obtain a gummy residue. 
Recrystallization from petroleum ether produced the respective desired 
quinolizines. Yield and spectral data of the prepared intermediate matched 
data described in literature (127). 
 
 
 
 
OHC
Br
S
N
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Procedure for the preparation of Benzo[a]-5,6,8,9-tetrahydro-12bH-
thieno[2,3-h]quinolizine (23) 
 
A solution of 1.8g (7 mmol) of 2-(2-hydroxyethyl)-1-(3-thienyl)-1,2,3,4- 
tetrahydroiso- quinoline in 40 ml polyphosphoric acid was heated to reflux for 
6 hours under inert atmosphere. The reaction mixture was then poured into 
ice water and extracted with 50 ml diethyl ether. The organic layer was then 
neutralized with 1M sodium hydroxide solution and again extracted with 50 ml 
diethyl ether twice. The collected organic layers were collected and dried over 
anhydrous sodium sulphate, evaporated under reduced pressure, and the 
product was recrystallized from ethanol. Yield and spectral data of the 
prepared intermediate matched data described in literature (120). 
 
 
 
 
Procedure for the preparation of 5,6,8,9-tetrahydro-14bH-
benzo[h]benzothieno[2,3-a]quinolizine (29) 
 
To a solution of 1.9g (11 mmol) of 2-(benzo[b]thiophene-3-yl) ethyl amine (27) 
in 40 ml of dry dioxane, was added 2.8g (13 mmol) of 2-(2-bromoethyl) 
benzaldehyde (11) and 1.3g (11 mmol) of TFA. The reaction mixture was then 
heated to reflux under inert atmosphere for 6 hours. The produced pale yellow 
precipitate was then filtered off, washed with dry dioxane, and dried under 
vacuum to yield the respective quinolizine in its trifluoro acetate salt. 
This salt was then suspended in water, treated with drops of 33% NH3 
solution, and then extracted with diethyl ether (2X15 ml). The combined 
organic layers were washed with water, dried over anhydrous Na2SO4 and the 
organic solvent was evaporated under reduced pressure to produce a gummy 
S
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flakes residue. Re-crystallization from petroleum ether yielded pale yellow 
crystals of the respective quinolizine. Yield and spectral data of the prepared 
intermediate matched data described in literature (127).  
5,6,8,9-tetrahydro-14bH-benzo[h]benzothieno[2,3-a]quinolizinium 
trifluoroacetate (28) 
S
N
H
.CF3COO-
1
2 3
4
5
6
89
10
11
12
13 14
14b
9a9b
 
Yield: 3.5g, 81%,  buff crystals  
 
m.p. 218- 220 0C 
1HNMR (DMSO-d6) 2.96- 3.61 (m, 8H, 4 X CH2), 6.20 (s, 1H, C14b), 7.30- 
7.94 (m, 8H, aromatic), 12.54 (s, 1H, N+H) 
5,6,8,9-tetrahydro-14bH-benzo[h]benzothieno[2,3-a]quinolizine (29) 
 
 
 
 
General Procedure for the preparation of the carbamate derivatives (16, 
24, 30) 
 
A solution of 2 mmol of the respective quinolizine derivative in 30 ml dry THF 
was cooled in methanol/dry ice at -80oC. To the solution was added 1g (10 
mmol) of ethylchloroformate under inert atmosphere. The reaction mixture 
was stirred for 4 hours and then a solution of 0.37g (6 mmol) of sodium 
cyanoborohydride in 20 ml dry THF was added after cooling again to -80 oC. 
The reaction mixture was allowed to reach to room temperature and stirred for 
48 hours. It was then treated with 100 ml 2N NaOH, and the organic layer was 
S
N
Experimental 
 111
separated, washed with brine solution (2X 30 ml), and the organic solvent was 
then evaporated under reduced pressure. The residue obtained was purified 
on silica gel column chromatography using Hexane: Ethyl acetate 3:1. 
4,5,6,7,8,13-hexahydrobenzo[d]thieno[2,3-g]azecine-6-carboxylic acid 
ethylester (16) 
 
S
N
COOCH2CH3
1
2
3
3a
4 5
7
8
8a
9
1011
12
12a
1313a
1' 2'
 
Yield: 0.5g, 78%, yellow resin  
 
1HNMR (CDCl3): 0.92 (t, 3H, J= 7 Hz -CH2CH3), 2.66- 3.57 (m, 8H, 4X 
CH2), 3.73 (q, 2H, J= 7 Hz, -CH2CH3), 4.09- 4.17 (d, 
2H, C13), 6.69 (d, 1H, J= 5 Hz, aromatic), 6.79 (d, 1H, 
J= 5 Hz, aromatic), 7.00- 7.20 (m, 4H, aromatic) 
 
13CNMR (CDCl3): 14.20 (C2,), 28.47 (C4), 32.50 (C13), 32.83 (C8), 34.05 
(C1,), 53.92 (C5), 61.00 (C7), 122.54 (C3a), 126.73 
(C10), 126.98 (C11), 130.19 (C9), 130.36 (C12), 
131.14 (C 3), 135.87 (C2), 138.45 (C13a), 138.59 
(C8a), 139.27 (C12a), 156.48 (C=O) 
 
IR (cm-1):  
 
1680 (C=O) 
 
GC/MS: 
m/z 104 (100%), m/z 115 (80 %), m/z 184 (60%), m/z 
211 (30%), 315 (M+, 20%) 
 
Elemental 
analysis: 
for C18H21NO2S: calcd. C 68.54, H 6.71, N 4.44 ; found 
C 68.31; H 6.41; N 4.42 
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4,5,6,7,8,13-hexahydrobenzo[d]thieno[3,2-g]azecine-6-carboxylic acid 
ethylester (24) 
 
S
N COOCH2CH3
1
2
3
4
5
7
8
3a
8a
910
11
12 12a
13
13a
1' 2'
 
Yield: 0.47g, 75%, yellow resin  
 
1HNMR (CDCl3): 0.95 (t, 3H, J= 7 Hz -CH2CH3), 2.66- 3.56 (m, 8H, 4X 
CH2), 3.75 (q, 2H, J= 7 Hz, -CH2CH3), 3.96 (d, 2H, 
C13), 6.82- 7.28 (m, 6H, aromatic) 
 
13CNMR (CDCl3): 14.20 (C2,), 27.83 (C8), 31.57 (C13), 32.72 (C4), 33.99 
(C1,), 54.23 (C7), 60.98 (C5), 121.58 (C13a), 126.60 
(C10), 126.94 (C11), 130.23 (C9), 130.58 (C12), 
131.28 (C1), 136.65 (C2), 137.14 (C3a), 139.04 (C8a), 
139.19 (C12a), 156.50 (C=O) 
 
IR (cm-1):  
 
1684 (C=O) 
GC/MS: m/z 104 (100%), m/z 115 (85 %), m/z 184 (70%), m/z 
211 (25%), 315 (M+, 15%) 
 
Elemental 
analysis: 
for C18H21NO2S: calcd. C 68.54, H 6.71, N 4.44 ; found 
C 68.21; H 6.53; N 4.35 
 
 
 
5,6,7,8,9,15-hexahydrobenzo[d]benzothieno[2,3-g]azecine-7-carboxylic 
acid ethylester (30) 
 
S
N
COOCH2CH3
1
2
4
5
6
8910
11
12
13 14
15
9a9b
3
4a14a15a
1' 2'
 
Yield: 0.64g, 88%, pale yellow resin  
 
Experimental 
 113
1HNMR (CDCl3): 0.82- 0.93 (t, 3H, -CH2CH3), 2.06 (brs, 2H,  
-CH2CH3), 2.75- 3.73 (m, 8H, 4X CH2), 4.26 (d, 2H,  
C15), 7.14- 7.78 (m, 8H, aromatic) 
 
13CNMR (CDCl3): 13.16 (C2,), 26.13 (C9), 32.81 (C15), 33.07 (C5), 34.34 
(C1,), 54.17 (C8), 60.91 (C6), 120.53 (C13), 121.96 
(C9a), 123.68 (C10), 123.79 (C11), 126.71 (C12), 
127.03 (C3), 127.32 (C2), 129.02 (C9b), 130.29 (C4), 
130.66 (C1), 138.28 (C13a), 138.96 (C14a), 140.00 
(C4a), 141.32 (C15a), 156.40 (C=O) 
 
IR (cm-1):  
 
1692 (C=O) 
GC/MS: m/z 104 (100%), m/z 115 (75 %), m/z 234 (80%), m/z 
249 (70%), 365 (M+, 35%) 
 
Elemental 
analysis: 
for C22H23NO2S: calcd. C 72.30, H 6.34, N 3.83 ; found 
C 71.93; H 6.36; N 3.72 
 
General procedure for the preparation of the azecine derivatives (1, 2, 3) 
To an ice-cooled suspension of 1g (2.6 mmol) LiAlH4 in 15 ml dry THF was 
added a solution of 6 mmol of the respective carbamate derivative in 10 ml 
dry THF, while stirring under inert atmosphere. The ice bath was then 
removed and the reaction mixture was heated to reflux for 3 hours. It was then 
allowed to cool to room temperature and the excess un-reacted LiAlH4 was 
quenched with the careful addition of saturated Rochelle solution under inert 
atmosphere and with cooling in an ice bath till no H2 evolves. The reaction 
mixture was then filtered, washed with dry THF, and the filtrate was 
evaporated under reduced pressure. The obtained residue was subjected to 
purification process on silica gel chromatography using Hexane: Ethyl acetate 
3:2. 
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6-Methyl-4,5,6,7,8,13-hexahydrobenzo[d]thieno[2,3-g]azecine (1) 
S
N
CH3
1
2
3
3a
4 5
7
8
8a
9
1011
12
12a
1313a
 
Yield: 1.07g, 70%, yellow resin  
 
1HNMR (CDCl3): 2.22 (s, 3H, N-CH3), 2.59- 2.87 (m, 8H, 4X CH2), 4.35 
(s, 2H, C13), 6.72 (d, 1H, J= 5Hz, aromatic), 7.03 (d, 
1H, J= 5Hz, aromatic), 7.06- 7.18 (m, 4H, aromatic) 
 
13CNMR (CDCl3): 29.42 (C4), 32.84 (C13), 35.00 (C8), 46.20 (N-CH3), 
59.51 (C5), 59.59 (C7), 121.63 (C3a), 126.35 (C10), 
126.50 (C11), 129.93 (C9), 130.21 (C12), 130.30 (C 3), 
137.37 (C2), 139.66 (C13a), 139.78 (C8a), 140.28 
(C12a) 
 
GC/MS: m/z 115 (95%), m/z 152 (90%), m/z 165 (70%), m/z 
184 (100%), m/z 199 (60%), 257 (M+, 25%) 
 
Elemental 
analysis: 
for C16H19NS: calcd. C 74.66, H 7.44, N 5.44 ; found C 
74.59; H 6.98; N 5.38 
 
6-Methyl-4,5,6,7,8,13-hexahydrobenzo[d]thieno[3,2-g]azecine (2) (67) 
S
N CH3
1
2
3
4
5
7
8
3a
8a
910
11
12 12a
13
13a
 
Yield: 1.12g, 73%, yellow resin  
 
1HNMR (CDCl3): 2.26 (s, 3H, N-CH3), 2.65- 3.09 (m, 8H, 4X CH2), 4.34 
(s, 2H, C13), 6.92 (d, 1H, J= 5.2 Hz, aromatic), 7.01- 
7.26 (m, 4H, aromatic) 7.31 (d, 1H, J= 5.8 Hz, 
aromatic),  
 
13CNMR (CDCl3): 29.91 (C8), 33.71 (C13), 34.88 (C4), 46.29 (N-CH3), 
59.41 (C7), 60.67 (C5), 121.45 (C13a), 126.28 (C10), 
129.93 (C11), 130.37 (C9), 130.49 (C12), 131.36 (C1), 
137.77 (C2), 138.32 (C3a), 139.94 (C8a), 140.35 
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(C12a) 
 
GC/MS: m/z 115 (90%), m/z 152 (80%), m/z 165 (60%), m/z 
184 (100%), m/z 199 (40%), 257 (M+, 25%) 
 
Elemental 
analysis: 
for C16H19NS: calcd. C 74.66, H 7.44, N 5.44 ; found C 
74.38; H 7.05; N 5.48 
 
7-Methyl-5,6,7,8,9,15-hexahydrobenzo[d]benzothieno[2,3-g]azecine (3) 
S
N
CH3
1
2
4
5
6
8910
11
12
13 14
15
9a9b
3
4a14a15a
 
Yield: 1.25g, 68%, yellowish white crystals  
 
m.p. 96-98 0C 
1HNMR (CDCl3): 2.18 (s, 3H, N-CH3), 2.71- 2.94 (m, 8H, 4X CH2), 4.47 
(s, 2H,  C15), 7.09- 7.45 (m, 6H, aromatic), 7.57 (dd, 
1H, J= 1.2, 8 Hz, aromatic), 7.77 (dd, 1H, J= 1.5, 7 Hz, 
aromatic) 
 
13CNMR (CDCl3): 25.63 (C9), 33.80 (C15), 34.93 (C5), 46.38 (N-CH3), 
59.22 (C8), 59.50 (C6), 121.01 (C13), 122.26 (C9a), 
123.55 (C10), 123.75 (C11), 126.47 (C12), 126.84 
(C3), 127.30 (C2), 130.39 (C9b), 130.55 (C4), 130.83 
(C1), 138.80 (C13a), 138.92 (C14a), 140.25 (C4a), 
140.36 (C15a) 
 
GC/MS: m/z 115 (90 %), m/z 234 (100%), m/z 249 (40%), 307 
(M+, 40%) 
 
Elemental 
analysis: 
for C20H21NS: calcd. C 78.13, H 6.88, N 4.56 ; found C 
78.48; H 7.10; N 4.13 
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General procedure for the preparation of Arylmethylphenylpiperazine 
derivatives  
 
To 5 mmol of the halomethylaryl derivative was added 5 mmol of the 
corresponding phenylpiperazine, 1.5g (15 mmol) TEA, and 40 ml Acetonitrile. 
The reaction mixture was allowed to reflux for 48 hours under inert 
atmosphere then left to cool to room temperature. The organic solvent was 
then evaporated under reduced pressure and the oily residue obtained was 
subjected to purification on Silica gel column chromatography eluting with 
Methylene chloride: Methanol 100: 1.    
 1-Phenyl-4-thiophen-2-yl-methylpiperazine (31a) 
 
 
 
 
 
 
Yield: 0.9g, 71%, brown crystals 
 
m.p.: 75-77 oC 
 
1H-NMR (CDCl3): 
 
2.68 (t, 4H, J= 5 Hz, 2 X –CH2, piperazine), 3.24 (t, 4H, 
J= 5 Hz, 2 X –CH2, piperazine), 4.08 (s, 2H, -CH2), 
6.85- 7.01 (m, 5H, aromatic), 7.25- 7.32 (m, 3H, 
aromatic) 
 
GC/MS: m/z 97 (100%), m/z 125 (15 %), m/z 258 (M+, 10%). 
 
Elemental 
analysis: 
for C15H18N2S.0.25H2O: calcd. C 68.57, H 6.85, N 
10.66 ; found C 68.49; H 7.16; N 10.45. 
 
 
 
 
 
 
 
 
 
S
N N
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1-(2-Fluoro-phenyl)-4-thiophen-2-ylmethylpiperazine (31b) 
 
 
 
Yield: 1g, 78%, brown crystals. 
 
m.p.: 60- 62 oC. 
 
1H-NMR (CDCl3): 
 
2.71 (t, 4H, J= 4.7Hz, 2 X –CH2, piperazine), 3.16 (t, 
4H, J= 4.7Hz, 2 X –CH2, piperazine), 3.82 (s, 2H, 
-CH2), 6.66- 7.05 (m, 7H, aromatic) 
 
IR (cm-1):  
 
1203 (C-F) 
GC/MS: m/z 97 (100%), m/z 125 (70%), m/z 179 (20%), m/z 
276 (M+, 20%). 
 
Elemental analysis: for C15H17FN2S.0.1H2O   calcd. C 64.79, H 6.11, N 
10.07 ; found C 64.75; H 6.09; N 9.83. 
 
 
1-(2-Chlorophenyl)-4-thiophen-2-ylmethylpiperazine (31c) 
 
 
 
 
 
 
Yield: 1g, 71%, brown crystals. 
 
m.p.: 68-70 oC. 
 
1H-NMR (CDCl3): 
 
2.72 (t, 4H, J= 4.5Hz, 2 X –CH2, piperazine), 3.10 (t, 4H, J= 
4.5Hz, 2 X –CH2, piperazine), 3.81 (s, 2H, -CH2), 6.93-7.07 
(m, 4H, aromatic), 7.19- 7.26 (m, 3H, aromatic) 
 
GC/MS : m/z 97 (100%), m/z 125 (90%), m/z 195 (25%), m/z 292 (M+, 
10%). 
 
S
N
N
F
S
N
N
Cl
Experimental 
 118
Elemental analysis: for C15H17ClN2S.0.2H2O  calcd. C 60.89, H 5.75, N 9.47 ; 
found C 60.58; H 5.39; N 9.22. 
 
 
1-(2,3-Dichlorophenyl)-4-thiophen-2-ylmethylpiperazine (31d) 
 
 
 
Yield: 1.2g, 70%, brown crystals 
 
m.p.: 64- 66 oC. 
 
1H-NMR (CDCl3): 
 
2.69 (brs, 4H, 2 X –CH2, piperazine), 3.08 (brs, 4H, 2 X –
CH2, piperazine), 3.81 (s, 2H, -CH2), 6.94-6.97 (m, 3H, 
aromatic), 7.13- 7.26 (m, 3H, aromatic)  
 
GC/MS : m/z 97 (100%), m/z 125 (30%), m/z 174 (10%), m/z 326 
(M+, 5%). 
 
Elemental analysis: for C15H16Cl2N2S.0.7H2O   calcd. C 53.16, H 4.72, N 8.26 
; found C 52.83; H 4.64; N 8.15. 
 
1-(2-Ethoxyphenyl)-4-thiophen-2-ylmethylpiperazine (31e) 
 
 
 
 
 
 
 
Yield: 1.1g, 72%, brown crystals. 
 
m.p.: 105-107 oC. 
 
1H-NMR (CDCl3): 
 
1.40 (t, 3H, J= 7Hz, -OCH2CH3), 2.73 (brs, 4H, 2 X –CH2, 
piperazine), 3.15 (brs, 4H, 2 X –CH2, piperazine), 3.81 (s, 2H, 
-CH2), 4.05 (q, 2H, J= 7Hz, 2H, -OCH2CH3), 6.82- 7.26 (m, 7H, 
aromatic) 
 
GC/MS   : m/z 97 (100%), m/z 120 (65%), m/z 150 (60%), m/z 302 (M+, 
10%). 
 
S
N
N
Cl
Cl
S
N N
H3CH2CO
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Elemental analysis: for C17H22N2OS.0.95H2O calcd. C 63.92, H 6.89, N 8.77 ; found 
C 63.53; H 7.18; N 8.97. 
 
 
2-(4-Thiophen-2-ylmethylpiperazin-1-yl)phenol (31f) 
 
 
 
Yield: 0.8g, 63%, brown crystals 
 
m.p.: 99-101 oC. 
 
1H-NMR (CDCl3): 
 
2.63 (brs, 4H, 2 X –CH2, piperazine), 3.08 (brs, 4H, 2 X –
CH2, piperazine), 4.28 (s, 2H, -CH2), 6.72- 7.02 (m, 7H, 
aromatic). Phenolic proton signal was not shown.  
  
 
IR (cm-1):  
 
3235 (OH) 
GC/MS : m/z 97 (100%), m/z 120 (70%), m/z 274 (M+, 15%). 
 
Elemental analysis: for C15H18N2OS calcd. C 65.66, H 6.03, N 10.21 ; found 
C 65.93; H 6.15; N 9.98. 
 
 
1-(4-Fluorophenyl)-4-thiophen-2-ylmethylpiperazine (31g) 
 
 
 
Yield: 1g, 74%, brown crystals. 
 
m.p.: 73-75 oC. 
 
1H-NMR (CDCl3): 
 
2.65 (t, 4H, J= 4.85Hz, 2 X –CH2, piperazine), 3.12 (t, 
4H, J= 4.85Hz, 2 X –CH2, piperazine), 3.78 (s, 2H, 
-CH2), 6.83- 6.25 (m, 7H, aromatic) 
 
S
N
N
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IR (cm-1):  
 
1210 (C-F) 
GC/MS : m/z 97 (100%), m/z 125 (40%), m/z 179 (15%), m/z 
276 (M+, 15%). 
 
Elemental analysis: for C15H17FN2S.0.7H2O   calcd. C 62.29, H 5.89, N 
9.70 ; found C 62.18; H 5.85; N 9.29. 
 
1-(4-Chlorophenyl)-4-thiophen-2-ylmethylpiperazine (31h) 
 
 
 
 
 
 
Yield: 0.9g, 67%, brown crystals. 
 
m.p.: 76-78 oC. 
 
1H-NMR (CDCl3): 
 
2.64 (t, 4H, J= 5Hz, 2 X –CH2, piperazine), 3.17 (t, 
4H, J= 5Hz, 2 X –CH2, piperazine), 3.78 (s, 2H, 
-CH2), 6.89 (d, 2H, J= 7Hz, aromatic), 6.96 (d, 2H, J= 
7Hz, aromatic), 7.16- 7.25 (m, 3H, aromatic)   
 
GC/MS : m/z 97 (100%), m/z 125 (90%), m/z 195 (55%), m/z 
292 (M+, 40%). 
 
Elemental analysis: for C15H17ClN2S.0.2H2O   calcd. C 60.89, H 5.75, N 
9.47 ; found C 60.82; H 6.26; N 9.46. 
 
 
1-(3,4-Dichlorophenyl)-4-thiophen-2-ylmethylpiperazine (31i) 
 
 
 
Yield: 0.9g, 61%, brown crystals. 
 
m.p.: 67-69 oC. 
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1H-NMR (CDCl3): 
 
2.64 (t, 4H, J= 5Hz, 2 X –CH2, piperazine), 3.19 (t, 
4H, J= 5Hz, 2 X –CH2, piperazine), 3.67 (s, 2H, 
-CH2), 6.72 (dd, 1H, aromatic), 6.93- 6.98 (m, 3H, 
aromatic), 7.24- 7.27 (m, 2H, aromatic)  
  
GC/MS : m/z 97 (100%), m/z 125 (70%), m/z 172 (30%), m/z 
326 (M+, 10%). 
 
Elemental analysis: for C15H16Cl2N2S.0.2H2O   calcd. C 54.61, H 4.85, N 
8.49 ; found C 54.42; H 5.04; N 8.05. 
 
 
4-(4-Thiophen-2-ylmethylpiperazin-1-yl)phenol (31j) 
 
 
 
 
 
 
 
Yield: 0.9g, 68%, brown crystals 
 
m.p.: 101- 103 oC. 
 
1H-NMR (CDCl3): 
 
2.64 (brs, 4H, 2 X –CH2, piperazine), 3.09 (brs, 4H, 2 X –
CH2, piperazine), 4.30 (s, 2H, -CH2), 6.71-6.96 (m, 7H, 
aromatic). Phenolic proton signal was not shown.  
  
 
IR (cm-1):  
 
3200 (OH)  
GC/MS : m/z 97 (100%), m/z 120 (40%), m/z 274 (M+, 15%). 
 
Elemental analysis: for C15H18N2OS calcd. C 65.66, H 6.03, N 10.21 ; found 
C 65.86; H 6.23; N 9.94. 
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1-(2-Ethoxyphenyl)-4-pyridin-3-ylmethylpiperazine (32a) 
 
 
 
 
 
 
 
Yield: 1.3g, 85%, yellow crystals 
 
m.p. 82- 84 oC 
1H-NMR (CDCl3): 
 
1.44 (t, 3H, J= 6.75Hz, -OCH2CH3), 2.68 (t, 4H, 2 X –
CH2, piperazine), 3.13 (brs, 4H, 2 X –CH2, piperazine), 
3.62 (s, 2H, -CH2), 4.05 (q, 2H, J= 6.75Hz, 2H, -
OCH2CH3), 6.82- 6.99 (m, 4H, aromatic), 7.25- 7.30 
(m, 1H, aromatic), 7.75 (d, 1H, J= 7.75, aromatic), 8.52 
(d, 1H, J= 3.5, aromatic). 
 
GC/MS : m/z 92 (85%), m/z 120 (100%), m/z 150 (60%), m/z 
297 (M+, 10%). 
Elemental analysis: for C18H23N3O calcd. C 72.70, H 7.80, N 14.13 ; found 
C 72.28; H 8.26; N 13.76. 
 
 
1-(2,3-Dichlorophenyl)-4-pyridin-3-ylmethylpiperazine (32b) 
 
 
 
 
 
 
 
Yield: 1.3g, 83%, yellowish white crystals  
 
m.p. 78- 80 oC 
1H-NMR (CDCl3): 
 
2.75 (t, 4H, J= 4.5, 2 X –CH2, piperazine), 3.16 (t, 4H, 
J= 4.5, 2 X –CH2, piperazine), 3.69 (s, 2H, -CH2), 7.01- 
7.56 (m, 4H, aromatic), 7.81 (d, 1H, J= 7.75, aromatic), 
8.62 (d, 2H, J= 4, aromatic). 
 
GC/MS : m/z 92 (90%), m/z 120 (100%), m/z 174 (30%), m/z 
321 (M+, 10%). 
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Elemental analysis: for C16H17Cl2N3 calcd. C 59.64, H 5.32, N 13.04 ; found 
C 59.33; H 5.70; N 13.04. 
 
1-(2-Ethoxyphenyl)-4-naphthalen-1-ylmethylpiperazine (33a) 
 
 
 
 
 
 
 
Yield: 1.4g, 84%, yellow crystals  
 
m.p. 90-92oC 
1H-NMR (CDCl3): 
 
1.47 (t, 3H, J= 7Hz, -OCH2CH3), 2.74 (t, 4H, 2 X –CH2, 
piperazine), 3.12 (brs, 4H, 2 X –CH2, piperazine), 4.01 
(s, 2H, -CH2), 4.08 (q, 2H, J= 7Hz, 2H, -OCH2CH3), 
6.83- 7.01 (m, 4H, aromatic), 7.40- 7.57 (m, 4H, 
aromatic), 7.82- 8.35 (m, 3H, aromatic). 
 
GC/MS : m/z 65 (20%), m/z 115 (45%), m/z 141 (100%), m/z 
346 (M+, 5%). 
 
Elemental analysis: for C23H26N2O calcd. C 79.73, H 7.56, N 8.09 ; found C 
79.20; H 7.98; N 8.23. 
 
 
1-(2,3-Dichlorophenyl)-4-naphthalen-1-ylmethylpiperazine (33b) 
 
 
 
 
 
 
 
Yield: 1.5g, 81%, yellow crystals  
 
m.p. 83-85 oC 
1H-NMR (CDCl3): 
 
2.72 (brs, 4H, 2 X –CH2, piperazine), 3.05 (brs, 4H, 2 X 
–CH2, piperazine), 4.03 (s, 2H, -CH2), 6.91- 7.14 (m, 
3H, aromatic), 7.39- 7.56 (m, 4H, aromatic), 7.78- 8.34 
(m, 3H, aromatic). 
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GC/MS : m/z 115 (95%), m/z 141 (100%), m/z 370 (M+, 5%). 
Elemental analysis: for C21H20Cl2N2 calcd. C 67.93, H 5.43, N 7.54 ; found 
C 67.46; H 5.87; N 7.68. 
 
 
1-Benzo[b]thiophen-3-ylmethyl-4-(2-ethoxyphenyl)piperazine (34a)(128) 
 
 
 
 
 
 
Yield: 1.3g, 77%, yellow resin  
 
1H-NMR (CDCl3): 
 
1.46 (t, 3H, J= 7Hz, -OCH2CH3), 2.73 (brs, 4H, 2 X –
CH2, piperazine), 2.74 (brs, 4H, 2 X –CH2, piperazine), 
3.83 (s, 2H, -CH2), 4.07 (q, 2H, J= 7Hz, 2H, -
OCH2CH3), 6.83- 8.03 (m, 9H, aromatic). 
 
GC/MS : m/z 122 (100%), m/z 210 (30%), m/z 352 (M+, 15%). 
 
Elemental analysis: for C21H24N2 OS calcd. C 71.55, H 6.86, N 7.95 ; found 
C 71.08; H 6.68; N 7.72. 
 
 
1-Benzo[b]thiophen-3-ylmethyl-4-(2,3-dichlorophenyl)-piperazine 
(34b)(128) 
 
 
 
 
 
 
Yield: 1.5g, 79%, pale yellow crystals  
 
m.p. 98- 100 OC 
1H-NMR (CDCl3): 
 
2.71 (brs, 4H, 2 X –CH2, piperazine), 3.07 (brs, 4H, 2 X 
–CH2, piperazine), 3.84 (s, 2H, -CH2), 6.92- 7.86 (m, 
9H, aromatic). 
 
GC/MS : m/z 122 (100%), m/z 237 (20%), m/z 377 (M+, 10%). 
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Elemental analysis: for C19H18Cl2N2S calcd. C 60.48, H 4.81, N 7.42 ; 
found C 60.22; H 4.88; N 7.43. 
 
1-Benzyl-4-(2-ethoxyphenyl)piperazine (35a) 
 
 
 
 
 
 
 
 
Yield: 1.1g, 77%, yellow resin. 
 
1H-NMR (CDCl3): 
 
1.40 (t, 3H, J= 7Hz, -OCH2CH3), 2.67 (t, 4H, 2 X –CH2, 
piperazine), 3.13 (brs, 4H, 2 X –CH2, piperazine), 3.59 
(s, 2H, -CH2), 4.02 (q, 2H, J= 7Hz, 2H, -OCH2CH3), 
6.83- 7.00 (m, 4H, aromatic), 7.26- 7.36 (m, 5H, 
aromatic) 
 
GC/MS : m/z 91 (100%), m/z 150 (90%), m/z 296 (M+, 20%) 
 
Elemental analysis: for C19H24N2O calcd. C 76.99, H 8.16, N 9.45 ; found C 
76.58; H 8.15; N 9.38. 
 
1-Benzyl-4-(2,3-dichlorophenyl)piperazine (35b) 
 
 
 
 
 
 
 
 
Yield: 1.2g, 74%, pale yellow crystals  
 
m.p. 107-109 OC 
1H-NMR (CDCl3): 
 
2.67 (t, 4H, J= 4.75Hz, 2 X –CH2, piperazine), 3.07 (t, 
4H, J= 4.75Hz, 2 X –CH2, piperazine), 3.59 (s, 2H, 
-CH2), 6.97 (dd, 1H, J= 3.5Hz, 7Hz, aromatic), 7.15 (d, 
2H, J= 7Hz, aromatic), 7.26- 7.36 (m, 5H, aromatic) 
 
GC/MS : m/z 91 (100%), m/z 174 (10%), m/z 320 (M+, 5%) 
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Elemental analysis: for C17H18Cl2N2 calcd. C 63.56, H 5.65, N 8.72 ; found 
C 63.62; H 5.81; N 9.06. 
 
 
Procedure for the preparation of 3-[4-Phenylpiperazin-1-ylmethyl]-1H-
indole derivatives 
 
Indole (1.2g, 10 mmol) together with 10 mmol of the corresponding phenyl 
piperazine free base and 10g (300 mmol) of HCHO 37% were mixed with 5 ml 
glacial acetic acid at 0 OC for 1 hour. The mixture was then alkalinized with 
5M NaOH and extracted twice with 30 ml diethyl ether. The combined organic 
layers were dried over anhydrous Na2SO4 and evaporated under reduced 
pressure. The crude residue was then subjected to Silica gel column 
chromatography eluting with Methylene chloride: Methanol 9.5: 0.5. 
3-[4-(2-Ethoxyphenyl)-piperazin-1-ylmethyl]-1H-indole (36a) 
 
 
 
 
 
 
 
Yield: 2.2g, 66%, yellowish brown crystals  
 
m.p. 52- 54oC 
1H-NMR (CDCl3): 
 
1.36 (t, 3H, J= 7Hz, -OCH2CH3), 3.15 (brs, 4H, 2 X –
CH2, piperazine), 3.23 (brs, 4H, 2 X –CH2, piperazine), 
3.98 (q, 2H, J= 7Hz, 2H, -OCH2CH3), 4.41 (s, 2H, 
-CH2), 6.77- 6.96 (m, 4H, aromatic), 7.09- 7.16 (m, 2H, 
aromatic), 7.26- 7.56 (m, 3H, aromatic), 8.78 (s, 1H, 
NH). 
 
GC/MS : m/z 77 (60%), m/z 120 (100%), m/z 164 (70%), m/z 
206 (40%), m/z 335 (M+, 2%). 
Elemental analysis: for C21H25N3O calcd. C 75.19, H 7.51, N 12.53 ; found 
C 74.53; H 7.90; N 12.94. 
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3-[4-(2,3-Dichlorophenyl)-piperazin-1-ylmethyl]-1H-indole (36b) 
 
 
 
 
 
 
 
Yield: 2.1g, 58%, yellowish white crystals  
 
m.p. 49-51 oC 
1H-NMR (CDCl3): 
 
2.06 (brs, 4H, 2 X –CH2, piperazine), 2.28 (brs, 4H, 2 X 
–CH2, piperazine), 3.84 (s, 2H, -CH2), 6.93- 7.79 (m, 
8H, aromatic), 8.24 (brs, 1H, NH). 
 
GC/MS : m/z 77 (40%), m/z 120 (100%), m/z 231 (80%), m/z 
206 (40%), m/z 360 (M+, 1%). 
Elemental analysis: for C19H19Cl2N3 calcd. C 63.34, H 5.32, N 11.66 ; found 
C 63.93; H 5.65; N 12.01. 
 
 
Procedure for the preparation of 2-(3-Chloropropyl)-isoindole-1,3-dione 
(46) 
 
A mixture of 1.48g (10 mmol) of Phthalic anhydride and 1.43g (11 mmol) of 3-
Chloropropylamine hdrochloride salt was heated in an oil bath at 160 oC till 
fusion occurred. The fused mixture was maintained at the same temperature 
for 15 minutes. The reaction mixture was cooled to room temperature and 30 
ml water was added just before solidification to form slurry. The product was 
filtered, washed twice with water and purified on Silica gel column 
chromatography eluting with Methylene chloride. The yield and Spectroscopy 
data of the intermediate matched data found in literature (142). 
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General procedure for the preparation of 2-[3-(4-Arylpiperazin-1-yl)-
propyl]isoindole-1,3-dione derivatives  
 
To a solution of 1.0g (4.5 mmol) of (46) in 40 ml dry acetonitrile, were added 
4.5 mmol of the corresponding phenyl piperazine and 1.5g (15 mmol) of TEA. 
The reaction mixture was allowed to reflux under innert atmosphere for 48 
hours and then left to cool to room temperature. The organic solvent was 
removed under reduced pressure and the remained residue was subjected to 
purification on Silica gel column chromatography eluting with Methylene 
chloride: Methanol 100: 2. 
2-{3-[4-(2-Ethoxyphenyl)piperazin-1-yl]propyl}isoindole-1,3-dione (40a) 
 
 
 
 
 
 
 
Yield: 1.3g, 71%,  yellow crystals  
 
m.p. 109- 111 oC 
1H-NMR (CDCl3): 
 
1.43 (t, 3H, J= 7 Hz, -OCH2CH3), 1.89- 1.95 (m, 2H, 
CH2, C2, propyl), 2.50 (t, 2H, J= 6.9 Hz, CH2, C3, 
propyl), 2.59 (brs, 4H, 2 X –CH2, piperazine), 2.96 (brs, 
4H, 2 X –CH2, piperazine), 3.79 (t, 2H, J= 6.9 Hz, CH2, 
C1, propyl), 4.05 (q, 2H, J= 7Hz, -OCH2CH3), 6.78- 
6.96 (m, 4H, aromatic), 7.68- 7.82 (m, 4H, aromatic)  
 
IR (cm-1):  
 
1708, 1737 (2 X C=O) 
GC/MS : m/z 77 (10%), m/z 104 (5%), m/z 130 (10%), m/z 191 
(60%), m/z 219 (90%), m/z 378 (40%), m/z 393 (M+, 
100%) 
 
Elemental analysis: for C23H27N3O2 calcd. C 70.21, H 6.92, N 10.68 ; found 
C 69.74; H 7.08; N 10.89. 
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2-{3-[4-(2,3-Dichlorophenyl)piperazin-1-yl]propyl}isoindole-1,3-dione 
(40b)(142) 
 
 
 
 
 
 
 
Yield: 1.3g, 70%,  yellowish white crystals  
 
m.p. 103- 105 oC 
1H-NMR (CDCl3): 
 
1.88- 1.96 (m, 2H, CH2, C2, propyl), 2.51 (t, 2H, J= 6.9 
Hz, CH2, C3, propyl), 2.57 (brs, 4H, 2 X –CH2, 
piperazine), 2.90 (brs, 4H, 2 X –CH2, piperazine), 3.80 
(t, 2H, J= 6.9 Hz, CH2, C1, propyl), 6.80- 7.15 (m, 3H, 
aromatic), 7.70 (dd, 2H, J= 3, 5.5 Hz, aromatic), 7.85 
(dd, 2H, J= 3, 5.5 Hz, aromatic)  
 
IR (cm-1):  
 
1711, 1766 (2 X C=O) 
GC/MS : m/z 77 (20%), m/z 104 (100%), m/z 130 (40%), m/z 
174 (10%), m/z 243 (80%), m/z 269 (20%), m/z 417 
(M+, 90%), m/z 419 (M++2, 55%), m/z 421 (M++4, 20%)
 
Elemental analysis: for C21H21Cl2N3O2 calcd. C 60.30, H 5.06, N 10.05 ; 
found C 60.44; H 4.90; N 9.98. 
 
 
2-{3-[4-(2-Fluorophenyl)piperazin-1-yl]propyl}isoindole-1,3-dione (40c) 
 
 
 
 
 
 
 
Yield: 1.2g, 71%, yellow crystals  
 
m.p. 96-98 oC 
1H-NMR (CDCl3): 
 
1.84- 1.95 (m, 2H, CH2, C2, propyl), 2.48 (t, 2H, J= 6.8 
Hz, CH2, C3, propyl), 2.56 (t, 4H, J= 4.8 Hz, 2 X –CH2, 
piperazine), 2.94 (t, 4H, J= 4.8 Hz, 2 X –CH2, 
piperazine), 3.79 (t, 2H, J= 6.8 Hz, CH2, C1, propyl), 
6.79- 7.05 (m, 4H, aromatic), 7.67- 7.72 (m, 4H, 
aromatic), 7.67- 7.72 (m, 4H, aromatic) 
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IR (cm-1):  
 
1709, 1765 (2 X C=O), 1200 (C-F) 
GC/MS : m/z 77 (80%), m/z 104 (100%), m/z 130 (20%), m/z 
193 (60%), m/z 352 (10%), m/z 368 (M+, 30%) 
 
Elemental analysis: for C21H22FN3O2 calcd. C 68.65, H 6.04, N 11.44 ; 
found C 69.02; H 6.11; N 11.41. 
 
2-{3-[4-(2-Chlorophenyl)piperazin-1-yl]propyl}isoindole-1,3-dione (40d) 
 
 
 
 
 
 
 
Yield: 1.1g, 66%, yellow crystals  
 
m.p. 127-129 oC 
1H-NMR (CDCl3): 
 
1.84- 1.95 (m, 2H, CH2, C2, propyl), 2.49 (t, 2H, J= 
6.85 Hz, CH2, C3, propyl), 2.56 (brs, 4H, 2 X –CH2, 
piperazine), 2.89 (brs, 4H, 2 X –CH2, piperazine), 3.79 
(t, 2H, J= 6.85 Hz, CH2, C1, propyl), 6.87- 7.20 (m, 4H, 
aromatic), 7.26- 7.72 (m, 4H, aromatic) 
 
IR (cm-1):  
 
1714, 1779 (2 X C=O) 
GC/MS : m/z 77 (35%), m/z 104 (100%), m/z 130 (20%), m/z 
209 (85%), m/z 348 (20%), m/z 383 (M+, 35%), m/z 
385 (M++2, 10%) 
 
Elemental analysis: for C21H22ClN3O2 calcd. C 65.71, H 5.78, N 10.95 ; 
found C 65.32; H 5.41; N 10.76. 
 
 
2-{3-[4-(2-Hydroxyphenyl)piperazin-1-yl]propyl}isoindole-1,3-dione (40e) 
 
 
 
 
 
 
 
Yield: 1.0g, 60%,  yellow crystals  
 
m.p. 135- 137 oC 
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1H-NMR (CDCl3): 
 
1.88- 1.93 (m, 2H, CH2, C2, propyl), 2.49 (t, 2H, J= 6.7 
Hz, CH2, C3, propyl), 2.53 (brs, 4H, 2 X  –CH2, 
piperazine), 2.70 (brs, 4H, 2 X –CH2, piperazine), 3.81 
(t, 2H, J= 6.7 Hz, CH2, C1, propyl), 6.81- 7.04 (m, 4H, 
aromatic), 7.74 (dd, 2H, J= 3, 5.4 Hz, aromatic), 7.87 
(dd, 2H, J= 3, 5.4 Hz, aromatic). Phenolic proton signal 
was not shown.  
 
IR (cm-1):  
 
3220 (-OH), 1712, 1769 (2 X C=O) 
GC/MS : m/z 77 (20%), m/z 104 (10%), m/z 163 (100%), m/z 
217 (95%), m/z 230 (40%), m/z 350 (30%), m/z 365 
(M+, 20%) 
 
Elemental analysis: for C21H23N3O3 calcd. C 69.02, H 6.34, N 11.50 ; found 
C 68.78; H 6.32; N 11.24. 
 
 
2-{3-[4-(4-Fluorophenyl)piperazin-1-yl]propyl}isoindole-1,3-dione (40f) 
 
 
 
 
 
 
Yield: 1.2g, 72%, brown crystals  
 
m.p. 103-105 oC 
 
1H-NMR (CDCl3): 
 
1.76- 1.95 (m, 2H, CH2, C2, propyl), 2.47 (t, 2H, J= 6.9 
Hz, CH2, C3, propyl), 2.53 (t, 4H, J= 4.8 Hz, 2 X –CH2, 
piperazine), 2.95 (t, 4H, J= 4.8 Hz, 2 X –CH2, 
piperazine), 3.79 (t, 2H, J= 6.9 Hz, CH2, C1, propyl), 
6.76- 6.96 (m, 4H, aromatic), 7.68 (dd, 2H, J= 3, 5.5 
Hz Aromatic), 7.83 (dd, 2H, J= 3, 5.5 Hz Aromatic) 
  
 
IR (cm-1):  
 
1707, 1758 (2 X C=O), 1214 (C-F) 
GC/MS : m/z 77 (90%), m/z 104 (100%), m/z 130 (50%), m/z 
193 (30%), m/z 352 (15%), m/z 368 (M+, 35%) 
 
Elemental analysis: for C21H22FN3O2 calcd. C 68.65, H 6.04, N 11.44 ; 
found C 68.70; H 5.80; N 11.07. 
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2-{3-[4-(4-Chlorophenyl)piperazin-1-yl]propyl}isoindole-1,3-dione (40g) 
 
 
 
 
 
 
 
Yield: 1.3g, 72%, pale yellow crystals  
 
m.p. 
 
119-121 oC 
1H-NMR (CDCl3): 
 
1.84- 1.95 (m, 2H, CH2, C2, propyl), 2.46 (t, 2H, J= 7 
Hz, CH2, C3, propyl), 2.52 (t, 4H, J= 5.1 Hz, 2 X –CH2, 
piperazine), 2.98 (t, 4H, J= 5.1 Hz, 2 X –CH2, 
piperazine), 3.79 (t, 2H, J= 7 Hz, CH2, C1, propyl), 
6.75 (d, 2H, J= 4.7 Hz, aromatic), 7.16 (d, 2H, J= 4.7 
Hz Aromatic), 7.66- 7.84 (m, 4H, aromatic) 
 
IR (cm-1):  
 
1701, 1774 (2 X C=O) 
GC/MS : m/z 77 (40%), m/z 104 (100%), m/z 130 (10%), m/z 
209 (90%), m/z 348 (15%), m/z 383 (M+, 50%), m/z 
385 (M++2, 15%) 
 
Elemental analysis: for C21H22ClN3O2 calcd. C 65.71, H 5.78, N 10.95 ; 
found C 65.83; H 5.68; N 11.37. 
 
 
2-{3-[4-(3,4-Dichlorophenyl)piperazin-1-yl]propyl}isoindole-1,3-dione 
(40h) 
 
 
 
 
 
 
 
Yield: 1.3g, 67%,  yellow crystals  
 
m.p. 88- 90 oC 
1H-NMR (CDCl3): 
 
1.83- 1.94 (m, 2H, CH2, C2, propyl), 2.46 (t, 2H, J= 6.8 
Hz, CH2, C3, propyl), 2.51 (t, 4H, J= 5.2 Hz, 2 X –CH2, 
piperazine), 2.99 (t, 4H, J= 5.2 Hz, 2 X –CH2, 
piperazine), 3.79 (t, 2H, J= 6.8 Hz, CH2, C1, propyl), 
6.67 (dd, 1H, J= 2.85, 9 Hz, aromatic), 6.85 (d, 1H, J= 
2.85 Hz, aromatic), 7.23 (d, 1H, J= 9 Hz, aromatic), 
7.67- 7.83 (m, 4H, aromatic) 
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IR (cm-1):  
 
1713, 1760 (2 X C=O) 
GC/MS : m/z 77 (50%), m/z 104 (100%), m/z 130 (10%), m/z 
174 (20%), m/z 243 (90%), m/z 269 (15%), m/z 417 
(M+, 90%), m/z 419 (M++2, 55%), m/z 421 (M++4, 20%)
 
Elemental analysis: for C21H21Cl2N3O2 calcd. C 60.30, H 5.06, N 10.05 ; 
found C 60.20; H 4.95; N 9.99. 
 
2-{3-[4-(4-Hydroxyphenyl)piperazin-1-yl]propyl}isoindole-1,3-dione (40i) 
 
 
 
 
 
 
 
Yield: 1.0g, 62%,  brown crystals  
 
m.p. 145- 147 oC 
 
1H-NMR (CDCl3): 
 
1.85- 1.96 (m, 2H, CH2, C2, propyl), 2.51 (t, 2H, J= 6.9 
Hz, CH2, C3, propyl), 2.55 (t, 4H, J= 4.7 Hz, 2 X –CH2, 
piperazine), 2.90 (t, 4H, J= 6.7 Hz, 2 X –CH2, 
piperazine), 3.78 (t, 2H, J= 6.9 Hz, CH2, C1, propyl), 
6.69- 7.77 (m, 4H, aromatic), 7.69 (dd, 2H, J= 3, 5.5 
Hz, aromatic), 7.83 (dd, 2H, J= 3, 5.5 Hz, aromatic). 
Phenolic proton signal was not shown.  
  
 
IR (cm-1):  
 
3209 (-OH), 1704, 1759 (2 X C=O) 
 
GC/MS : m/z 77 (20%), m/z 104 (10%), m/z 163 (100%), m/z 
217 (80%), m/z 230 (50%), m/z 350 (40%), m/z 365 
(M+, 25%) 
 
Elemental analysis: for C21H23N3O3 calcd. C 69.02, H 6.34, N 11.50 ; found 
C 68.71; H 6.24; N 11.62. 
 
2-[3-(4-Phenyl piperazin-1-yl)propyl]isoindole-1,3-dione (40j) 
 
 
 
 
 
 
 
Yield: 1.2g, 76%, yellow crystals  
 
m.p. 105-107 oC 
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1H-NMR (CDCl3): 
 
1.86- 1.97 (m, 2H, CH2, C2, propyl), 2.50 (t, 2H, J= 7 
Hz, CH2, C3, propyl), 2.56 (t, 4H, J= 5 Hz, 2 X –CH2, 
piperazine), 3.06 (t, 4H, J= 5 Hz, 2 X –CH2, 
piperazine), 3.80 (t, 2H, J= 7 Hz, CH2, C1, propyl), 
6.80- 7.26 (m, 5H, aromatic), 7.68 (dd, 2H, J= 3, 5.4 
Hz, aromatic), 7.84 (dd, 2H, J= 3, 5.4 Hz, aromatic) 
 
IR (cm-1):  
 
1703, 1760 (2 X C=O) 
GC/MS : m/z 77 (95%), m/z 104 (100%), m/z 130 (50%), m/z 
160 (60%), m/z 175 (30%), m/z 349 (M+, 10%) 
 
Elemental analysis: for C21H23N3O2 calcd. C 72.18, H 6.63, N 12.03 ; found 
C 72.09; H 6.67; N 11.98. 
 
 
General procedure for the preparation of 3-(4-Arylpiperazin-1-yl) 
propylamine derivatives (48a-j) 
 
A solution of 2 mmol of the corresponding isoindole-1,3-dione derivative and 
0.25g (6 mmol) hydrazine hydrate 80% in 20 ml ethanol was heated to reflux 
for 5 hours. After cooling to room temperature, any insoluble material was 
filtered off, washed with ethanol (2 X 20 ml) and the filterate was evaporated 
under reduced pressure. The product was extracted with chloroform (2 X 30 
ml) and the desired amine obtained was introduced to the following reaction 
without further purification. 
Procedure for the preparation of Thiophene-2-carbonyl chloride (50) 
 
 
 
 
To a 100-ml round bottom flask containing 0.5g (4 mmol) of thiophene-2-
carboxylic acid was added slowly and with continuous stirring 10g (85 mmol) 
of thionyl chloride. After complete addition, the reaction mixture was allowed 
to reflux for 6 hours. The flask was then cooled to room temperature, 50 ml of 
water was added, and the desired organic product was extracted with 
S
Cl
O
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Methylene chloride (2X50 ml). The organic layers were collected and dried 
over anhydrous Na2SO4 and evaporated under reduced pressure. The final 
product was retrieved in a form of brownish black oil and was used for the 
further reaction without extra purification.  
General procedure for the preparation of Arylamidopropylphenyl- 
piperazin derivatives  
A solution of 2 mmol of thiophene-2-carbonyl chloride (0.30g) or benzoyl 
chloride (0.28g) in 10 ml dry THF was added slowly to a solution of the 
corresponding amine derivative (2.3 mmol) and TEA (0.5g, 5 mmol) in dry 
THF (30 ml) at 0 oC. The mixture was then allowed to stir at room temperature 
for 5 hours. The reaction mixture was then poured into 30 ml water and 
extracted with Methylene chloride (2 X 40ml). The organic layers were 
collected and dried over anhydrous Na2SO4 and evaporated to yield a residue 
of the desired product that was purified on Silica gel column chromatography 
using Methylene chloride : Methanol 200 : 3 as mobile phase.  
N-{3-[4-(2-Ethoxyphenyl)piperazin-1-yl]propyl}benzamide (42a) 
 
 
 
 
 
 
 
 
Yield: 0.53g, 72%, yellow crystals 
 
m.p. 121- 123 oC 
1H-NMR (CDCl3): 
 
1.44 (t, 3H, J= 7 Hz, -OCH2CH3), 1.80- 1.87 (m, 2H, 
CH2, C2, propyl), 2.64 (t, 2H, J= 5.75 Hz, CH2, C3, 
propyl), 2.71 (brs, 4H, 2 X –CH2, piperazine), 3.11 (brs, 
4H, 2 X –CH2, piperazine), 3.59 (q, 2H, J= 5.5 Hz, 
CH2, C1, propyl), 4.06 (q, 2H, J= 7 Hz, -OCH2CH3), 
6.84- 6.99 (m, 4H, aromatic), 7.35- 7.50 (m, 3H, 
aromatic), 7.74- 7.83 (m, 2H, aromatic), 8.31 (brs, 1H, 
NH
N N
O
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-NH) 
 
IR (cm-1):  
 
1637 (C=O) 
GC/MS : m/z 77 (100%), m/z 105 (95%), m/z 120 (95%), m/z 
219 (20%), m/z  352 (15%), m/z 367 (M+, 10%) 
Elemental analysis: for C22H29N3O2 calcd. C 71.90, H 7.95, N 11.43 ; found 
C 71.38; H 7.74; N 10.81. 
 
N-{3-[4-(2,3-Dichlorophenyl)piperazin-1-yl]propyl}benzamide (42b)  
 
 
 
 
 
 
 
 
Yield: 0.6g, 78%, yellowish white crystals 
 
m.p. 112- 114 oC 
1H-NMR (CDCl3): 
 
1.81- 1.86 (m, 2H, CH2, C2, propyl), 2.65 (t, 2H, J= 
6.25 Hz, CH2, C3, propyl), 2.70 (brs, 4H, 2 X –CH2, 
piperazine), 3.04 (brs, 4H, 2 X –CH2, piperazine), 3.60 
(q, 2H, J= 5.75 Hz, CH2, C1, propyl), 6.86- 6.90 (m, 
1H, aromatic), 7.12- 7.20 (m, 2H, aromatic), 7.37- 7.51 
(m, 3H, aromatic), 7.81- 7.85 (m, 2H, aromatic), 8.11 
(brs, 1H, -NH) 
 
IR (cm-1):  
 
1640 (C=O) 
GC/MS : m/z 77 (80%), m/z 105 (100%), m/z 219 (30%), m/z  
375 (15%), m/z 392 (M+, 10%) 
Elemental analysis: for C20H23Cl2N3O calcd. C 61.23, H 5.91, N 10.71 ; 
found C 60.76; H 5.84; N 10.47. 
 
 
Thiophene-2-carboxylic acid {3-[4-(2-ethoxyphenyl)piperazin-1-yl]propyl} 
amide (44a) 
 
 
 
Yield: 0.5g, 68%, yellow resin 
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1H-NMR (CDCl3): 
 
1.45 (t, 3H, 7 Hz, -OCH2CH3), 1.76- 1.86 (m, 2H, CH2, 
C2, propyl), 2.62 (t, 2H, J= 6 Hz, CH2, C3, propyl), 
2.71 (brs, 4H, 2 X –CH2, piperazine), 3.17 (brs, 4H, 2 X 
–CH2, piperazine), 3.57 (q, 2H, J= 5.6 Hz, CH2, C1, 
propyl), 4.07 (q, 2H, J= 7 Hz, -OCH2CH3), 6.84- 7.04 
(m, 5H, aromatic), 7.41 (dd, 1H, J= 1.05, 5 Hz, 
aromatic), 7.56- 7.58 (m, 1H, aromatic), 7.79 (brs, 1H, 
-NH) 
 
IR (cm-1):  
 
1636 (C=O) 
GC/MS : m/z 77 (20%), m/z 111 (35%), m/z 168 (30%), m/z 219 
(70%), m/z  358 (100%), m/z 372 (M+, 50%) 
 
Elemental analysis: for C20H27N3O2S calcd. C 64.31, H 7.29, N 11.25 ; 
found C 64.72; H 7.25; N 11.25. 
 
 
Thiophene-2-carboxylic acid {3-[4-(2,3-dichlorophenyl)piperazin-1-yl]-
propyl}amide (44b) 
 
 
 
 
Yield: 0.52g, 65%, yellow resin 
 
1H-NMR (CDCl3): 
 
1.80- 1.87 (m, 2H, CH2, C2, propyl), 2.64 (t, 2H, J= 6 
Hz, CH2, C3, propyl), 2.71 (brs, 4H, 2 X –CH2, 
piperazine), 3.11 (t, 4H, J= 4.8 Hz, 2 X –CH2, 
piperazine), 3.58 (q, 2H, J= 5.6 Hz, CH2, C1, propyl), 
6.91- 6.95 (m, 1H, aromatic), 7.06 (dd, 1H, J= 3.6, 5 
Hz, aromatic), 7.12- 7.20 (m, 2H, aromatic), 7.43 (dd, 
1H, J= 1.15, 5 Hz, aromatic), 7.57 (dd, 1H, J= 1.15, 3.6 
Hz, aromatic), 7.85 (brs, 1H, -NH) 
 
IR (cm-1):  
 
1639 (C=O) 
GC/MS : m/z 77 (20%), m/z 111 (80%), m/z 168 (80%), m/z 197 
(100%), m/z  381 (20%), m/z 398 (M+, 10%) 
 
Elemental analysis: for C18H21Cl2N3OS calcd. C 54.27, H 5.31, N 10.55 ; 
found C 54.11; H 5.36; N 10.52. 
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Thiophene-2-carboxylic acid {3-[4-(2-fluorophenyl)piperazin-1-yl]propyl} 
amide (44c) 
 
 
 
Yield: 0.48g, 69%, brown resin  
 
1H-NMR (CDCl3): 
 
1.79- 1.84 (m, 2H, CH2, C2, propyl), 2.63 (t, 2H, J= 6 
Hz, CH2, C3, propyl), 2.70 (t, 4H, J= 4.8 Hz, 2 X –CH2, 
piperazine), 3.16 (t, 4H, J= 4.8 Hz, 2 X –CH2, 
piperazine), 3.57 (q, 2H, J= 5.5 Hz, CH2, C1, propyl), 
6.90- 7.06 (m, 5H, aromatic), 7.40- 7.56 (m, 2H, 
aromatic), 7.98 (brs, 1H, -NH) 
 
IR (cm-1):  
 
1643 (C=O), 1201 (C-F) 
GC/MS : m/z 77 (15%), m/z 111 (100%), m/z 122 (80%), m/z 
193 (40%), m/z  331 (40%), m/z 347 (M+, 10%) 
 
Elemental analysis: for C18H22FN3OS calcd. C 62.22, H 6.38, N 12.09 ; 
found C 62.47; H 6.29; N 12.07. 
 
 
Thiophene-2-carboxylic acid {3-[4-(2-chlorophenyl)piperazin-1-yl]propyl} 
amide (44d) 
 
 
 
Yield: 0.45g, 63%, yellow resin  
 
1H-NMR (CDCl3): 
 
1.78- 1.96 (m, 2H, CH2, C2, propyl), 2.60 (t, 2H, J= 6 
Hz, CH2, C3, propyl), 2.91 (brs, 4H, 2 X –CH2, 
piperazine), 3.25 (brs, 4H, 2 X –CH2, piperazine), 3.62 
(q, 2H, J= 5.5 Hz, CH2, C1, propyl), 6.99- 7.28 (m, 4H, 
aromatic), 7.35- 7.68 (m, 3H, aromatic), 8.09 (brs, 1H, 
-NH) 
 
IR (cm-1):  
 
1634 (C=O) 
GC/MS : m/z 77 (25%), m/z 111 (85%), m/z 168 (100%), m/z 
197 (95%), m/z  347 (40%), m/z 364 (M++2, 10%) 
 
Elemental analysis: for C18H22ClN3OS calcd. C 59.41, H 6.09, N 11.55 ; 
found C 59.56; H 6.04; N 11.52. 
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Thiophene-2-carboxylic acid {3-[4-(2-hydroxyphenyl)piperazin-1-
yl]propyl}amide (44e) 
 
 
 
Yield: 0.47g, 68%, yellow resin 
 
1H-NMR (CDCl3): 
 
1.78- 1.85 (m, 2H, CH2, C2, propyl), 2.63 (t, 2H, J= 6 
Hz, CH2, C3, propyl), 2.66 (brs, 4H, 2 X –CH2, 
piperazine), 2.97 (brs, 4H, 2 X –CH2, piperazine), 3.58 
(q, 2H, J= 5.5 Hz, CH2, C1, propyl),  6.88- 7.61 (m, 7H, 
aromatic), 7.95 (brs, 1H, -NH). Phenolic proton signal 
was not shown.  
 
 
IR (cm-1):  
 
3208 (-OH), 1647 (C=O) 
GC/MS : m/z 77 (15%), m/z 111 (75%), m/z 168 (80%), m/z 197 
(100%), m/z  330 (10%), m/z 345 (M+, 15%) 
 
Elemental analysis: for C18H23N3O2S calcd. C 62.58, H 6.71, N 12.16 ; 
found C 62.51; H 6.78; N 12.24. 
 
Thiophene-2-carboxylic acid {3-[4-(4-fluorophenyl)piperazin-1-yl]propyl} 
amide (44f) 
 
 
 
Yield: 0.48g, 70%, yellowish white crystals  
 
m.p. 103-105 oC 
1H-NMR (CDCl3): 
 
1.79- 1.86 (m, 2H, CH2, C2, propyl), 2.60 (t, 2H, J= 6 
Hz, CH2, C3, propyl), 2.66 (t, 4H, J= 5.1 Hz, 2 X –CH2, 
piperazine), 3.16 (t, 4H, J= 5.1 Hz, 2 X –CH2, 
piperazine), 3.57 (q, 2H, J= 5.6 Hz, CH2, C1, propyl), 
6.84- 7.03 (m, 5H, aromatic), 7.38- 7.53 (m, 2H, 
aromatic), 7.82 (brs, 1H, -NH) 
 
IR (cm-1):  
 
1648 (C=O), 1221 (C-F) 
GC/MS : m/z 77 (20%), m/z 111 (100%), m/z 122 (50%), m/z 
197 (90%), m/z  331 (60%), m/z 347 (M+, 20%) 
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Elemental analysis: for C18H22FN3OS calcd. C 62.22, H 6.38, N 12.09 ; 
found C 62.65; H 6.52; N 12.30. 
 
Thiophene-2-carboxylic acid {3-[4-(4-chlorophenyl)piperazin-1-yl]propyl} 
amide (44g) 
 
 
 
 
Yield: 0.54g, 74%, pale yellow crystals  
 
m.p. 144-146 oC 
1H-NMR (CDCl3): 
 
1.79- 1.86 (m, 2H, CH2, C2, propyl), 2.60 (t, 2H, J= 6 
Hz, CH2, C3, propyl), 2.66 (t, 4H, J= 5 Hz, 2 X –CH2, 
piperazine), 3.20 (t, 4H, J= 5 Hz, 2 X –CH2, 
piperazine), 3.57 (q, 2H, J= 5.7 Hz, CH2, C1, propyl), 
6.83 (d, 2H, J= 9 Hz, aromatic), 7.01 (dd, 1H, J= 3.7, 5 
Hz, aromatic), 7.21 (d, 2H, J= 9 Hz, aromatic), 7.38- 
7.52 (m, 2H, aromatic), 7.78 (brs, 1H, -NH) 
 
IR (cm-1):  
 
1641 (C=O) 
GC/MS : m/z 77 (20%), m/z 111 (55%), m/z 168 (70%), m/z 197 
(100%), m/z  347 (35%), m/z 362 (M+, 20%) 
 
Elemental analysis: for C18H22ClN3OS calcd. C 59.41, H 6.09, N 11.55 ; 
found C 59.45; H 6.21; N 11.62. 
 
Thiophene-2-carboxylic acid {3-[4-(3,4-dichlorophenyl)piperazin-1-yl]-
propyl}amide (44h) 
 
 
 
Yield: 0.58g, 73%, pale yellow crystals  
 
m.p. 107-109 oC 
 
1H-NMR (CDCl3): 
 
1.76- 1.86 (m, 2H, CH2, C2, propyl), 2.58 (t, 2H, J= 6 
Hz, CH2, C3, propyl), 2.64 (t, 4H, J= 5.2 Hz, 2 X –CH2, 
piperazine), 3.20 (t, 4H, J= 5.2 Hz, 2 X –CH2, 
piperazine), 3.56 (q, 2H, J= 5.7 Hz, CH2, C1, propyl), 
6.73 (dd, 1H, J= 2.8, 8.8 Hz, aromatic), 6.94 (d, 1H, J= 
2.8 Hz, aromatic), 7.02 (dd, 1H, J= 3.6, 5 Hz, 
aromatic), 7.28 (d, 1H, J= 8.8 Hz, aromatic), 7.40 (dd, 
S
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1H, J= 1, 5 Hz, aromatic), 7.52 (d,, J= 3.6 Hz, 
aromatic), 7.78  (brs, 1H, -NH) 
IR (cm-1):  
 
1649 (C=O) 
GC/MS : m/z 77 (20%), m/z 111 (55%), m/z 168 (70%), m/z 197 
(100%), m/z  381 (30%), m/z 398 (M+, 15%) 
 
Elemental analysis: for C18H21Cl2N3OS calcd. C 54.27, H 5.31, N 10.55 ; 
found C 54.20; H 5.29; N 10.57. 
 
 
Thiophene-2-carboxylic acid {3-[4-(4-hydroxyphenyl)piperazin-1-yl] 
propyl}amide (44i) 
 
 
 
Yield: 0.51g, 74%, creamy white crystals 
 
m.p. 156- 158 oC 
 
1H-NMR (CDCl3): 
 
1.77- 1.87 (m, 2H, CH2, C2, propyl), 2.70 (t, 2H, J= 6 
Hz, CH2, C3, propyl), 2.75 (t, 4H, J= 4.9 Hz, 2 X –CH2, 
piperazine), 3.23 (t, 4H, J= 4.9 Hz, 2 X –CH2, 
piperazine), 3.57 (q, 2H, J= 5.5 Hz, CH2, C1, propyl),  
6.97- 7.38 (m, 7H, aromatic), 8.01 (brs, 1H, -NH). 
Phenolic proton signal was not shown.  
 
 
IR (cm-1):  
 
3217, (-OH), 1639 (C=O) 
GC/MS : m/z 77 (20%), m/z 111 (35%), m/z 168 (40%), m/z 197 
(100%), m/z  330 (70%), m/z 345 (M+, 80%) 
 
Elemental analysis: for C18H23N3O2S calcd. C 62.58, H 6.71, N 12.16 ; 
found C 62.46; H 6.80; N 12.17. 
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Thiophene-2-carboxylic acid [3-(4-phenyl piperazin-1-yl)propyl]amide 
(44j) 
 
 
 
Yield: 0.5g, 76%, creamy white crystals  
 
m.p. 162-164 0C 
1H-NMR (CDCl3): 
 
1.77- 1.87 (m, 2H, CH2, C2, propyl), 2.61 (t, 2H, J= 6 
Hz, CH2, C3, propyl), 2.67 (t, 4H, J= 5 Hz, 2 X –CH2, 
piperazine), 3.25 (t, 4H, J= 5 Hz, 2 X –CH2, 
piperazine), 3.56 (q, 2H, J= 5.6 Hz, CH2, C1, propyl), 
6.85- 7.02 (m, 4H, aromatic), 7.25- 7.40 (m, 3H, 
aromatic), 7.55 (d, 1H, aromatic), 7.97 (brs, 1H, -NH) 
 
IR (cm-1):  
 
1635 (C=O) 
GC/MS : m/z 77 (95%), m/z 111 (100%), m/z 132 (40%), m/z 
175 (30%), m/z 197 (25%), m/z  314 (15%), m/z 329 
(M+, 10%) 
Elemental analysis: for C18H23N3OS calcd. C 65.62, H 7.04, N 12.75 ; 
found C 65.61; H 6.89; N 12.57. 
 
Procedure for the preparation of 2-(4-Bromobutyl) isoindole-1,3-dione 
(47) 
 
To 1.85g (10 mmol) of phthalimide potassium salt was added slowly over a 
period of 10 minutes to a solution of 2.41g (11 mmol) of 1,4 dibromobutane in 
60 ml of acetone. The reaction mixture was refluxed for 24 hours and was 
then hot filtered. The filtrate was evaporated under reduced pressure and the 
pale yellow oil produced was subjected to column chromatography on Silica 
gel eluting with Methylene chloride to get creamy white crystals of the desired 
product. The yield and spectroscopy data of the intermediate matched what 
found in literature (142).  
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General procedure for the preparation of 2-[4-(4-Aryl piperazin-1-
yl)butyl] isoindole-1,3-dione derivatives  
 
To a solution of 1.2g (4.5 mmol) of (47) in 40 ml dry acetonitrile, were added 
4.5 mmol of the corresponding phenylpiperazin and 1.5g (15 mmol) of TEA. 
The reaction mixture was allowed to reflux under innert atmosphere for 48 
hours and then left to cool to room temperature. The organic solvent was 
removed under reduced pressure and the remained residue was subjected to 
purification on Silica gel column chromatography eluting with Methylene 
chloride: Methanol 100: 2. 
2-{4-[4-(2-Ethoxyphenyl)piperazin-1-yl]butyl}isoindole-1,3-dione (41a) 
 
 
 
 
 
 
 
Yield: 1.2g, 68%, orange oil 
 
1H-NMR (CDCl3): 
 
1.45 (t, 3H, J= 7 Hz, -OCH2CH3), 1.64- 1.74 (m, 4H, 2 
X CH2, C2, C3, butyl), 2.45 (t, 2H, J= 7.2 Hz, CH2, C4, 
butyl), 2.64 (brs, 4H, 2 X CH2, piperazine), 3.11 (brs, 
4H, 2 X CH2, piperazine), 3.73  (t, 2H, J= 7.2 Hz, CH2, 
C1, butyl), 4.06 (q, 2H, J= 7 Hz, -OCH2CH3), 6.82- 
6.92 (m, 4H, aromatic), 7.71 (dd, 2H, J= 3, 5.5 Hz, 
aromatic), 7.84 (dd, 2H, J= 3, 5.5 Hz, aromatic) 
IR (cm-1):  
 
1705, 1741 (2 X C=O) 
GC/MS : m/z 70 (40%), m/z 104 (20%), m/z 130 (70%), m/z 160 
(100%), m/z 172 (30%), m/z 407 (M+, 15%) 
 
Elemental analysis: for C24H29N3O3 calcd. C 70.74, H 7.17, N 10.31 ; found 
C 71.03; H 7.42; N 9.96. 
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2-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}-isoindole-1,3-dione      
(41b) (142) 
 
 
 
 
 
 
Yield: 1.3g, 69%, yellow crystals 
 
m.p. 119- 121 oC 
 
1H-NMR (CDCl3): 
 
1.57- 1.77 (m, 4H, 2 X CH2, C2, C3, butyl), 2.44 (t, 2H, 
J= 7 Hz, CH2, C4, butyl), 2.61 (brs, 4H, 2 X CH2, 
piperazine), 3.04 (brs, 4H, 2 X CH2, piperazine), 3.73  
(t, 2H, J= 7 Hz, CH2, C1, butyl), 6.92- 6.14 (m, 3H, 
aromatic), 7.69- 7.83 (m, 4H, aromatic) 
IR (cm-1):  
 
 
1710, 1744 (2 X C=O) 
GC/MS : m/z 70 (60%), m/z 104 (30%), m/z 130 (50%), m/z 160 
(100%), m/z 172 (30%), m/z 243 (50%), m/z 432 (M+, 
5%) 
 
Elemental analysis: for C22H23Cl2N3O2 calcd. C 61.12, H 5.36, N 9.72 ; 
found C 60.73; H 5.42; N 9.93. 
 
2-{4-[4-(2-Fluorophenyl)piperazin-1-yl]butyl} isoindole-1,3-dione (41c) 
 
 
 
 
 
Yield: 1.2g, 72%, yellowish white crystals 
 
m.p. 120- 122 oC 
1H-NMR (CDCl3): 
 
1.51- 1.79 (m, 4H, 2 X CH2, C2, C3, butyl), 2.43 (t, 2H, 
J= 7 Hz, CH2, C4, butyl), 2.61 (t, 4H, J= 4.7 Hz, 2 X 
CH2, piperazine), 3.09 (t, 4H, J= 4.7 Hz, 2 X CH2, 
piperazine), 3.73  (t, 2H, J= 7 Hz, CH2, C1, butyl), 
6.87- 6.07 (m, 4H, aromatic), 7.70 (dd, 2H, J= 3, 5.5 
Hz Aromatic), 7.81 (d, 2H, J= 4 Hz, aromatic) 
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IR (cm-1):  
 
1703, 1746 (2 X C=O), 1206 (C-F) 
GC/MS : m/z 70 (90%), m/z 104 (30%), m/z 122 (90%), m/z 160 
(100%), m/z 193 (80%), m/z 366 (5%), m/z 381 (M+, 
10%) 
 
Elemental analysis: for C22H24FN3O2 calcd. C 69.27, H 6.34, N 11.02 ; 
found C 69.43; H 6.03; N 10.95. 
 
 
2-{4-[4-(2-Chlorophenyl)piperazin-1-yl]butyl} isoindole-1,3-dione (41d) 
 
 
 
 
 
Yield: 1.3g, 74%, yellowish white crystals 
 
m.p. 141- 143 oC 
1H-NMR (CDCl3): 
 
1.57- 1.77 (m, 4H, 2 X CH2, C2, C3, butyl), 2.45 (t, 2H, 
J= 7.1 Hz, CH2, C4, butyl), 2.62 (brs, 4H, 2 X CH2, 
piperazine), 3.06 (brs, 4H, 2 X CH2, piperazine), 3.73  
(t, 2H, J= 7.1 Hz, CH2, C1, butyl), 6.92- 6.35 (m, 4H, 
aromatic), 7.71 (dd, 2H, J= 3, 5.5 Hz Aromatic), 7.83 
(d, 2H, J= 3 Hz, aromatic) 
IR (cm-1):  
 
1704, 1745 (2 X C=O) 
GC/MS : m/z 70 (50%), m/z 104 (30%), m/z 138 (50%), m/z 160 
(100%), m/z 209 (70%), m/z 382 (2%), m/z 397 (M+, 
5%) 
 
Elemental analysis: for C22H24ClN3O2 calcd. C 66.41, H 6.08, N 10.56 ; 
found C 66.20; H 6.02; N 10.43. 
 
2-{4-[4-(2-Hydroxyphenyl)piperazin-1-yl]butyl}isoindole-1,3-dione (41e) 
 
 
 
 
 
 
 
Yield: 1.0g, 63%, yellowish white crystals 
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m.p. 118- 120 oC 
 
1H-NMR (CDCl3): 
 
1.57- 1.75 (m, 4H, 2 X CH2, C2, C3, butyl), 2.45 (t, 2H, 
J= 7.3 Hz, CH2, C4, butyl), 2.61 (brs, 4H, 2 X CH2, 
piperazine), 2.91 (brs, 4H, 2 X CH2, piperazine), 3.73  
(t, 2H, J= 7.3 Hz, CH2, C1, butyl), 6.81- 6.17 (m, 4H, 
aromatic), 7.70- 7.86 (m, 4H, aromatic). Phenolic 
proton signal was not shown.  
 
 
IR (cm-1):  
 
3215 (-OH), 1716, 1741 (2 X C=O) 
 
GC/MS : m/z 70 (50%), m/z 104 (35%), m/z 120 (100%), m/z 
160 (90%), m/z 191 (20%), m/z 364 (5%), m/z 379 
(M+, 5%) 
 
Elemental analysis: for C22H25N3O3 calcd. C 69.64, H 6.64, N 11.07; found 
C 69.31; H 6.83; N 10.89. 
 
2-{4-[4-(4-Fluorophenyl)piperazin-1-yl]butyl} isoindole-1,3-dione (41f) 
 
 
 
 
Yield: 1.3g, 76%,  pale yellow crystals 
 
m.p. 116- 118 oC 
 
1H-NMR (CDCl3): 
 
1.53- 1.80 (m, 4H, 2 X CH2, C2, C3, butyl), 2.43 (t, 2H, 
J= 7.1 Hz, CH2, C4, butyl), 2.58 (t, 4H, J= 5.1 Hz, 2 X 
CH2, piperazine), 3.10 (t, 4H, J= 5.1 Hz, 2 X CH2, 
piperazine), 3.73  (t, 2H, J= 7.1 Hz, CH2, C1, butyl), 
6.82- 6.98 (m, 4H, aromatic), 7.71 (dd, 2H, J= 3, 5.5 
Hz Aromatic), 7.81 (d, 2H, J= 4 Hz, aromatic) 
 
IR (cm-1):  
 
1717, 1776 (2 X C=O) 
GC/MS : m/z 70 (80%), m/z 104 (30%), m/z 122 (80%), m/z 160 
(100%), m/z 193 (70%), m/z 366 (5%), m/z 381 (M+, 
10%) 
 
Elemental analysis: for C22H24FN3O2 calcd. C 69.27, H 6.34, N 11.02 ; 
found C 69.48; H 6.01; N 10.92. 
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2-{4-[4-(4-Chlorophenyl)piperazin-1-yl]butyl} isoindole-1,3-dione (41g) 
 
 
 
 
 
Yield: 1.4g, 77%,  pale yellow crystals 
 
m.p. 149- 151 oC 
1H-NMR (CDCl3): 
 
1.56- 1.77 (m, 4H, 2 X CH2, C2, C3, butyl), 2.42 (t, 2H, 
J= 7.3 Hz, CH2, C4, butyl), 2.57 (t, 4H, J= 4.8 Hz, 2 X 
CH2, piperazine), 3.14 (t, 4H, J= 4.8 Hz, 2 X CH2, 
piperazine), 3.73 (t, 2H, J= 7.3 Hz, CH2, C1, butyl), 
6.82 (d, 2H, J= 9 Hz, aromatic), 7.19 (d, 2H, J= 9 Hz 
Aromatic), 7.71 (dd, 2H, J= 3, 5.5 Hz, aromatic), 7.84 
(dd, 2H, J= 3, 5.5 Hz, aromatic) 
 
IR (cm-1):  
 
1707, 1755 (2 X C=O) 
GC/MS : m/z 70 (60%), m/z 104 (30%), m/z 138 (40%), m/z 160 
(100%), m/z 209 (50%), m/z 382 (5%), m/z 397 (M+, 
15%) 
 
Elemental analysis: for C22H24ClN3O2 calcd. C 66.41, H 6.08, N 10.56 ; 
found C 66.14; H 6.04; N 10.43. 
 
2-{4-[4-(3,4-Dichlorophenyl)piperazin-1-yl]butyl}-isoindole-1,3-dione 
(41h) 
 
 
 
 
 
 
 
 
Yield: 1.4g, 72%, yellow crystals 
 
m.p. 125- 127 oC 
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1H-NMR (CDCl3): 
 
1.56- 1.77 (m, 4H, 2 X CH2, C2, C3, butyl),  2.41 (t, 2H, 
J= 7.3 Hz, CH2, C4, butyl), 2.55 (t, 4H, J= 5.25 Hz, 2 X 
CH2, piperazine), 3.14 (t, 4H, J= 5.25 Hz, 2 X CH2, 
piperazine), 3.73  (t, 2H, J= 7.3 Hz, CH2, C1, butyl), 
6.72 (dd, 1H, J= 2.75, 9 Hz, aromatic), 6.93 (d, 1H, J=  
2.75 Hz Aromatic), 7.25 (d, 1H, J= 9 Hz, aromatic), 
7.71 (dd, 2H, J= 3, 5 Hz, aromatic), 7.84 (dd, 2H, J= 3, 
5 Hz, aromatic) 
IR (cm-1):  
 
1711, 1742 (2 X C=O) 
GC/MS : m/z 70 (50%), m/z 104 (35%), m/z 130 (60%), m/z 160 
(100%), m/z 172 (60%), m/z 243 (50%), m/z 432 (M+, 
15%) 
Elemental analysis: for C22H23Cl2N3O2 calcd. C 61.12, H 5.36, N 9.72 ; 
found C 61.16; H 5.49; N 10.17. 
 
2-{4-[4-(4-Hydroxyphenyl)piperazin-1-yl]butyl}isoindole-1,3-dione (41i) 
 
 
 
 
 
 
Yield: 1.0g, 62%, yellow crystals 
 
m.p. 151- 153 oC 
1H-NMR (CDCl3): 
 
1.65- 1.78 (m, 4H, 2 X CH2, C2, C3, butyl), 2.40 (t, 2H, 
J= 7 Hz, CH2, C4, butyl), 2.57 (brs, 4H, 2 X CH2, 
piperazine), 3.01 (brs, 4H, 2 X CH2, piperazine), 3.64  
(t, 2H, J= 7 Hz, CH2, C1, butyl), 6.68 (d, 2H, J= 9 Hz, 
aromatic), 6.78 (d, 2H, J= 9 Hz, aromatic), 7.68- 7.76 
(m, 4H, aromatic). Phenolic proton signal was not 
shown.  
 
IR (cm-1):  
 
3217 (-OH), 1712, 1748 (2 X C=O) 
 
GC/MS : m/z 70 (15%), m/z 104 (5%), m/z 120 (20%), m/z 160 
(25%), m/z 191 (100%), m/z 364 (20%), m/z 379 (M+, 
90%) 
 
Elemental analysis: for C22H25N3O3 calcd. C 69.64, H 6.64, N 11.07; found 
C 69.84; H 7.03; N 10.79. 
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2-[4-(4-Phenyl piperazin-1-yl)butyl] isoindole-1,3-dione (41j) 
 
 
 
 
Yield: 1.2g, 73%, yellow crystals 
 
m.p. 137- 139 oC 
1H-NMR (CDCl3): 
 
1.54- 1.80 (m, 4H, 2 X CH2, C2, C3, butyl), 2.43 (t, 2H, 
J= 7 Hz, CH2, C4, butyl), 2.59 (t, 4H, J= 5 Hz, 2 X CH2, 
piperazine), 3.18 (t, 4H, J= 5 Hz, 2 X CH2, piperazine), 
3.73  (t, 2H, J= 7 Hz, CH2, C1, butyl), 6.81- 6.93 (m, 
3H, aromatic), 7.22- 7.28 (m, 2H, aromatic), 7.69- 7.84 
(m, 4H, aromatic) 
 
IR (cm-1):  
 
1710, 1756 (2 X C=O) 
GC/MS : m/z 77 (95%), m/z 104 (100%), m/z 130 (40%), m/z 
160 (80%), m/z 175 (70%), m/z 348 (5%), m/z 363 
(M+, 15%) 
 
Elemental analysis: for C22H25N3O2 calcd. C 72.70, H 6.93, N 11.56 ; found 
C 72.41; H 6.96; N 11.53. 
 
General procedure for the preparation of 4-(4-Aryl piperazin-1-yl)-
butylamine derivatives (49a-j) 
 
A solution of 2 mmol of the corresponding 1,3 isoindole dione derivative and 
0.25g (6 mmol) hydrazine hydrate 80% in 20 ml ethanol was heated to reflux 
for 5 hours. After cooling to room temperature, any insoluble material was 
filtered off, washed with ethanol (2 X 20 ml) and the filterate was evaporated 
under reduced pressure. The product was extracted with chloroform (2 X 30 
ml) and the desired amine obtained was introduced to the following reaction 
without further purification. 
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General procedure for the preparation of Arylamidobutylphenyl- 
piperazine derivatives  
 
A solution of 2 mmol of thiophene-2-carbonyl chloride (0.30g) or benzoyl 
chloride (0.28g) in 10 ml dry THF was added slowly to a solution of the 
corresponding amine derivative (2.3 mmol) and 0.5g TEA (5 mmol) in dry THF 
(30 ml) at 0 oC. The mixture was then allowed to stir at room temperature for 5 
hours. The reaction mixture was then poured into 30 ml water and extracted 
with Methylene chloride (2 X 40ml). The organic layers were collected and 
dried over anhydrous Na2SO4 and evaporated to yield a residue of the desired 
product that was purified on Silica gel column chromatography using 
Methylene chloride : Methanol 200 : 3 as mobile phase. 
N-{4-[4-(2-Ethoxyphenyl)piperazin-1-yl]butyl}benzamide (43a) 
 
 
 
 
 
 
 
Yield: 0.5g, 66%, pale yellow crystals 
 
m.p. 106- 108 oC 
 
1H-NMR (CDCl3): 
 
1.44 (t, 3H, J= 7 Hz, OCH2CH3), 1.60- 1.71 (m, 4H, 2 X 
CH2, C2, C3, butyl), 2.53 (t, 2H, J= 6.75 Hz, CH2, C4, 
butyl), 2.70 (brs, 4H, 2 X CH2, piperazine), 3.12 (brs, 
4H, 2 X CH2, piperazine), 3.48 (q, 2H, J= 6.2 Hz, CH2, 
C1, butyl), 4.06 (q, 2H, J= 7 Hz, OCH2CH3), 6.82- 6.97 
(m, 5H, aromatic and NH), 7.38- 7.48 (m, 3H, 
aromatic), 7.76- 7.87 (m, 2H, aromatic) 
 
IR (cm-1):  1641 (C=O) 
GC/MS : m/z 77 (60%), m/z 105 (100%), m/z 120 (30%), m/z 
219 (20%),m/z 297 (10%), m/z 366 (10%), m/z 382 
(M+, 5%) 
 
Elemental analysis: for C23H31N3O2 calcd. C 72.41, H 8.19, N 11.01; found 
C 71.87; H 7.98; N 10.87. 
N N
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N-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl}benzamide (43b) (143) 
 
 
 
 
 
 
Yield: 0.64g, 80%, yellowish white crystals 
 
m.p. 128- 130 oC 
 
1H-NMR (CDCl3): 
 
1.62- 1.72 (m, 4H, 2 X CH2, C2, C3, butyl), 2.47 (t, 2H, 
J= 6.9 Hz, CH2, C4, butyl), 2.62 (brs, 4H, 2 X CH2, 
piperazine), 3.02 (brs, 4H, 2 X CH2, piperazine), 3.47 
(q, 2H, J= 6.25 Hz, CH2, C1, butyl), 6.69 (brs, 1H, NH), 
6.87- 6.91 (m, 1H, aromatic), 7.09- 7.17 (m, 2H, 
aromatic), 7.38- 7.51 (m, 3H, aromatic), 7.74- 7.82 (m, 
2H, aromatic) 
IR (cm-1):  1643 (C=O) 
 
GC/MS : m/z 77 (100%), m/z 105 (95%), m/z 172 (80%), m/z 
205 (70%),m/z 243 (60%), m/z 410 (M++4, 5%) 
 
Elemental analysis: for C21H25Cl2N3O calcd. C 62.07, H 6.20, N 10.34; 
found C 61.84; H 6.66; N 10.34. 
 
Thiophene-2-carboxylic acid {4-[4-(2-ethoxyphenyl)piperazin-1-yl]butyl}  
amide (45a) 
 
 
 
 
 
 
Yield: 0.57g, 74%, orange oil 
 
1H-NMR (CDCl3): 
 
1.45 (t, 3H, J= 7 Hz, OCH2CH3), 1.67- 1.85 (m, 4H, 2 X 
CH2, C2, C3, butyl), 2.47 (t, 2H, J= 6.7 Hz, CH2, C4, 
butyl), 2.65 (brs, 4H, 2 X CH2, piperazine), 3.12 (brs, 
4H, 2 X CH2, piperazine), 3.47 (q, 2H, J= 5.8 Hz, CH2, 
C1, butyl), 4.06 (q, 2H, J= 7 Hz, OCH2CH3), 6.46 (brs, 
1H, NH), 6.82- 7.07 (m, 5H, aromatic), 7.43- 7.49 (m, 
2H, aromatic) 
 
IR (cm-1):  1641 (C=O) 
 
GC/MS : m/z 70 (30%), m/z 111 (100%), m/z 121 (40%), m/z 
134 (20%),m/z 219 (20%), m/z 372 (5%), m/z 387 (M+, 
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5%) 
 
Elemental analysis: for C21H29N3O2S calcd. C 65.08, H 7.54, N 10.84; 
found C 64.73; H 7.28; N 10.47. 
 
Thiophene-2-carboxylic acid {4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-
butyl}amide (45b) 
 
 
 
 
 
Yield: 0.58g, 71%, yellowish brown resin 
 
1H-NMR (CDCl3): 
 
1.77- 1.94 (m, 4H, 2 X CH2, C2, C3, butyl), 2.95 (t, 2H, 
J= 6.8 Hz, CH2, C4, butyl), 3.12 (brs, 4H, 2 X CH2, 
piperazine), 3.36 (brs, 4H, 2 X CH2, piperazine), 3.53 
(q, 2H, J= 6.2 Hz, CH2, C1, butyl), 6.96 (brs, 1H, NH), 
6.99- 7.16 (m, 4H, aromatic), 7.46 (d, 1H, J= 3 Hz, 
aromatic), 7.51 (d, 1H, J= 2.3 Hz, aromatic) 
IR (cm-1):  1637 (C=O) 
 
GC/MS : m/z 70 (50%), m/z 130 (60%), m/z 160 (100%), m/z 
174 (40%),m/z 243 (40%), m/z 397 (5%), m/z 412 (M+, 
5%) 
 
Elemental analysis: for C19H23Cl2N3OS calcd. C 55.34, H 5.62, N 10.19; 
found C 55.44; H  5.62; N 9.94. 
 
Thiophene-2-carboxylic acid {4-[4-(2-fluorophenyl)piperazin-1-yl]butyl} 
amide (45c) 
 
 
 
 
 
 
Yield: 0.51g, 71%, creamy white crystals 
 
m.p. 135- 137 oC 
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1H-NMR (CDCl3): 
 
1.60- 1.65 (m, 4H, 2 X CH2, C2, C3, butyl), 2.45 (t, 2H, 
J= 6.7 Hz, CH2, C4, butyl), 2.62 (t, 4H, J= 4.9 Hz, 2 X 
CH2, piperazine), 3.10 (t, 4H, J= 4.9 Hz, 2 X CH2, 
piperazine), 3.46 (q, 2H, J= 6.3 Hz, CH2, C1, butyl), 
6.44 (brs, 1H, NH), 6.89- 7.07 (m, 5H, aromatic), 7.44 
(d, 1H, J= 4.3 Hz, aromatic), 7.50 (d, 1H, J= 3.6 Hz, 
aromatic) 
IR (cm-1):  1634 (C=O), 1200 (C-F) 
 
 
GC/MS : m/z 70 (50%), m/z 111 (100%), m/z 122 (60%), m/z 
193 (40%),m/z 211 (20%), m/z 346 (10%), m/z 361 
(M+, 5%) 
 
Elemental analysis: for C19H24FN3OS calcd. C 63.13, H 6.69, N 11.62; 
found C 62.84; H 6.72; N 12.03. 
 
Thiophene-2-carboxylic acid {4-[4-(2-chlorophenyl)piperazin-1-yl]butyl} 
amide (45d) 
 
 
 
 
 
Yield: 0.53g, 71%, yellowish brown oil 
 
1H-NMR (CDCl3): 
 
1.67- 1.80 (m, 4H, 2 X CH2, C2, C3, butyl), 2.47 (t, 2H, 
J= 6.8 Hz, CH2, C4, butyl), 2.65 (brs, 4H, 2 X CH2, 
piperazine), 3.08 (brs, 4H, 2 X CH2, piperazine), 3.47 
(q, 2H, J= 6 Hz, CH2, C1, butyl), 6.39 (brs, 1H, NH), 
6.93- 7.46 (m, 7H, aromatic) 
IR (cm-1):  1649 (C=O) 
 
GC/MS : m/z 70 (70%), m/z 111 (100%), m/z 138 (50%), m/z 
194 (10%),m/z 211 (40%), m/z 362 (5%), m/z 377 (M+, 
5%) 
Elemental analysis: for C19H24ClN3OS calcd. C 60.38, H 6.40, N 11.12; 
found C 60.01; H 6.39; N 10.79. 
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Thiophene-2-carboxylic acid {4-[4-(2-hydroxyphenyl)piperazin-1-yl]butyl} 
amide (45e) 
 
 
 
 
 
Yield: 0.46g, 64%, reddish brown oil 
1H-NMR (CDCl3): 
 
1.66- 1.69 (m, 4H, 2 X CH2, C2, C3, butyl),  2.52 (t, 2H, 
J= 6.7 Hz, CH2, C4, butyl), 2.68 (brs, 4H, 2 X CH2, 
piperazine), 2.94 (t, 4H, J= 4.75 Hz, 2 X CH2, 
piperazine), 3.47 (q, 2H, J= 5.8 Hz, CH2, C1, butyl), 
6.56 (brs, 1H, NH), 6.82- 6.95 (m, 2H, aromatic), 7.04- 
7.14 (m, 3H, aromatic), 7.45 (d, 1H, J= 4.8 Hz, 
aromatic), 7.54 (d, 1H, J= 3.8 Hz, aromatic). Phenolic 
proton signal was not shown.  
 
IR (cm-1):  3225 (OH), 1635 (C=O) 
 
GC/MS : m/z 70 (40%), m/z 111 (50%), m/z 148 (25%), m/z 199 
(40%),m/z 211 (100%), m/z 355 (10%), m/z 359 (M+, 
5%) 
 
Elemental analysis: for C19H25N3O2S calcd. C 63.48, H 7.01, N 11.69; 
found C 63.11; H 6.95; N 11.72. 
 
 
Thiophene-2-carboxylic acid {4-[4-(4-fluorophenyl)piperazin-1-yl]butyl} 
amide (45f) 
 
 
 
 
 
Yield: 0.53g, 74%, greish white crystals 
 
m.p. 143- 145 oC 
 
1H-NMR (CDCl3): 
 
1.61- 1.67 (m, 4H, 2 X CH2, C2, C3, butyl), 2.46 (t, 2H, 
J= 6.7 Hz, CH2, C4, butyl), 2.62 (t, 4H, J= 5 Hz, 2 X 
CH2, piperazine), 3.12 (t, 4H, J= 5 Hz, 2 X CH2, 
piperazine), 3.45 (q, 2H, J= 6.3 Hz, CH2, C1, butyl), 
6.40 (brs, 1H, NH), 6.83- 7.06 (m, 5H, aromatic), 7.44 
(d, 1H, J= 4.9 Hz, aromatic), 7.50 (d, 1H, J= 3.8 Hz, 
aromatic) 
IR (cm-1):  1644 (C=O), 1218 (C-F) 
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GC/MS : m/z 70 (35%), m/z 111 (100%), m/z 122 (35%), m/z 
193 (20%),m/z 211 (15%), m/z 346 (5%), m/z 361 (M+, 
5%) 
 
Elemental analysis: for C19H24FN3OS calcd. C 63.13, H 6.69, N 11.62; 
found C 62.94; H 6.83; N 11.35. 
 
Thiophene-2-carboxylic acid {4-[4-(4-chlorophenyl)piperazin-1-yl]butyl} 
amide (45g) 
 
 
 
 
 
Yield: 0.57g, 76%, creamy white crystals 
 
m.p. 158- 160 oC 
 
1H-NMR (CDCl3): 
 
1.66- 1.74 (m, 4H, 2 X CH2, C2, C3, butyl), 2.46 (t, 2H, 
J= 6.8 Hz, CH2, C4, butyl), 2.60 (t, 4H, J= 4.8 Hz, 2 X 
CH2, piperazine), 3.16 (t, 4H, J= 4.8 Hz, 2 X CH2, 
piperazine), 3.47 (q, 2H, J= 6 Hz, CH2, C1, butyl), 6.29 
(brs, 1H, NH), 6.83 (d, 2H, J= 9 Hz, aromatic), 7.04- 
7.07 (m, 1H, aromatic), 7.20 (d, 2H, J= 9 Hz, 
aromatic), 7.44- 7.48 (m, 2H, aromatic) 
 
IR (cm-1):  2887 (-CH Aliphatic), 1649 (C=O) 
 
GC/MS : m/z 70 (70%), m/z 111 (100%), m/z 140 (35%), m/z 
196 (10%),m/z 211 (45%), m/z 362 (5%), m/z 377 (M+, 
5%) 
Elemental analysis: for C19H24ClN3OS calcd. C 60.38, H 6.40, N 11.12; 
found C 60.80; H 6.55; N 10.82. 
 
Thiophene-2-carboxylic acid {4-[4-(3,4-dichlorophenyl)piperazin-1-yl] 
butyl}amide (45h) 
 
 
 
 
 
 
Yield: 0.62g, 76%, pale yellow crystals 
 
m.p. 132- 134 oC 
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1H-NMR (CDCl3): 
 
1.65- 1.74 (m, 4H, 2 X CH2, C2, C3, butyl), 2.43 (t, 2H, 
J= 6.7 Hz, CH2, C4, butyl), 2.57 (t, 4H, J= 5 Hz, 2 X 
CH2, piperazine), 3.16 (t, 4H, J= 5 Hz, 2 X CH2, 
piperazine), 3.47 (q, 2H, J= 6.2 Hz, CH2, C1, butyl), 
6.28 (brs, 1H, NH), 6.72 (dd, 1H, J= 3, 8.8 Hz, 
aromatic), 6.94 (d, 1H, J= 3 Hz, aromatic), 7.06 (d, 1H, 
J= 8.8 Hz, aromatic), 7.24- 7.47 (m, 3H, aromatic) 
 
IR (cm-1):  1641 (C=O) 
 
GC/MS : m/z 70 (80%), m/z 130 (40%), m/z 160 (100%), m/z 
174 (30%),m/z 243 (50%), m/z 397 (5%), m/z 416 
(M++4, 5%) 
 
Elemental analysis: for C19H23Cl2N3OS calcd. C 55.34, H 5.62, N 10.19; 
found C 55.54; H  5.67; N 10.15. 
 
Thiophene-2-carboxylic acid {4-[4-(4-hydroxyphenyl)piperazin-1-yl]butyl} 
amide (45i) 
 
 
 
 
 
 
Yield: 0.46g, 64%, buff crystals 
 
m.p. 139- 141 oC 
 
1H-NMR (CDCl3): 
 
1.66- 1.69 (m, 4H, 2 X CH2, C2, C3, butyl), 2.52 (t, 2H, 
J= 6.7 Hz, CH2, C4, butyl), 2.68 (brs, 4H, 2 X CH2, 
piperazine), 2.95 (brs, 4H, 2 X CH2, piperazine), 3.47 
(q, 2H, J= 5.8 Hz, CH2, C1, butyl), 6.56 (brs, 1H, NH), 
6.82- 7.55 (m, 7H, aromatic). Phenolic proton signal 
was not shown.  
 
 
IR (cm-1):  3236 (OH), 1633 (C=O) 
 
GC/MS : m/z 70 (60%), m/z 111 (90%), m/z 148 (30%), m/z 199 
(45%),m/z 211 (100%), m/z 355 (20%), m/z 359 (M+, 
10%) 
 
Elemental analysis: for C19H25N3O2S calcd. C 63.48, H 7.01, N 11.69; 
found C 63.87; H 6.65; N 11.75. 
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Thiophene-2-carboxylic acid [4-(4-phenylpiperazin-1-yl)butyl]amide (45j) 
 
 
 
 
 
 
Yield: 0.5g, 73%, creamy white crystals 
 
m.p. 115- 117 oC 
 
1H-NMR (CDCl3): 
 
1.65- 1.68 (m, 4H, 2 X CH2, C2, C3, butyl), 2.46 (t, 2H, 
J= 6.8 Hz, CH2, C4, butyl), 2.63 (t, 4H, J= 5 Hz, 2 X 
CH2, piperazine), 3.19 (t, 4H, J= 5 Hz, 2 X CH2, 
piperazine), 3.46 (q, 2H, J= 6.2 Hz, CH2, C1, butyl), 
6.42 (brs, 1H, NH), 6.83- 7.45 (m, 8H, aromatic) 
IR (cm-1):  1641 (C=O) 
 
GC/MS : m/z 70 (30%), m/z 104 (40%), m/z 111 (50%), m/z 132 
(60%), m/z 211 (100%), m/z 328 (50%), m/z 343 (M+, 
30%) 
Elemental analysis: for C19H25N3OS calcd. C 66.44, H 7.34, N 12.23; found 
C 66.56; H 7.36; N 12.07. 
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4.2 Radioligand binding assay 
4.2.1 Radioligand binding of dopamine receptors in 
intact HEK293 cells 
 
One T75 flask of HEK293 cells (~90% confluent) recombinantly expressing 
the respective receptor was harvested by trypsinisation (0.05% trypsin/0.02% 
EDTA), and cells were resuspended in phosphate-buffered saline (PBS), 
pelleted and rinsed once with PBS. Pelleted cells were then resuspended in 
Krebs-HEPES buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 4.2 mM NaHCO3, 11.7 mM D-glucose, 1.3 mM CaCl2, 10 mM 
HEPES, pH 7.4) and evenly distributed into pretreated microcentrifuge tubes 
(sigmacote; protein content: ~90 μg/tube). Binding assays were carried out in 
triplicate in a total volume of 1 ml. Incubation was initiated by addition of 100 
μl of [3H]ligand and was carried out at 27°C for 1 h. It was stopped by rapid 
filtration through pretreated glass fibre filters (0.25% polyethyleneimin), 
followed by 2×5-ml washes with ice-cold water. Radioactivity retained on the 
filters was counted by liquid scintillation spectroscopy using a Beckman 
scintillation counter. For binding studies at the hD1 and hD5 receptors, [N-
methyl-3H]SCH23390 (83.0 Ci/mmol; Nycomed Amersham, Buckinghamshire, 
UK) was used. [3H]Spiperone (97.0 Ci/mmol; Nycomed Amersham) was used 
for binding studies at the hD2L and hD3 receptors (66).  
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4.2.2 Radioligand binding of dopamine receptors in 
CHO cells 
  
One T75 flask of CHO cells (~90% confluent) recombinantly expressing the 
respective receptor was harvested by trypsinisation (0.05% trypsin/0.02% 
EDTA), and cells were resuspended in ice-cold 50 mM Tris-HCl/5 mM MgCl2, 
pH 7.4. Cells were then disrupted using a Polytron on ice. After centrifugation 
at 40,000 g, supernatant was discarded, and pellet was 3 times washed with 
ice-cold Tris-HCl/MgCl2 buffer. Eventually, the pellet was resuspended in Tris-
HCl/MgCl2 buffer and evenly distributed into pretreated microcentrifuge tubes 
(sigmacote; protein content: ~120 μg/tube). Binding assays were carried out 
in triplicate in a total volume of 1 ml as described for HEK293 cells (66).  
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4.3 Molecular Modeling 
4.3.1 Energy minimization procedure 
 
The compounds were drawn on ChemSketch 11 and saved as mol file, the 
latter were  subjected to energy minimization using Force Field MMFF94x by 
Molecular Operating EnvironMent (MOE) (114) software, MOE, Chemical 
Computing Group Inc. http://www.chemcomp/com and the basic piperazine 
nitrogen is protonated. 
4.3.2 Source of target proteins 
 
The Crystal structure of Human D3 receptors complexed with its antagonist 
eticlopride (PDB ID code: 3PBL), was downloaded from the Protein data bank 
and opened with MOE software. The Homology model of human D4 receptor 
was downloaded from the supporting information of the article published by 
McRobb et al (139). 
4.3.3 Docking procedure of D3 receptors 
 
The co-crystallized compound was selected, and the binding site was 
identified according to residues in 4Ao proximity to those interacted with the 
co-crystallized antagonist eticlopride. Ligand interactions were computed for 
the X-ray co-crystallized compound, eticlopride, to reveal the different types of 
interaction as a validation for the coming docking procedure. Default settings 
of MOE-Dock (114) were used, including “Rotate Bonds” option in order to allow 
flexible ligand-rigid receptor docking. The scoring function was London dG 
with a replacement of Triangle Matcher. Thirty poses of each ligand docked to 
the identified binding site were retained and ranked in order of increasing 
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scoring function. The 2D ligand-receptor interactions of these poses were 
viewed using the "compute ligand interaction" option of MOE.   
4.3.4 Docking procedure of D2 and D4 receptors 
 
The binding site was isolated off the validated homology model using the 
default settings of the site finder panel option of MOE (114). Again the default 
settings of MOE-Dock were used, including “Rotate Bonds” option in order to 
allow flexible ligand-rigid receptor docking. The scoring function was London 
dG with a replacement of Triangle Matcher. Thirty poses of each ligand 
docked to the identified binding site were retained and ranked in order of 
increasing scoring function. The 2D ligand-receptor interactions of these 
poses were viewed using the "compute ligand interaction" option of MOE (114).   
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 5. Conclusion  
This work aimed at modulating the selectivity and affinity of some 
dopaminergic ligands towards the different subtypes of the two families of 
dopamine receptors; the D1-like and the D2-like receptors via developing new 
thieno and benzothieno ligands so that we could achieve novel receptor 
subtype selectivity and/or better pharmacokinetic properties.  
In the first part of the work we have targeted the D1-like receptor subtypes; 
D1 and D5 that are characterized by sharing high level of molecular structure 
identity within their transmembrane helices. We aimed at developing new 
azecine- bearing ligands characterized by being sub selective to either one of 
the two D1 family subtypes and/or with cross affinity to D2 family members. 
The work has started by observing that increasing the electron cloud of the D1 
selective dibenzazecine LE410 by hydroxylation (LE405) shifts the affinity 
towards the D5 receptor subtype. We have also noticed that the thiophene 
containing Olanzapine shows for D1, D2, and D5 a much higher affinity than 
Clozapine. Thus we have prepared two regioisomers carrying a thiophene in 
different orientations, namely the benzo[d]thieno[2,3-g]azecine 1, and the 
benzo[d]thieno[3,2-g]azecine 2 and furthermore the benzothiophene 
derivative 3, Schemes 2, 3, 4. 
Conclusion 
 163
N CH3
HO
LE 405
S
N
CH3
S
N
CH3 S
N CH3
1 2 3
N CH3
LE 410
N
H
N
N
N
Cl
S
HN
N
N
N
Olanzapine Clozapine
Based on the results obtained in this work, the following conclusions can be 
made: • The bioisosteric replacement of the benzene (LE410) with thiophene or 
benzothiophene in right orientation (compounds 1, 3) have shifted the 
selectivity from D1 to D5 receptor subtypes, the same effect achieved 
by replacing benzene with hydroxybenzene (LE405), suggesting that 
increasing the electron cloud on the ligand's scaffold could be one of 
the prominent factors to enhance the ligand's affinity at D5 receptor 
subtypes. In this case thiophene system would ensure better 
pharmacokinetics over its hydroxybenzene analogue.  
• Reversing the orientation of the thiophene ring (compound 2) has 
restored back the original selectivity pattern of LE410 towards D1 
rather than D5 subtypes revealing the importance of the position of the 
thiophene sulfur atom in binding to D5 subtypes. 
• Aligning the reported D1 and D5 sequences according to Ballesteros 
and Weinreb numbering (134- 136) reveled that Tyrosine, Glutamine, 
Serine, and Therionine residues in D5 could serve as hydrogen bond 
acceptors from ligands owning electron donating moieties contrary to 
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their counterparts in the D1 binding site, thus providing a possible 
explanation for the importance of having the thiopene ring in the 
appropriate orientation (134- 136). 
• Compounds 1, 3 with the appropriate thiophene positioning were those 
that showed better affinity to D2 and D3 receptor subtypes when 
compared to the lead compounds LE410 and LE405. Compound 3 was 
found to be much more selective to D2, and D3 receptors with Ki 
values of 1.5, and 18 nM respectively versus 40 nM on D1 receptor 
subtype showing to be the first azecine derivative with this reversed 
selectivity pattern. It also has a Ki of 1.9 nM at D5 receptors showing to 
be the first azecine with comparable cross affinity between the two 
families of dopamine receptors. 
• Based on the suggested molecular structure of the D2 and D3, it was 
proved that Serine residues contribute to protein-ligand interaction 
serving as hydrogen bond acceptors, concluding the importance of 
having the regularly positioned thiophene or benzothiophene as 
electron donating moieties. 
In the second part of this work, our interest was shifted towards D2-like family 
members, where we aimed at developing new phenylpiperazine bearing 
ligands with subtype receptor selectivity towards D3/D4 rather than D2 
receptor subtypes. We started with a series of 10 
thienomethylphenylpiperazines serving as D4 selective analogues for 
PD168077, L-745870, and FAUC113. Based on the binding affinity data 
obtained, some of the synthesized derivatives had their thiophene ring 
replaced with other aryl and heteroaryl moieties to demonstrate the effect of 
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this particular part of the structure on the affinity towards the target protein 
and to configure out an interactive Structure Affinity Relationship study, thus 
another 10 analogues have been prepared, Schemes 5, 6. 
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 Based on the results obtained in this work, the following conclusions can be 
made: • Presence of oxygenated rather than halogenated substituent on the 
phenylpiperazine unit is crucial for getting optimum D4 affinity. 
Compounds with unsubstituted phenylpiperazine unit shown even 
lower affinity to the target receptor. This is may be due to the influence 
of this substituent either on the pKa of the basic piperazine that affords 
salt bridge interaction with Aspartate 115 residue in the D4 binding 
pocket or on the dispersion force of the phenyl ring that is necessary to 
afford Van der Waals interaction with the imidazole ring of Histidine 
414 residue. 
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• Compound 31e having 2-OEt substituent on the phenypiperazine unit 
showed the best affinity to D4 receptors among the 
thienylmethylphenyl- piperazine series, while compound 31d having 
the 2,3-Cl was shown to have better affinity towards D3 rather than D4, 
indicating that the nature of the substituent at this part of the scaffold 
could also manipulate receptor subtype selectivity.  
S
N N
H3CH2CO
31e
S
N
N
Cl
Cl
31d  • Viewing the binding pockets of D4 versus D3 model could show that 
the Phenylalanine 91 residue is conserved in the D4 pocket and faces 
the also conserved and the less bulky Valine 86 in D3. Thus, we could 
conclude that the relatively more bulky dihalogenated bearing 
compound 31d is more likely to show better affinity towards D3 (with a 
relative larger pocket than D4 subtypes) among this series.  
• The position of the substituent on the phenylpiperazine unit seems to 
be also essential for modulating ligands' affinity towards D4 receptors, 
where ortho substituted ligands were found to be 2- 10 folds more 
affinitive to D4 receptors than their para substituted congeners. A 
certain degree of non coplanarity achieved through a dihedral angle of 
about 60o between the phenyl and the piperazine rings lead to optimum 
D4 affinity. 
• Replacing the thiophene system with more or less electronically similar 
arene systems such as benzene, naphthaline, and benzothiophene 
lead to ligands with similar binding affinity data towards D4, while 
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replacing the thiophene system with relatively more electronegative 
arene moieties such as pyridine (compound 32a) and indole 
(compound 36a) lead to dramatic increase in D4 affinity and selectivity 
over D2 and D3 receptor subtypes. Compound 36a had Ki value of 
0.03 nM on D4 receptors showing to be 100 times more potent than the 
D4 selective FAUC113.  
N
N
OCH2CH3N N
H
N
N
H3CH2CO
32a 36a
 • Molecular docking studies at D4 receptor model revealed the 
involvement of the D4 unique residue Arginine 186 in affording a first to 
report cation arene interaction with the docked ligands, providing a 
possible explanation why compounds bearing pyridine and indole 
systems were among the highest D4 affinitive ligands.  
In a further attempt to develop D3/D4 selective ligands we have prepared 
three series of compounds bearing related chemical scaffolds, namely 
phenylpiperazinylalkylisoindoledione; compounds 40a- b, 41a- b, benzamido 
alkylphenylpiperazine, compounds 42a- b, 43a- b, and thienoamidophenyl- 
piperazine, compounds 44a- b, 45a- b, Schemes 7, 8, 9. The design of these 
probes was inspired from the structures of some typical and atypical 
antipsychotic agents having variable affinity and selectivity patterns towards 
different dopamine and/or serotonin receptor subtypes, so that our prepared 
probes could be able to serve as hybrids of these marketed agents.   
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Based on the results obtained in this work, the following conclusions can be 
made: • Compounds bearing propyl linker between the phenylpiperazine unit 
and the terminal arene unit were shown to have better affinity at D2 
subtypes, while those having butyl linker were much selective to D3 
subtypes. Both types of compounds have shown appreciable affinity at 
D4 receptor subtypes. 
• Molecular docking studies at the D2, D3, and D4 models have revealed 
that probes with propyl linker would have their terminal aromatic 
appendage in contact to Isoleucine 183 in D2 receptors that faces 
Serine 182 in D3 receptors. The chemical nature of Isoleucine enables 
it to be more hydrophobic than Serine and thus would afford better 
hydrophobic interaction with the ligands’ aromatic appendage 
explaining the better affinity of the compounds bearing the propyl linker 
towards D2 receptor subtypes. 
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• Docking also has shown that butyl linker bearing probes are able to 
deliver their aromatic appendage to interact with the Valine 180 residue 
in the EL2 of D3 receptors that faces the more polar Glutamate 181 in 
D2 subtypes. Again the more hydrophobic nature of Valine relative to 
Glutamate residues would ensure better hydrophobic interaction with 
ligands’ aromatic appendage. This might explain the better affinity of 
the compounds bearing the butyl linker towards D3 receptor subtypes.  
• It was found that Isoleucine 183 of D2 is occupied with Arginine 186 in 
D4 and the Glutamate 181 in D2 is occupied with Valine 184 in D4 
receptor subtypes. Both Arginine 186 and Valine 184 residues in the 
D4 binding site are able to interact properly with the aromatic 
appendage of our probes and this might explain the noticeable 
preferentiality of both propyl and butyl linker bearing ligands towards 
D4 receptor subtypes rather than D2 ones. Furthermore, the carbonyl 
group of the synthesized propes was found to afford hydrogen bonding 
interaction with the unique Arginine 186 in D4 binding site. 
• Thiophene bearing probes showed the best affinity towards the target 
receptor subtypes among the whole series. 
• As for the phenylpiperazine part of the scaffold, substitution with 2-OEt 
or 2,3-Cl was optimum for the affinity of the synthesized probes 
towards the target receptor subtypes. 
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6. Zusammenfassung 
Ziel dieser Arbeit war es, potente Liganden mit neuen Subtypselektivitäts-
Mustern an Dopamin Rezeptoren zu finden.  Eine Chance dazu, wurde in der 
Etablierung des Thiophenringes in bioaktiven, aber Thiophen-freien 
Strukturen gesehen. Methodisch enthält die Arbeit in erster Linie, 
Strukturdesign, Synthese, truktursicherung, Radioligandbindungsexperi- 
mente zur Bestimmung der Rezeptoraffinitäten und Molecular Modelling zur 
Analyse der Struktur-Wirkungsbeziehungen.  
Im ersten Teil der Arbeit wurden neue Substanzen mit Selektivität zu den D1-
like Rezeptoren (D1, D5) angestrebt, wobei hier eine interne Subtyp-
Selektivität problematisch ist und bisher kaum verwirklicht wurde, da D1 and 
D5 ein hohes Maß an struktureller Identität aufweisen. Die Idee der 
Fokussierung auf Thiophenderivate ergab sich z.B. aus der Beobachtung, 
dass bei den in unserer Arbeitsgruppe enwickelten Dopamin Rezeptor 
Antagonisten des Azecin-Typs die Erhöhung der Elektronendichte eines der 
beiden Benzenringe im Dibenzo-azecin-Derivat LE 410 durch Hydroxylierung 
zu LE 405, eine Verschiebung der Affinität hin zu D5 bewirkte. Die Frage stellt 
sich, ob die Erhöhung der Elektronendichte hierfür der auslösende Faktor ist 
und ob dann auch der Ersatz des Benzenringes durch elektronenreiches 
Thiophen zum Ziel führt. Motivierend war auch, dass das Thiophenderivat 
Olanzapin an den Subtypen D1, D2, und D5 sehr viel affiner ist als das 
Benzen-analoge Clozapin. Aus diesen Gründen wurden in dieser Arbeit zwei 
regioisomere Azecine mit einem Thiophenring in unterschiedlicher 
Orientierung, nämlich das Benzo[d]thieno[2,3-g]azecine 1 und das 
Benzo[d]thieno[3,2-g]azecine 2, darüber hinaus auch noch des 
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Benzothiophen-Derivat 3 jeweils in Mehourstufensynthesen hergestellt, wie 
sie in Schemata 2, 3, und 4 wiedergegeben sind. Deren Affinitäten wurden 
durch Radioligand-Bindungsexperimente an klonierten humanen Dopamin 
Rezeptoren bestimmt. Im Rahmen der Synthesearbeit wurden auch ein 
ungewöhnlicher Abbau des Thiophenringes beobachtet und damit neue 
Erkenntnisse zur Thiophenchemie erhalten. 
Basierend auf den Ergebnissen dieses Arbeitsabschnittes können hier die 
folgenden Schlüsse gezogen werden. 
  • Der bioisostere Austausch des Benzens in LE410 gegen Thiophen 
oder Benzothiophen in der Orientierung der Verbindungen 1 und 3 
führt zu Hochaffinen Substanzen und verschiebt die Selektivität vom 
D1 zum D5 Subtyp. Ähnliches war schon bei der Hydroxylierung von 
LE 410 zu LE 405 zu beobachten, was den Schluß naheleg, dass die 
Steigerung der Elektronendichte an einem der Aromaten generell eine 
D5 Affinität begünstigt. Aus pharmakokinetischer Sicht sollte bei einem 
ZNS-Target der Einbau von Thiophen vorteilhafter sein als die 
Hydroxylierung, die praktisch schon einen ersten Schritt eines 
metabolischen Abbaus darstellt.   
• Die Umkehrung der Orientierung des Thiophenringes (Verbindung 2 im 
Vergleich zu 1 und 3) bringt das bekannte Selektivitätsmuster von 
LE410 mit Bevorzugung von  D1 gegenüber D5 wieder zurück, d.h., die 
Position des Schwefels ist relevant.  
• Aus der von Ballesteros and Weinreb (134- 136) publizierten Sequenz 
in der Bindungstasche des D5 Rezeptors mit den Aminosäuren 
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Tyrosin, Glutamin, Serin, und Threonin läßt sich ebenfalls eine 
Präferenz von  Thiophenderivaten ableiten. 
• Die Verbindungen 1, 3 mit vorteilhafter Thiophen Positionierung zeigen 
höhere Affinität zu D2 und D3 im Vergleich zu den Azecin-leads LE410 
und LE405. 3 war dabei hochaffin an D2 und D3 mit Ki Werten von 1.5 
und 18 nM, gegenüber nur 40 nM an D1. Bei zugleich sehr hoher 
Affinität zu D5 mit Ki = 1.9 nM steht fest, dass Verbindung 3 das erste 
cross-affinity Azecin ist, die Substanz ist gleichermaßen hochaffin an 
D2 und D5, belegt also beide Dopamin Rezeptor Familien.   
• Die vorgeschlagenen molekularen Strukturen von D2 und D3 Rezeptor 
legen nahe, dass die Aminosäure Serin als 
Wasserstoffbrückenakzeptor wesentlich zur Protein-Ligand Interaktion 
beiträgt und dass regular positioniertes Thiophen einen bedeutenden 
Beitrag zur Interaktion leisten kann.  
Im zweiten Teil der Arbeit focussierten wir uns mehr auf Liganden an den 
Rezeptoren der D2-Familie und synthetisierten zunächst 10 verschiedene 
Thienomethylphenylpiperazine, die als Thiophenanaloga der Thiophen-freien 
D4 selektiven Liganden PD168077, L-745870, und FAUC113 betrachtet 
werden können. Weiterhin wurde bei einigen der Syntheseprodukte der 
Thiophenring wieder gegen andere Aryl,bzw. Heteroaryl-Reste ausgetauscht 
um den Einfluss des Strukturelementes Thiophen noch besser erkennen zu 
können, Schemata 5, 6. 
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Folgende Erkenntnisse konnten in dieser Piperazinreihe gewonnen werden. 
 • Ethoxy am Phenylpiperazine-Teil sind offensichtlich günstiger als 
Halogen, d.h. optimale Affinitäten am D4 Rezeptor werden mit den 
Ethoxyderivaten erreicht. Dies mag am positiven Einfluss der 
Alkoxygruppe auf die Basizität der Piperazin-Stickstoffe liegen, 
wodurch die Interaktion mit dem Aspartat 115 der Bindungstasche 
begünstigt wird oder an der Verstärkung der Möglichkeit des 
Phenylrestes zur van der Waals Interaktion mit dem Histidin 414 .  
• Das 2-Ethoxy-thienomethylphenylpiperazin Derivat 31e zeigt die 
höchste Affinität zum humanen D4 Rezeptor, während die Affinität des 
strukturell analogen 2,3-Dichlor-thienomethylphenylpiperazin 31d am 
D4 sogar geringer als die am D3 Rezeptor  ist.  
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31d  • Ein Vergleich der Bindungstaschen zeigt dass ein Phenylalanin 91 in 
D4 einem weniger raumerfüllenden Valin 86 in D3 entspricht. So 
leuchtet ein, dass Verbindungen mit dem sterisch anspruchsvolleren 
Dihalogenphenyl-rest wie in 31d mit D3 besser zur Interaktion kommen 
als mit D4.  
• Die Position der Substituenten an der Phenylpiperazin-Teilstruktur 
moduliert ebenfalls die Affinität zu D4. Orthosubstituierte Derivate sind 
2-10 fach günstiger als parasubstituierte. Ein gewisses Verdrehen aus 
der Koplanarität durch die Orthosubstituenten - z.B. ca. 60° 
Diederwinkel zwischen Phenyl- und Piperazinring - führt zur optimalen 
D4 Affinität in der Verbindungsgruppe.  
• Der Austausch von Thiophen mit elektronisch relativ ähnlichen Arenen, 
wie Benzen, Naphthalin und Benzothiophen führt auch zu Liganden mit 
ähnlicher D4 Affinität. Ersatz des Thiophens durch Pyridin (32a) oder 
Indol (36a) steigert die D4 Affinität und die Selektivität gegenüber D2 
und D3 dramatisch. Tatsächlich hat Verbindung (36a) einen Ki Wert 
von 0.03 nM am D4 Rezeptor und ist damit 100x potenter als der D4 
selektive Ligand  FAUC113.  
N
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• Molecular docking Studien am D4 Rezeptor Modell belegen die 
Beteiligung eines D4 spezifischen Arginin 186 in Form einer bisher 
nicht berichteten Kation-Aren-Wechselwirkung mit dem angedockten 
Liganden. Dies könnte erklären, dass die Verbindungen mit Pyridin und 
Benzothiophen Komponenten  zu den höchstaffinen D4 Liganden 
gehören. 
In Fortsetzung der Suche nach D3/D4 selektiven Liganden wurden drei 
weitere Serien von Phenylpiperazinen synthetisiert, nämlich 
Phenylpiperazinylalkyl-isoindoledione (40a- b, 41a- b), 
Benzamidoalkylphenylpiperazine (42a- b, 43a- b), and 
Thienoamidophenylpiperazine ( 44a- b, 45a- b), Schemata 7, 8, 9. The 
Design dieser Kandidaten wurde durch Strukturelemente von typischen und 
atypischen Antipsychotika inspiriert, deren aromatische/heteroaromatische 
Teilstrukturen über Linker als aromatische Endgruppen an den 
Phenylpiperazinteil eingebracht wurde, so dass von Hybridverbindungen 
gesprochen werden kann. 
Die Ergebnisse dieses Arbeitsabschnittes lassen wie folgt zusammenfassen: 
• Verbindungen mit einem Propyllinker zwischen Phenylpiperazin und 
der terminalen Areneinheit entwickeln höhere D2, die mit einem 
Butyllinker  höhere D3 Affinität. Beide Typen zeigen dazu akzeptable 
D4 Affinität. 
• Molecular docking Studien an D2, D3, and D4 Modellen ergaben, dass 
die Strukturen im Falle eines Propyllinkers ihren terminalen 
aromatischen Teil in Kontakt mit  dem Isoleucine 183 im D2 receptors 
bringen können. Strukturen mit Butyllinker wiederum ermöglichen eine 
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gute Interaktion der aromatischen Endgruppe mit Valin 180 im EL2 des 
D3 Rezeptors.  
• Durch Docking wurde auch gefunden, dass das Isoleucin 183 in D2 
durch Arginin 186 in D4 und das Glutamate 181 in D2 durch Valine 184 
in D4 ersetzt ist. Beide Varianten ermöglichen eine Wechselwirkung 
mit den aromatischen Endgruppen unserer Versuchsubstanzen und 
dies mag die Affinität sowohl der Propyllinker als auch der Butyllinker 
Derivate vorzugsweise zu D4 und weniger zu D2 erklären. Hinzu 
kommt, dass die Carbonylgruppen der Testverbindungen eine 
Wasserstoffbrückenbindung mit dem typischen Arginine 186 in der D4 
Bindungstasche ausbilden können.  
• Generell zeigen die Thiophen-haltigen Strukturen die höchsten 
Affinitäten gegenüber den verschiedenen Targets, was das 
Ausgangskonzept dieser Arbeit unterstützt.  
• Im Phenylpiperazine-Teil ist tatsächlich die Substitution mit 2-OEt oder 
2,3-Cl das Optimum.  
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List of Abbreviations 
 
AC: Adenylyl cyclase. 
ADHD: 
AMPA:      
ATP: 
Attention deficit hyperactivity disorder.  
Alpha amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
Adenosine triphosphate. 
cAMP: Cyclic adenosine monophosphate. 
CNS: Central nervous system. 
COMT: 
CTZ: 
DARPP-32: 
DAT-1: 
Catechol - o - methyl transferase. 
Chemoreceptor trigger zone. 
Dopamine and cyclic AMP- regulated phosphoprotein. 
Dopamine transporter 
DMSO: Dimethyl sulfoxide. 
GABA: Gama amino butyric acid. 
GPCRs: G protein coupled receptors. 
L-DOPA: L-3,4-dihydroxyphenylalanine. 
m.p.: Melting point. 
MAO: Monoamine oxidase. 
MOE: Molecular Operating EnvironMent. 
MS: 
NET: 
NMDARs: 
Mass spectrometry. 
Norepinephrine transporter. 
N-methyl D-aspartate receptors. 
NMR: 
PD: 
Nuclear magnetic resonance. 
Parkinson's disease. 
PDB: 
PET: 
Protein data bank. 
Positron emission tomography. 
PIH: Prolactin inhibiting hormone. 
PKA: Protein kinase A. 
PP 1: Phosphatase 1. 
Rf: Retention factor. 
VTA: Ventral tegmental area. 
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